https://www.harmreductionadvocate.com/educational-resources daily 0.75 2026-10-29 https://www.harmreductionadvocate.com/educational-resources/womens-health monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223952930-CZ88TJQ1ZPHM47LGII4X/illustration-womens-health.jpg Educational Resources - Women’s Health https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1b381691-7888-4545-b3ce-c19ad918198e/study-1.png Educational Resources - Women’s Health Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Argento E, Strathdee SA, Tupper K, et al. Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open. 2017;7(9):e016025. https://doi.org/10.1136/bmjopen-2017-016025 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/57106de6-9081-408b-b0f4-cce15acdb36a/study-2.png Educational Resources - Women’s Health Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Argento E, Goldenberg S, Deering K, et al. Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada. Drug Alcohol Depend Rep. 2022;3:100044. https://doi.org/10.1016/j.dadr.2022.100044 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/92da1a82-e9fc-465f-a44e-2398fca8b2d9/study-3.png Educational Resources - Women’s Health Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023;29(8):1947-1953. https://doi.org/10.1038/s41591-023-02455-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/89c5434f-f778-4959-8379-8adb302b6523/study-4.png Educational Resources - Women’s Health Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Han Y, Li P, Miao M, et al. S-ketamine as an adjuvant in patient-controlled intravenous analgesia for preventing postpartum depression: a randomized controlled trial. BMC Anesthesiol. 2022;22(1):49. https://doi.org/10.1186/s12871-022-01588-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d2f315cb-a487-4700-a21f-8a353370d822/study-5.png Educational Resources - Women’s Health Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Song Z, Miao M, Huang F, et al. Effect of a single low-dose esketamine administration during surgical abortion on postoperative sleep disturbance: a randomized controlled trial. Nat Commun. 2025;16(1):7533. https://doi.org/10.1038/s41467-025-62933-1 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3a73ac22-4e82-4c4c-95c6-fa9d7dd7fe2a/study-6.png Educational Resources - Women’s Health Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ma Q, Li H, Wang X, et al. Effect of a Subanesthetic Dose of Esketamine on Postoperative Sleep Disturbance After Oocyte Retrieval Under Intravenous Anesthesia: A Randomized Controlled Trial. Drug Des Devel Ther. 2026;20:630545. https://doi.org/10.2147/dddt.s630545 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a479960b-5192-4d88-b3c3-bac8553ddbe5/study-7.png Educational Resources - Women’s Health Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zhou YH, Li L, Gao R, et al. Effect of low-dose supplemental esketamine infusion on the intraoperative frontal electroencephalography dynamics and postoperative sleep disturbance during gynecological laparoscopic surgery: a double-blind, randomized clinical trial. Int J Surg. 2025;111(10):6988-7000. https://doi.org/10.1097/js9.0000000000002836 https://www.harmreductionadvocate.com/educational-resources/obsessive-compulsive-disorder monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223801994-BQRPCI3XXP404W2U2FT5/illustration-obsessive-compulsive-disorder.jpg Educational Resources - Obsessive-Compulsive Disorder https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a0577280-818d-42c7-a0c3-b2b7a4fec3fa/study-1.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Moreno FA, Allen KE, Wiegand CB, et al. A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder. J Psychopharmacol. 2026;40(5):837-849. https://doi.org/10.1177/02698811261424214 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/827341ea-2d25-4770-811f-21bb014c21db/study-2.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pellegrini L, Fineberg NA, O'Connor S, et al. Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study. Compr Psychiatry. 2025;142:152619. https://doi.org/10.1016/j.comppsych.2025.152619 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/50b23a92-0c8c-46f9-aa0a-cbc8a2c83770/study-3.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Beaglehole B, Glue P, Neehoff S, et al. Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study. J Psychopharmacol. 2025;39(1):23-28. https://doi.org/10.1177/02698811241301215 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/aca22347-21f8-4f80-8001-ec9cb277dfbd/study-4.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735-1740. https://doi.org/10.4088/jcp.v67n1110 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/dcc9b481-9b14-4dac-9cd1-aa37477dcbaf/study-5.png Educational Resources - Obsessive-Compulsive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):2475-2483. https://doi.org/10.1038/npp.2013.150 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f702c498-cb71-402b-b69f-3ddd273236ea/study-6.png Educational Resources - Obsessive-Compulsive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Heroiu I, Le GH, Sioufi MC, et al. Ketamine for the Treatment of Obsessive-Compulsive Disorder (OCD): A Systematic Review on Efficacy and Tolerability. Clin Neuropharmacol. 2026. https://doi.org/10.1097/wnf.0000000000000692 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f1617213-cdc1-4c19-83a4-17c2ef3dfb55/study-7.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Shnayder S, Agin-Liebes G, Hubert TJ, et al. Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD. Front Psychiatry. 2026;17:1799543. https://doi.org/10.3389/fpsyt.2026.1799543 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e220a9fc-eeec-44e9-ac81-eae0ac733f1f/study-8.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ferguson AA, Khan AI, Abuzainah B, et al. Clinical Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Adult Obsessive-Compulsive Disorder (OCD) Treatment: A Systematic Review. Cureus. 2023;15(4):e37833. https://doi.org/10.7759/cureus.37833 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bf5bb48f-ea23-4ef6-b34e-5f09548b1d7a/study-9.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: López-Rodríguez S, Segalàs C, Real E, et al. Repeated intranasal esketamine augmentation in treatment-resistant obsessive-compulsive disorder with comorbid major depressive disorder: a prospective case series. BMC Psychiatry. 2026;26(1):469. https://doi.org/10.1186/s12888-026-08119-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/27b3e0c7-fb76-4516-a630-3c6e44343b2c/study-10.png Educational Resources - Obsessive-Compulsive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Alves-Pereira R, Fontes M, Cordeiro V, et al. Esketamine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Retrospective Chart Review. Clin Neuropharmacol. 2024;47(1):17-21. https://doi.org/10.1097/wnf.0000000000000578 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/64263a4f-e7fe-4e06-8460-57439a4e8c9f/study-11.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Beaglehole B, Glue P, Neehoff S, et al. Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder. J Psychopharmacol. 2025;39(6):571-576. https://doi.org/10.1177/02698811251344710 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b94ecb55-8d62-489b-ad1d-281e15edff3c/study-12.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Marmureanu M, Besoiu MV, Dionisie V, et al. Ketamine and Esketamine in Obsessive-Compulsive Disorder: A Scoping Review of Clinical and Mechanistic Evidence. Pharmaceuticals (Basel). 2026;19(4):628. https://doi.org/10.3390/ph19040628 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/98139598-c732-4df7-9fb3-7e398cf6cccf/study-13.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Buot A, Pallares C, Oganesyan A, et al. Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey. Sci Rep. 2023;13(1):13378. https://doi.org/10.1038/s41598-023-39812-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/81e12a50-ea65-4c2d-880c-3a6cad3de13b/study-14.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Agin-Liebes G, Shnayder S, Fram G, et al. Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD. Front Psychiatry. 2026;17:1791689. https://doi.org/10.3389/fpsyt.2026.1791689 https://www.harmreductionadvocate.com/educational-resources/personality-and-traits monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223987814-5P46YIIHCN5901YY2DG8/illustration-personality-and-traits.jpg Educational Resources - Personality and Traits https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/77f29a96-8d8d-4235-b1c3-bd3fe926e4a2/study-1.png Educational Resources - Personality and Traits Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Weiss B, Ginige I, Shannon L, Giribaldi B, Murphy-Beiner A, Murphy R, et al. Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychological medicine. 2024;54(1):178-192. https://doi.org/10.1017/s0033291723001514 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/284752dd-ab0c-4745-a413-3ea50c1b3677/study-2.png Educational Resources - Personality and Traits Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pagni BA, Zeifman RJ, Mennenga SE, Carrithers BM, Goldway N, Bhatt S, et al. Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial. The American journal of psychiatry. 2025;182(1):114-125. https://doi.org/10.1176/appi.ajp.20230887 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7c63ff5c-4f86-40ea-b895-aa1fa3b2a1c4/study-3.png Educational Resources - Personality and Traits Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, Carhart-Harris RL. Effects of psilocybin therapy on personality structure. Acta psychiatrica Scandinavica. 2018;138(5):368-378. https://doi.org/10.1111/acps.12904 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/10762201-47e7-47aa-ba51-2e21eacbaea6/study-4.png Educational Resources - Personality and Traits Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Netzband N, Ruffell S, Linton S, et al. Modulatory effects of ayahuasca on personality structure in a traditional framework. Psychopharmacology (Berl). 2020;237(10):3161-3171. https://doi.org/10.1007/s00213-020-05601-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/75fe2a82-d8c6-40fc-b3f7-52fda88bc84a/study-5.png Educational Resources - Personality and Traits Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Vicentini AB, de Paula CC, Silva Reis JA, et al. Classic psychedelics and personality: An updated systematic review. J Psychopharmacol. 2026;40(8):1187-1212. https://doi.org/10.1177/02698811261449386 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c0935ea9-e835-4573-979e-af55f45de1c8/study-6.png Educational Resources - Personality and Traits Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Weiss B, Miller JD, Carter NT, Keith Campbell W. Examining changes in personality following shamanic ceremonial use of ayahuasca. Sci Rep. 2021;11(1):6653. https://doi.org/10.1038/s41598-021-84746-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d8b84b02-7601-482d-8e5b-df6d9d7ca647/study-7.png Educational Resources - Personality and Traits Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sjöström DK, Claesdotter-Knutsson E, Kajonius PJ. Personality traits explain the relationship between psychedelic use and less depression in a comparative study. Sci Rep. 2024;14(1):10195. https://doi.org/10.1038/s41598-024-60890-1 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f79dd123-6fd3-463e-8fa5-072942173cba/study-8.png Educational Resources - Personality and Traits Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Carhart-Harris RL, Kaelen M, Bolstridge M, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016;46(7):1379-1390. https://doi.org/10.1017/s0033291715002901 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c52700a9-a3b6-4cd6-bd57-081aaacf5534/study-9.png Educational Resources - Personality and Traits Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Godfrey K, Weiss B, Zhang X, et al. An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers. Neurosci Appl. 2025;4:104092. https://doi.org/10.1016/j.nsa.2024.104092 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/03132594-416f-41a9-a765-496403dadb8b/study-10.png Educational Resources - Personality and Traits Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Irrmischer M, Puxty D, Yıldırım BO, et al. Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation. Psychopharmacology (Berl). 2025;242(4):725-740. https://doi.org/10.1007/s00213-024-06733-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0d6bd05c-6092-407e-a857-24f1db22580d/study-11.png Educational Resources - Personality and Traits Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Perkins D, Pagni BA, Sarris J, et al. Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study. Front Pharmacol. 2022;13:884703. https://doi.org/10.3389/fphar.2022.884703 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/129048f7-d657-4026-9ca6-6f03a684459c/study-12.png Educational Resources - Personality and Traits Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Orłowski P, Ruban A, Szczypiński J, et al. Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences. J Psychopharmacol. 2022;36(8):987-1000. https://doi.org/10.1177/02698811221089034 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/13e282e6-fd51-494c-a30d-237a533a020a/study-13.png Educational Resources - Personality and Traits Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: van Mulukom V, Patterson RE, van Elk M. Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism. Psychopharmacology (Berl). 2020;237(9):2725-2737. https://doi.org/10.1007/s00213-020-05568-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/90bb6076-c4c2-47ab-8bfc-0853e9bbb02b/study-14.png Educational Resources - Personality and Traits Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nour MM, Evans L, Carhart-Harris RL. Psychedelics, Personality and Political Perspectives. J Psychoactive Drugs. 2017;49(3):182-191. https://doi.org/10.1080/02791072.2017.1312643 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/643d53b5-32e7-4c5e-8376-ad069eac03a3/study-15.png Educational Resources - Personality and Traits Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Weiss B, Sleep CE, Beller NM, et al. Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: Toward a holistic model. Journal of Psychedelic Studies. 2023. https://doi.org/10.1556/2054.2023.00291 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f3eb7320-0352-4f1f-8d33-0235cf61dc7d/study-16.png Educational Resources - Personality and Traits Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Krabbe A, Sikka P, Jylkkä J. Acceptance as a possible link between past psychedelic experiences and psychological flexibility. Sci Rep. 2024;14(1):24253. https://doi.org/10.1038/s41598-024-75595-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a3f2a991-facf-4e07-8bf6-c76c60a138aa/study-17.png Educational Resources - Personality and Traits Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Erritzoe D, Smith J, Fisher PM, et al. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers. J Psychopharmacol. 2019;33(9):1068-1075. https://doi.org/10.1177/0269881119827891 https://www.harmreductionadvocate.com/educational-resources/microdosing monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793224008208-CD5IEKOQV40CP0W3MUUM/illustration-microdosing.jpg Educational Resources - Microdosing https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2f793b7b-059e-4440-adc0-0ef57a95e8b1/study-1.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mueller L, Santos de Jesus J, Schmid Y, et al. Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(6):555-562. https://doi.org/10.1001/jamapsychiatry.2025.0044 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1edeaf6f-a020-48d2-8d03-8489c2448424/study-2.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Murphy RJ, Sumner R, Evans W, et al. Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial. Biol Psychiatry. 2023;94(6):511-521. https://doi.org/10.1016/j.biopsych.2023.03.013 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6a4f0cd4-b577-484a-8e15-7c14121e42c1/study-3.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Polito V, Stevenson RJ. A systematic study of microdosing psychedelics. PLoS One. 2019;14(2):e0211023. https://doi.org/10.1371/journal.pone.0211023 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/54e28630-5eee-4232-abb7-ee1f9eebf570/study-4.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Szigeti B, Kartner L, Blemings A, et al. Self-blinding citizen science to explore psychedelic microdosing. Elife. 2021;10:e62878. https://doi.org/10.7554/elife.62878 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9a0ab6f7-f764-4d71-bf8b-23bf39bc4345/study-5.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Daldegan-Bueno D, Donegan CJ, Sumner R, et al. LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial. Prog Neuropsychopharmacol Biol Psychiatry. 2026;145:111645. https://doi.org/10.1016/j.pnpbp.2026.111645 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d27d59cd-f15b-4662-978b-f7f6f271eb24/study-6.png Educational Resources - Microdosing Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Murray CH, Tare I, Perry CM, et al. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Psychopharmacology (Berl). 2022;239(6):1735-1747. https://doi.org/10.1007/s00213-021-05991-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/925774e9-eb64-4402-9736-f5cd9a53e29d/study-7.png Educational Resources - Microdosing Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Petranker R, Anderson T, Maier LJ, et al. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. J Psychopharmacol. 2022;36(1):85-96. https://doi.org/10.1177/0269881120953994 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c3f62cda-5803-4628-8945-8a689f18790d/study-8.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Downar J, Lapenskie J, Anderson K, et al. PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial. Palliat Med. 2026;40(4):514-523. https://doi.org/10.1177/02692163261416269 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/22f72891-4abf-4a5a-89e1-bee8716298fb/study-9.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rootman JM, Kiraga M, Kryskow P, et al. Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. Sci Rep. 2022;12(1):11091. https://doi.org/10.1038/s41598-022-14512-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/94a93027-3f80-45cc-9093-82832102f2c8/study-10.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hutten NRPW, Mason NL, Dolder PC, et al. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. Eur Neuropsychopharmacol. 2020;41:81-91. https://doi.org/10.1016/j.euroneuro.2020.10.002 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a0661b3c-172c-408f-9d11-45b933e131f1/study-11.png Educational Resources - Microdosing Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hutten NRPW, Mason NL, Dolder PC, et al. Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers. ACS Pharmacol Transl Sci. 2021;4(2):461-466. https://doi.org/10.1021/acsptsci.0c00099 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7ea437c3-ecf3-420b-9429-cbb2c3232e74/study-12.png Educational Resources - Microdosing Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Cameron LP, Nazarian A, Olson DE. Psychedelic Microdosing: Prevalence and Subjective Effects. J Psychoactive Drugs. 2020;52(2):113-122. https://doi.org/10.1080/02791072.2020.1718250 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bcc9eba4-560d-47c1-a681-03cf3cde4f71/study-13.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Polito V, Liknaitzky P. Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research. J Psychopharmacol. 2024;38(8):701-711. https://doi.org/10.1177/02698811241254831 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9f5f317a-3c08-4eaa-b81e-f97d9b71226e/study-14.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC. Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers. Front Psychiatry. 2019;10:672. https://doi.org/10.3389/fpsyt.2019.00672 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/23604a94-6ade-4123-93fb-7ea272a551dc/study-15.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: van Elk M, Fejer G, Lempe P, et al. Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study. Psychopharmacology (Berl). 2022;239(6):1705-1720. https://doi.org/10.1007/s00213-021-05857-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/37a3623d-29cc-490c-a344-db97544ded7d/study-16.png Educational Resources - Microdosing Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Totomanova I, Haijen ECHM, Hurks PPM, et al. Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry? Int Rev Neurobiol. 2025;181:231-268. https://doi.org/10.1016/bs.irn.2025.03.002 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/dff640a9-bc39-437b-9ac9-224ca14572de/study-17.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Daldegan-Bueno D, Donegan CJ, Sumner R, et al. LSD microdosing in major depressive disorder: results from an open-label trial. Neuropharmacology. 2026;283:110762. https://doi.org/10.1016/j.neuropharm.2025.110762 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4471d950-1461-48f0-b63c-f26b1fa60efb/study-18.png Educational Resources - Microdosing Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lea T, Amada N, Jungaberle H, et al. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. Psychopharmacology (Berl). 2020;237(5):1521-1532. https://doi.org/10.1007/s00213-020-05477-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/38e8b6f6-d633-4743-af2e-013d968a414c/study-19.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Page J, Moore A, Hawkins BE, et al. The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing. Front Psychiatry. 2026;17:1866881. https://doi.org/10.3389/fpsyt.2026.1866881 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ef1ddc0b-ea1a-4375-bb0d-c8dffeeab4c6/study-20.png Educational Resources - Microdosing Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Molla H, Lee R, Tare I, de Wit H. Greater subjective effects of a low dose of LSD in participants with depressed mood. Neuropsychopharmacology. 2024;49(5):774-781. https://doi.org/10.1038/s41386-023-01772-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b3e52c43-eeb2-49f3-ab97-d36830142c01/study-21.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pop I, Dinkelacker J. Unlocking the self: Can microdosing psychedelics make one feel more authentic? Nordisk Alkohol Nark. 2024;41(2):142-155. https://doi.org/10.1177/14550725231175353 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a56b121e-edfe-47ab-8c7e-7fbddc6b78f2/study-22.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rootman JM, Kryskow P, Harvey K, et al. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Sci Rep. 2021;11(1):22479. https://doi.org/10.1038/s41598-021-01811-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a55ed2ca-119c-4820-8694-b3d413d453a9/study-23.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Joy Donegan C, Daldegan-Bueno D, Sumner RL, et al. What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial. Ther Adv Psychopharmacol. 2025;15:20451253251396253. https://doi.org/10.1177/20451253251396253 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/353ad5e5-dc9c-43d6-a564-d14daac381c5/study-24.png Educational Resources - Microdosing Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Glazer J, Murray CH, Nusslock R, et al. Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity. Neuropsychopharmacology. 2023;48(2):418-426. https://doi.org/10.1038/s41386-022-01479-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0a267571-7e95-4fd0-93a9-a8ecfc17a7d1/study-25.png Educational Resources - Microdosing Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Enriquez-Geppert S, Krc J, O'Higgins FJ, Lietz M. Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study. Philos Trans R Soc Lond B Biol Sci. 2024;379(1915):20230095. https://doi.org/10.1098/rstb.2023.0095 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/512d6c9f-5e80-4a3b-b109-3a7367983e73/study-26.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kuypers KPC. The therapeutic potential of microdosing psychedelics in depression. Ther Adv Psychopharmacol. 2020;10:2045125320950567. https://doi.org/10.1177/2045125320950567 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4e7e19bf-2d00-4b5a-ba28-9c220e4e93cd/study-27.png Educational Resources - Microdosing Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Atoian A, Bowles H, Gerhke S, et al. Micro-dose, macro-impact: Leveraging psychedelics in frontline healthcare workers during the COVID-19 pandemic. Journal of Psychedelic Studies. 2023. https://doi.org/10.1556/2054.2022.00227 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/eb002d4c-931c-41c0-9386-cf5fbb43d293/study-28.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Anderson T, Petranker R, Christopher A, et al. Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduct J. 2019;16(1):43. https://doi.org/10.1186/s12954-019-0308-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d2d192c0-b353-4dc1-bd9a-903c937490d9/study-29.png Educational Resources - Microdosing Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dressler HM, Bright SJ, Polito V. Exploring the relationship between microdosing, personality and emotional insight: A prospective study. Journal of Psychedelic Studies. 2021. https://doi.org/10.1556/2054.2021.00157 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f5321842-6ac8-4bd8-a9ba-6b799c6336c9/study-30.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ryan RS, Copello A, Fox AP. Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health. BMC Psychiatry. 2023;23(1):160. https://doi.org/10.1186/s12888-023-04628-9 https://www.harmreductionadvocate.com/educational-resources/drug-development-and-new-compounds monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793224019768-KZ7RLFNG6AD9V22UZOD7/illustration-drug-development-and-new-compounds.jpg Educational Resources - Drug Development and New Compounds https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2dd1f309-be9f-4969-a61d-c558fbdf9867/study-1.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: James E, Erritzoe D, Benway T, et al. Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial. Front Psychiatry. 2023;14:1305796. https://doi.org/10.3389/fpsyt.2023.1305796 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/334a81d3-a007-4c34-9642-46f06914b332/study-2.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rucker JJ, Roberts C, Seynaeve M, et al. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. J Psychopharmacol. 2024;38(8):712-723. https://doi.org/10.1177/02698811241246857 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a990ee6c-ff6c-48bc-8258-71140bf47174/study-3.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648. https://doi.org/10.1056/nejmoa2206443 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b886bab6-7f8a-4439-bada-13f7679cf3ae/study-4.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Robison R, Barrow R, Conant C, et al. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA. 2025;334(15):1358-1372. https://doi.org/10.1001/jama.2025.13481 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e8b90513-ff52-49ae-9238-14fb55d4ac3f/study-5.png Educational Resources - Drug Development and New Compounds Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Shelton RC, Litman RE, Hassman H, et al. Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study. J Clin Psychiatry. 2025;86(3):23m15246. https://doi.org/10.4088/jcp.23m15246 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/527b1f4c-065e-481e-94c6-4990afea25c9/study-6.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Erne L, Vogt SB, Müller L, et al. Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants. Neuropsychopharmacology. 2025;50(6):1008-1016. https://doi.org/10.1038/s41386-024-02041-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9e2b22dc-8a70-4d70-80e1-c684cc15a570/study-7.png Educational Resources - Drug Development and New Compounds Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Johnson MW, MacLean KA, Reissig CJ, et al. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend. 2011;115(1-2):150-155. https://doi.org/10.1016/j.drugalcdep.2010.11.005 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0dabf819-913c-4d1e-9333-ad0516f63f2f/study-8.png Educational Resources - Drug Development and New Compounds Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Preskorn S, Macaluso M, Mehra DO, et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21(2):140-149. https://doi.org/10.1097/01.pra.0000462606.17725.93 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b7f2609d-5e08-43dc-8902-1dcc3ad9cbdd/study-9.png Educational Resources - Drug Development and New Compounds Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Collyer C, Le GH, Hassan M, et al. Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2026;150:111966. https://doi.org/10.1016/j.pnpbp.2026.111966 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1b7c3c2f-34d9-4074-b613-9f6f24c119b0/study-10.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Garcia-Romeu A, Barrett FS, Carbonaro TM, et al. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. J Psychopharmacol. 2021;35(4):353-361. https://doi.org/10.1177/0269881121991822 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1f87fdf1-6e3c-44a2-9b87-74ba2e539a73/study-11.png Educational Resources - Drug Development and New Compounds Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016;3(5):481-488. https://doi.org/10.1016/s2215-0366(15)00576-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/85bbcb97-6cea-4dd2-89e6-339976670539/study-12.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Arikci D, Borgulya J, Straumann I, et al. Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants. Neuropsychopharmacology. 2026;51(8):1511-1518. https://doi.org/10.1038/s41386-026-02428-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5b551376-ff6b-47db-9bd6-6f61e8940105/study-13.png Educational Resources - Drug Development and New Compounds Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: van der Heijden KV, Jacobs GE, James EH, et al. Safety, pharmacokinetics, and pharmacodynamics of intravenously administered deuterated N,N-dimethyltryptamine (CYB004) in healthy volunteers. J Psychopharmacol. 2026:2698811261478616. https://doi.org/10.1177/02698811261478616 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/89844dd9-1d6f-4373-bd0e-2b8a91ecc95f/study-14.png Educational Resources - Drug Development and New Compounds Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Baggott MJ, Garrison KJ, Coyle JR, et al. Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. J Psychoactive Drugs. 2019;51(2):108-117. https://doi.org/10.1080/02791072.2019.1593560 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b67522e7-6d66-4b1b-ae4f-28522f38f069/study-15.png Educational Resources - Drug Development and New Compounds Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Perkins D, Halman A, Urokohara A, et al. Acute experiences and persisting psychological effects associated with an encapsulated DMT-harmala alkaloid combination: results of a phase 1 study. Sci Rep. 2025;15(1):41152. https://doi.org/10.1038/s41598-025-25767-x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/dbb51293-e6a1-426c-852f-f64a460eace2/study-16.png Educational Resources - Drug Development and New Compounds Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ludbrook G, Bryson N, Taylor B, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study. J Clin Psychopharmacol. 2025;45(5):441-453. https://doi.org/10.1097/jcp.0000000000002047 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d4ed0436-d6be-43ea-b5bf-f8b697071e46/study-17.png Educational Resources - Drug Development and New Compounds Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry. 2020;177(5):391-410. https://doi.org/10.1176/appi.ajp.2019.19010035 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/07b4dd95-33da-4a29-9943-6919b3aecee7/study-18.png Educational Resources - Drug Development and New Compounds Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Mathai DS, Hilbert S, Sepeda ND, et al. Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers. Psychedelic Med (New Rochelle). 2023;1(4):241-252. https://doi.org/10.1089/psymed.2023.0035 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0950bca2-e360-4af5-9414-1be460407772/study-19.png Educational Resources - Drug Development and New Compounds Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Glue P, Medlicott NJ, Surman P, et al. Ascending-Dose Study of Controlled-Release Ketamine Tablets in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability. J Clin Pharmacol. 2020;60(6):751-757. https://doi.org/10.1002/jcph.1573 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5549e58d-9e54-477d-9837-27fefe356a49/study-20.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Vogt SB, Ley L, Erne L, et al. Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Transl Psychiatry. 2023;13(1):172. https://doi.org/10.1038/s41398-023-02477-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/046684bb-9770-4ef6-8851-52c36463a7a2/study-21.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Reckweg JT, Uthaug MV, Szabo A, et al. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). J Neurochem. 2022;162(1):128-146. https://doi.org/10.1111/jnc.15587 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/68ccf2cf-f419-4edf-8df1-c8d5222cbbbf/study-22.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bonomo YA, Norman AF, Collins L, et al. DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers. Front Psychiatry. 2025;16:1545915. https://doi.org/10.3389/fpsyt.2025.1545915 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/18bc4229-fc24-46fe-861f-d3ffb6b83a8c/study-23.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Erne L, Mueller L, Straumann I, et al. Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants. Transl Psychiatry. 2026;16(1):213. https://doi.org/10.1038/s41398-026-03987-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/12dc2344-d844-4f8a-9eae-1a933dfc2667/study-24.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Raja SM, Guptill JT, Mack M, et al. A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers. Clin Pharmacol Ther. 2024;116(5):1314-1324. https://doi.org/10.1002/cpt.3391 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/757fea23-d478-466a-82fb-cef961e83b5a/study-25.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Dornbierer DA, Marten L, Mueller J, et al. Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine. Front Pharmacol. 2023;14:1246892. https://doi.org/10.3389/fphar.2023.1246892 https://www.harmreductionadvocate.com/educational-resources/implementation-and-service-delivery monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793224049715-A5K0CQAVCYWLPQHL1M20/illustration-implementation-and-service-delivery.jpg Educational Resources - Implementation and Service Delivery https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f74bfb09-2486-46c2-afd3-e847a59486c3/study-1.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Korthuis PT, Cook RR, Gregoire D, et al. Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services. JAMA Netw Open. 2026;9(8):e2630608. https://doi.org/10.1001/jamanetworkopen.2026.30608 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c6bc3483-8068-41e3-b6e5-0400693e3be6/study-2.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rucker JJ, Mantingh T, Kerr-Gaffney J, et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nat Med. 2026;32(9):3430-3437. https://doi.org/10.1038/s41591-026-04541-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/04ce5e56-eedb-404b-9684-6d92a48570b4/study-3.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lewis BR, Hendrick J, Byrne K, et al. Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLoS Med. 2025;22(9):e1004519. https://doi.org/10.1371/journal.pmed.1004519 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/88d85d89-2952-4657-b05b-9ffe40bc4c9d/study-4.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Dorval M, Audet-Croteau V, Chang SL, et al. Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation. Healthcare (Basel). 2026;14(11):1559. https://doi.org/10.3390/healthcare14111559 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/65e2b25c-db47-4c67-9d25-17db13db8cbd/study-5.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Tai SJ, Nielson EM, Lennard-Jones M, et al. Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research. Front Psychiatry. 2021;12:586682. https://doi.org/10.3389/fpsyt.2021.586682 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/799aea9e-6b12-40ee-a9da-212f13fc3689/study-6.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Li I, Fong R, Hagen M, Tabaac B. Medical student attitudes and perceptions of psychedelic-assisted therapies. Front Psychiatry. 2023;14:1190507. https://doi.org/10.3389/fpsyt.2023.1190507 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bb0537c5-0299-43ab-bfce-2e1828656694/study-7.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hu B, Ortiz-Cruz A, Sachidanandan R, et al. Implementation and Preliminary Evaluation of an Intravenous Ketamine Protocol for Psychiatric Conditions in Medical and Surgical Units: A 1-Year Pilot Study. J Acad Consult Liaison Psychiatry. 2026:S2667-2960(26)00103-5. https://doi.org/10.1016/j.jaclp.2026.09.005 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/344bc62e-4e75-434f-b283-02253ce58b69/study-8.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wang E, Mathai DS, Gukasyan N, et al. Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. Sci Rep. 2024;14(1):28022. https://doi.org/10.1038/s41598-024-78736-1 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/986bf4fe-941d-4117-b9e7-40d40c3b0c98/study-9.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Barnett BS, Arakelian M, Beebe D, et al. American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey. Psychedelic Med (New Rochelle). 2024;2(1):1-9. https://doi.org/10.1089/psymed.2023.0036 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/18298bda-5f2e-48ff-bfb3-292e12cf0de7/study-10.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Corrigan K, Haran M, McCandliss C, et al. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. Ir J Med Sci. 2022;191(3):1385-1397. https://doi.org/10.1007/s11845-021-02668-2 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0a1b66b9-7250-404b-b1e8-d426923bc2f7/study-11.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Nadeem Z, Parker S, McGovern H, Oestreich LK. Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia. Aust N Z J Psychiatry. 2024;58(10):904-913. https://doi.org/10.1177/00048674241261779 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4ff3635f-9e94-45c4-8a27-12a24fbab28c/study-12.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Giovannetti C, Loizaga-Velder A, Rush B, et al. Intercultural pathways to indigenous mental health: the integration of ayahuasca in community care in the Yaqui intercultural medicine clinic in Sonora, Mexico. Front Public Health. ;14. https://doi.org/10.3389/fpubh.2026.1918846 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8f87d528-2ee9-4269-9876-aee8bd799f2e/study-13.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Song-Smith C, Jacobs E, Rucker J, et al. UK medical students' self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study. BMJ Open. 2024;14(3):e083595. https://doi.org/10.1136/bmjopen-2023-083595 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8cfba682-9597-4004-ab40-5a5926ab3070/study-14.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dore J, Turnipseed B, Dwyer S, et al. Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. J Psychoactive Drugs. 2019;51(2):189-198. https://doi.org/10.1080/02791072.2019.1587556 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ba2dec3c-3330-46e9-b3fb-d7577f5c3976/study-15.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Spriggs MJ, Giribaldi B, Lyons T, et al. Body mass index (BMI) does not predict responses to psilocybin. J Psychopharmacol. 2023;37(1):107-116. https://doi.org/10.1177/02698811221131994 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/83e51bf0-dd2a-4a8b-a5de-828faafc306c/study-16.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Stefanuk I, Chivers-Wilson K, Jetly R, et al. A retrospective report of a ketamine-augmented, transdiagnostic psychiatric outpatient psychotherapy program. J Mil Veteran Fam Health. 2026;12(1):65-75. https://doi.org/10.3138/jmvfh-2025-0009 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3fcd0920-63ea-49af-8ac1-6a6cbea8475e/study-17.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bhuiya NMA, Jacobs RJ, Wang K, et al. Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin. Cureus. 2023;15(9):e45169. https://doi.org/10.7759/cureus.45169 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b3536007-8806-407b-855f-29ab153ba28e/study-18.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Liechti ME, Gasser P, Aicher HD, et al. Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program. Neurosci Appl. 2025;4:105525. https://doi.org/10.1016/j.nsa.2025.105525 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1827dd77-6073-4411-8c9e-17f58f9a8f86/study-19.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Page LA, Rehman A, Syed H, et al. The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy. Front Psychiatry. 2021;12:743599. https://doi.org/10.3389/fpsyt.2021.743599 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3e50b0a7-1c9c-4869-858e-6c6a517e0381/study-20.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Louie E, Towers E, Morse AR, et al. The Acceptability of Psychedelic-Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour. Int J Ment Health Nurs. 2025;34(1):e70010. https://doi.org/10.1111/inm.70010 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ed952263-5250-4045-b6a7-9e8901db336d/study-21.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ware OD. Mental health facilities with ketamine infusion therapy in the United States in 2020: Co-location of dual diagnosis mental health and substance use disorder treatment. Exp Clin Psychopharmacol. 2024;32(3):263-269. https://doi.org/10.1037/pha0000686 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e752a0c4-f1ad-4309-a5cd-b929efac0f3a/study-22.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Barta S, Brooker J, O'Callaghan C. Health Care Workers' Attitudes Toward and Knowledge of the Clinical Application of Classic Psychedelics for People with Serious Illness: A Systematic Review. J Palliat Med. 2025;28(6):815-828. https://doi.org/10.1089/jpm.2024.0306 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/753d88fb-bcae-40ee-836e-c30496b61c72/study-23.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Barnett BS, Beaussant Y, King F, Doblin R. Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey. J Psychoactive Drugs. 2022;54(3):269-277. https://doi.org/10.1080/02791072.2021.1957183 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1b3c651d-8adb-4af4-864c-b291aafc9df6/study-24.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Nadeem Z, Parker S, McGovern H, et al. Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers. Aust N Z J Psychiatry. 2025;59(9):798-809. https://doi.org/10.1177/00048674251346679 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3aed984a-1c61-4f96-8586-004b29e0b0a1/study-25.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Whitfield HJ, Schepers J, Mason NL, et al. Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventions. Journal of Psychedelic Studies. 2026. https://doi.org/10.1556/2054.2026.00530 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/aec8a838-40d3-4450-b1cc-ab5af7a2c63e/study-26.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Davis AK, Agin-Liebes G, España M, et al. Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. J Psychoactive Drugs. 2022;54(4):309-318. https://doi.org/10.1080/02791072.2021.1971343 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8a8f5354-5671-4bd7-9f5e-fd8d0855eedf/study-27.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Koolen M, Wirsching A, Krediet E, van Elk M. Assessing the Attitudes of Dutch Mental Health Care Professionals Toward Psychedelic-Assisted Psychotherapy: A Cross-Sectional Exploratory Study. J Psychoactive Drugs. 2025:1-11. https://doi.org/10.1080/02791072.2025.2508156 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/901ab6ea-d663-4c22-98c5-4cd6ee4adb0b/study-28.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Mitchell J, Neitzke-Spruill L, Mathai DS, et al. From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care. Transl Behav Med. 2026;16(1):ibag027. https://doi.org/10.1093/tbm/ibag027 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e2d0d2d6-d83b-481c-b728-a82bb68179e0/study-29.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Breeksema JJ, Niemeijer AR, Krediet E, et al. Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies. CNS Drugs. 2020;34(9):925-946. https://doi.org/10.1007/s40263-020-00748-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a0f0ec89-d903-41f3-9b68-c07ba8fd0b4e/study-30.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Buot A, Burdairon JD, Mallet L, et al. French psychiatric caregivers' perceptions of psychedelics: A national survey. Encephale. 2026:S0013-7006(26)00186-7. https://doi.org/10.1016/j.encep.2026.06.015 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/da4c2e9b-4b2a-4b4e-8b88-40a32387c013/study-31.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Castellano-Ramírez D, Hernández-Álvarez E, Borkel LF, et al. Attitudes toward psychedelic therapy among medical and nursing students: A cross-sectional survey study. PLoS One. 2026;21(3):e0344698. https://doi.org/10.1371/journal.pone.0344698 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ea4421e4-54ca-4b7c-8f6e-604ef4799e40/study-32.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lam K, Griffin C, Kantipudi S, et al. Assessing readiness for implementation of psychedelic-assisted mental health therapy, in low- and middle-income countries. Journal of Psychedelic Studies. 2026. https://doi.org/10.1556/2054.2025.00432 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a194eae5-8d02-4e02-be78-e2757132be8d/study-33.png Educational Resources - Implementation and Service Delivery Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Glynos NG, Baker A, Aday JS, et al. Going Underground: Demographics, Services, and Best Practices Endorsed by Practitioners Providing Support for Naturalistic Psychedelic Use. J Psychoactive Drugs. 2025;57(5):475-485. https://doi.org/10.1080/02791072.2024.2405685 https://www.harmreductionadvocate.com/educational-resources/health-economics-and-coverage monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793224043348-M9B36NJO01QVBS1XYJO3/illustration-health-economics-and-coverage.jpg Educational Resources - Health Economics and Coverage https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4ef77fb3-c91b-44a0-8c2a-4d81701080bd/study-1.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Marseille E, Mitchell JM, Kahn JG. Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial. PLoS One. 2022;17(2):e0263252. https://doi.org/10.1371/journal.pone.0263252 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/cf1f7ca0-fb09-470c-99f9-0382320a071e/study-2.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lebenbaum M, Mulsant B, Parikh SV, et al. Ketamine Versus Electroconvulsive Therapy for Nonpsychotic Treatment-Resistant Depression: A Cost-Effectiveness Analysis. Psychiatr Serv. 2026. https://doi.org/10.1176/appi.ps.20240407 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b196ff84-02db-4d09-a94c-2a28b22bf2c4/study-3.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Chatterton ML, Perez JK, Thai T, et al. Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS study. J Affect Disord. 2025;387:119502. https://doi.org/10.1016/j.jad.2025.119502 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c2b83b6f-a8e7-4f1b-ad69-057ed96e3410/study-4.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: McCrone P, Fisher H, Knight C, et al. Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model. Psychol Med. 2023;53(16):7619-7626. https://doi.org/10.1017/s0033291723001411 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4bae306c-79ef-435d-8b9a-627738c2be43/study-5.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Marseille E, Kahn JG, Yazar-Klosinski B, Doblin R. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. PLoS One. 2020;15(10):e0239997. https://doi.org/10.1371/journal.pone.0239997 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/98ea15cc-40e1-4037-83b2-4fa4926fcf10/study-6.png Educational Resources - Health Economics and Coverage Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Brendle M, Robison R, Malone DC. Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates. J Affect Disord. 2022;319:388-396. https://doi.org/10.1016/j.jad.2022.09.083 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f8694eb7-6bf3-41be-9133-c5caa007366a/study-7.png Educational Resources - Health Economics and Coverage Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Khan KA, Smyth M, Perkins GD, et al. Cost-effectiveness of paramedic administered ketamine compared to morphine for the management of acute severe pain from traumatic injury. Cost Eff Resour Alloc. 2026;24(1):28. https://doi.org/10.1186/s12962-025-00712-x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/19a7f3c9-145b-4e09-8129-4366c58215e9/study-8.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Avanceña ALV, Kahn JG, Marseille E. The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study. Clin Drug Investig. 2022;42(3):243-252. https://doi.org/10.1007/s40261-022-01122-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1990e9b1-0981-46b1-a58d-c2beb73c165d/study-9.png Educational Resources - Health Economics and Coverage Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Joshi K, Pilon D, Shah A, et al. Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans. J Med Econ. 2023;26(1):422-429. https://doi.org/10.1080/13696998.2023.2188845 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c5b52d9a-d621-43ac-a6c5-f79aabddddb7/study-10.png Educational Resources - Health Economics and Coverage Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Clemens K, Teeple A, Zhdanava M, et al. Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression. J Clin Psychiatry. 2025;86(1):24m15425. https://doi.org/10.4088/jcp.24m15425 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6ca74f69-58c1-42b9-976d-bf4a74e7bcb0/study-11.png Educational Resources - Health Economics and Coverage Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zhdanava M, Teeple A, Pilon D, et al. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States. J Med Econ. 2023;26(1):691-700. https://doi.org/10.1080/13696998.2023.2208993 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e557d4aa-16cd-4e6e-bc7e-d66ce6ce9755/study-12.png Educational Resources - Health Economics and Coverage Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lu T, D'Angelo S, Tayebali Z, et al. Impact analysis of expanded access to ketamine for treatment-resistant depression. J Comp Eff Res. 2025;14(6):e240233. https://doi.org/10.57264/cer-2024-0233 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8af2b3ad-d8c9-479b-9ea2-a05278987c85/study-13.png Educational Resources - Health Economics and Coverage Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Marseille E, Chernoloz O, Orlov O. The Potential Economic and Public Health Impact of MDMA‐Assisted Group Therapy for PTSD in Ukraine. World Medical & Health Policy. 2025. https://doi.org/10.1002/wmh3.70039 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/840e4e92-8a03-4c6c-9dea-104a2c4e29e5/study-14.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Marseille E, Stauffer CS, Agrawal M, et al. Group psychedelic therapy: empirical estimates of cost-savings and improved access. Front Psychiatry. 2023;14:1293243. https://doi.org/10.3389/fpsyt.2023.1293243 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/df9b5288-b43a-4758-82ee-7fb0776c3398/study-15.png Educational Resources - Health Economics and Coverage Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Clemens K, Teeple A, Rive B, et al. Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression. J Comp Eff Res. 2025;14(7):e240092. https://doi.org/10.57264/cer-2024-0092 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e51e98c3-f000-4564-9841-50a8153f0170/study-16.png Educational Resources - Health Economics and Coverage Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bhatt KV, Austin T, Alam D, et al. Real-World Effectiveness and Cost-Differential of Intranasal Esketamine Versus Intramuscular Ketamine. Psychiatr Res Clin Pract. 2026;8(3):112-119. https://doi.org/10.1176/appi.prcp.20260041 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ba0384c2-8520-4199-855e-67512bdee37c/study-17.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Stanicic F, Zah V, Grbic D, De Angelo D. Cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) in chronic and treatment-resistant post-traumatic stress disorder of moderate or higher severity: A health-economic model. PLoS One. 2024;19(11):e0313569. https://doi.org/10.1371/journal.pone.0313569 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7bdd0031-db5d-46e9-9fce-4b48d233e97b/study-18.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rognoni C, Falivena C, Costa F, Armeni P. Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy. Pharmacoeconomics. 2023;41(2):209-225. https://doi.org/10.1007/s40273-022-01220-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a2a57806-0728-4ca5-828d-e99a7a551f2c/study-19.png Educational Resources - Health Economics and Coverage Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Harding L, Zhdanava M, Teeple A, et al. Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States. Clin Ther. 2025;47(3):189-195. https://doi.org/10.1016/j.clinthera.2024.12.006 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4ef8c289-27e7-411a-bc41-1764ae70db00/study-20.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Avanceña ALV, Vuong L, Kahn JG, Marseille E. Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis. Transl Psychiatry. 2025;15(1):330. https://doi.org/10.1038/s41398-025-03556-4 https://www.harmreductionadvocate.com/educational-resources/equity-and-ethics monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793224037520-38DT6HO6LQRRZH1WBUII/illustration-equity-and-ethics.jpg Educational Resources - Equity and Ethics https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ff7fb8f6-3fda-4b22-92fc-8a25106b71a6/study-1.png Educational Resources - Equity and Ethics Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hughes ME, Garcia-Romeu A. Ethnoracial inclusion in clinical trials of psychedelics: a systematic review. EClinicalMedicine. 2024;74:102711. https://doi.org/10.1016/j.eclinm.2024.102711 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/57807980-2c20-49a4-9798-5499d7d29b1f/study-2.png Educational Resources - Equity and Ethics Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Haft SL, Downey AE, Raymond-Flesch M, et al. A systematic review of participant diversity in psychedelic-assisted psychotherapy trials. Psychiatry Res. 2025;345:116359. https://doi.org/10.1016/j.psychres.2025.116359 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/94a7a481-4073-419c-8766-4bc3407f5e3c/study-3.png Educational Resources - Equity and Ethics Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ham R, Gardner J, Carter A, Liknaitzky P. Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy. Brain Behav. 2026;16(2):e71262. https://doi.org/10.1002/brb3.71262 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/26a4ac24-af93-4b17-bc7a-2326203e27f1/study-4.png Educational Resources - Equity and Ethics Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Yu F, Tafur J, Moreno F, Dahmer S. Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization. Front Psychiatry. 2026;17:1777387. https://doi.org/10.3389/fpsyt.2026.1777387 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fe741f06-dc7c-4c89-92d3-ef9f42ec0245/study-5.png Educational Resources - Equity and Ethics Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Sandbrink JD, Johnson K, Gill M, et al. Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists. AJOB Neurosci. 2024;15(2):82-89. https://doi.org/10.1080/21507740.2024.2303154 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8de07569-c0aa-4cb6-8cfe-ba147cdee710/study-6.png Educational Resources - Equity and Ethics Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lancelotta R, DellaCrosse M, Quinn D, et al. Exploring Self-Reported Effects of Naturalistic Psychedelic Use Among Gender and Sexual Minorities: A Quantitative Survey Study. J Psychoactive Drugs. 2025:1-14. https://doi.org/10.1080/02791072.2025.2520224 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/62d5a3e6-f358-4752-9632-1502a9a3d965/study-7.png Educational Resources - Equity and Ethics Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jones JL. Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory survey among substance users. Front Psychiatry. 2023;14:1096298. https://doi.org/10.3389/fpsyt.2023.1096298 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9c68a8b1-7be6-485d-b8e8-3be20c95b30a/study-8.png Educational Resources - Equity and Ethics Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Carter S, Packard G, Coghlan C, et al. Perceptions of psychedelic-assisted therapy among Black Americans. J Mood Anxiety Disord. 2023;4:100023. https://doi.org/10.1016/j.xjmad.2023.100023 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ba27594d-a9ee-4bc9-b6d3-5330edbe37e0/study-9.png Educational Resources - Equity and Ethics Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lowe MX, Darby QA, Kalcheff-Korn S, Jackson H. LGBTQ+ Ayahuasca Retreat Experience is Associated with Benefits to Mental Health, Quality of Life, and Spiritual Well-Being: A Prospective, Naturalistic Study. J Psychoactive Drugs. 2026:1-12. https://doi.org/10.1080/02791072.2026.2644858 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bcfd1462-5fde-4699-bc95-739a9e80dadc/study-10.png Educational Resources - Equity and Ethics Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Glynos NG, Reid MR, Aday JS, et al. Racial Differences in Naturalistic Psychedelic Use - Motivations for Use, Communication with Health Care Providers, and Outcomes. J Psychoactive Drugs. 2025:1-12. https://doi.org/10.1080/02791072.2025.2491381 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9f14a39b-fd20-43fd-8e2a-60af99076a35/study-11.png Educational Resources - Equity and Ethics Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lovely JJ, Yardley H, Darda R, et al. Evidence in practice: implementing KAT in indigenous health services. Front Psychiatry. 2026;17:1722573. https://doi.org/10.3389/fpsyt.2026.1722573 https://www.harmreductionadvocate.com/educational-resources/public-health-and-prevention monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793224031239-5ZL9QARH7XH7WEVOGDOF/illustration-public-health-and-prevention.jpg Educational Resources - Public Health and Prevention https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/10af738c-a5f7-47c8-ab49-10acd13efa90/study-1.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Krebs TS, Johansen PØ. Psychedelics and mental health: a population study. PLoS One. 2013;8(8):e63972. https://doi.org/10.1371/journal.pone.0063972 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7f937601-a402-4e2f-951b-c51a6bf64a1b/study-2.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015;29(3):280-288. https://doi.org/10.1177/0269881114565653 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7b78f724-540c-4394-bf7a-7f5ec636cf4d/study-3.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. J Psychopharmacol. 2022;36(8):965-973. https://doi.org/10.1177/02698811221084063 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/88e5cf0c-90d6-4bc7-9055-eeb4a10a0254/study-4.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Montoy JCC, Wang RC, Coker AR, Smollin CG, Anderson BT. US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022. J Am Coll Emerg Physicians Open. 2025;6(5):100231. https://doi.org/10.1016/j.acepjo.2025.100231 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a502aa6e-96e3-4aa1-ae03-2a447aa9e76e/study-5.png Educational Resources - Public Health and Prevention Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Johansen PØ, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. 2015;29(3):270-279. https://doi.org/10.1177/0269881114568039 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8d1a40e4-fa57-48cd-ac6a-ab9f2f3dca46/study-6.png Educational Resources - Public Health and Prevention Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lake S, Lucas P. The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs. Psychedelic Med (New Rochelle). 2023;1(2):98-110. https://doi.org/10.1089/psymed.2023.0002 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8f6b97f8-f80b-40a4-bbe2-4797c0ab70bb/study-7.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Keygan J, Willoughby B, Bruno R, et al. Risk communication about high-dose MDMA: Impact of a hypothetical drug alert on future MDMA use. Drug Alcohol Rev. 2025;44(4):1169-1181. https://doi.org/10.1111/dar.14037 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5539671f-075b-4b55-988f-f03ba42e5d86/study-8.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Nayak SM, Jackson H, Sepeda ND, et al. Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey. Front Psychiatry. 2023;14:1199642. https://doi.org/10.3389/fpsyt.2023.1199642 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/829d4b86-b1c8-4c66-b35b-f2f76cc27ecf/study-9.png Educational Resources - Public Health and Prevention Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Herrmann Z, Levin AW, Cole SP, et al. Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States. Psychedelic Med (New Rochelle). 2023;1(3):139-149. https://doi.org/10.1089/psymed.2023.0030 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a01eaf26-5188-48d0-be0a-583d9be2e7c4/study-10.png Educational Resources - Public Health and Prevention Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Carlisle NA, Simonsson O, MacCarthy S, et al. Prevalence, types, and demographic characteristics associated with major life changes following psychedelic use. Sci Rep. 2026;16(1):6458. https://doi.org/10.1038/s41598-026-37609-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/30efdccd-e43a-4740-a082-c5a9bd45ff9c/study-11.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kvam TM, Uthaug MV, Andersen KAA, et al. Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample. Front Psychiatry. 2023;14:1287196. https://doi.org/10.3389/fpsyt.2023.1287196 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/012dc94e-c75d-4a16-93ef-3a02d735cada/study-12.png Educational Resources - Public Health and Prevention Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Fitzgerald ND, Palamar JJ. Increases in the use of drug testing kits among nightclub and festival attendees in New York City who use ecstasy, 2017-2022. Drug Alcohol Rev. 2024;43(4):975-983. https://doi.org/10.1111/dar.13829 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2d838ebb-ff2f-42ca-be86-77a7abfd46ba/study-13.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lawn W, Hallak JE, Crippa JA, et al. Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey. Sci Rep. 2017;7(1):15201. https://doi.org/10.1038/s41598-017-14700-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0e6b6601-8699-4431-b198-57af077ede62/study-14.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Whelan J, Noller G, Ward RD. Harm reduction behaviours and harm experiences of people who use 3,4-methylenedioxymethamphetamine (MDMA) in Aotearoa New Zealand. Harm Reduct J. 2024;21(1):67. https://doi.org/10.1186/s12954-024-00979-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7da84dfd-d3f1-4abf-b71e-e154489502c9/study-15.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Teixeira PJ, Jain R, Penn AD, et al. Health-related behavioral changes following the use of psychedelics in naturalistic settings. Prev Med Rep. 2025;56:103161. https://doi.org/10.1016/j.pmedr.2025.103161 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/58a0dc37-a32a-45d8-9437-e48d15db9c75/study-16.png Educational Resources - Public Health and Prevention Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Starks TJ, Scales D, Castiblanco J, et al. Correlates of Mpox Vaccination among Sexual Minority Men in the United States: Sexual Behavior, Substance Use, and Main Partner Relationships. J Sex Res. 2023;60(5):634-644. https://doi.org/10.1080/00224499.2023.2188443 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/79b3e654-25ac-4428-88c1-e1f4027c4d4c/study-17.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kopra EI, Ferris JA, Winstock AR, et al. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. J Psychopharmacol. 2023;37(7):733-748. https://doi.org/10.1177/02698811231158245 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b33cd82c-d9ab-4fad-9790-06e3302ef55e/study-18.png Educational Resources - Public Health and Prevention Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Koning RPJ, Benschop A, Wijffels C, Noijen J. Visitors of the Dutch drug checking services: Profile and drug use experience. Int J Drug Policy. 2021;95:103293. https://doi.org/10.1016/j.drugpo.2021.103293 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bd4f1877-c1e6-47c3-b19f-98d758559fba/study-19.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Grønnerød C, Rønningen T, Haugsjå IR, et al. Recreational MDMA use in Norway: results from an internet convenience sample. Front Psychiatry. 2025;16:1619676. https://doi.org/10.3389/fpsyt.2025.1619676 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1c89a52e-bd2c-4ed7-9978-821cc701cfab/study-20.png Educational Resources - Public Health and Prevention Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Cavanna F, Pallavicini C, Milano V, et al. Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic. Journal of Psychedelic Studies. 2021. https://doi.org/10.1556/2054.2021.00172 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d4798652-ea99-45fa-847f-d9c8c1163420/study-21.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Todesco S, Allan Z, Liu MYM, Schütz C. Effects of naturalistic psychedelic use on executive functioning: An online survey of lifetime history and recent use in university students. Prog Neuropsychopharmacol Biol Psychiatry. 2026;149:111888. https://doi.org/10.1016/j.pnpbp.2026.111888 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/26c5f79d-1213-463b-9646-5306930478c0/study-22.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Révész D, Ona G, Rossi GN, et al. Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study. Front Psychiatry. 2021;12:687546. https://doi.org/10.3389/fpsyt.2021.687546 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/67ae1478-da01-4f0f-a2a3-175b1da6326b/study-23.png Educational Resources - Public Health and Prevention Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kohek M, Ona G, van Elk M, et al. Ayahuasca and Public Health II: Health Status in a Large Sample of Ayahuasca-Ceremony Participants in the Netherlands. J Psychoactive Drugs. 2023;55(3):247-258. https://doi.org/10.1080/02791072.2022.2077155 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/30c482f3-8421-48ba-9611-8172c914147b/study-24.png Educational Resources - Public Health and Prevention Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ona G, Kohek M, Massaguer T, et al. Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users. J Psychoactive Drugs. 2019;51(2):135-145. https://doi.org/10.1080/02791072.2019.1567961 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5caaeb3e-401e-44c5-bbbc-2d0853ac4e7a/study-25.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bouso JC, Révész D, Ona G, et al. Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic. Sci Rep. 2023;13(1):14052. https://doi.org/10.1038/s41598-023-41199-x https://www.harmreductionadvocate.com/educational-resources/safety-and-risk-management monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793224025487-R14AQM3AL4WRL3L8K4X5/illustration-safety-and-risk-management.jpg Educational Resources - Safety and Risk Management https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c931dbc6-51e1-46a5-9125-7f5bf73eaf5e/study-1.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Becker AM, Holze F, Grandinetti T, et al. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clin Pharmacol Ther. 2022;111(4):886-895. https://doi.org/10.1002/cpt.2487 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/92632c30-1873-4c47-a320-89b65bb17140/study-2.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024;81(12):1225-1235. https://doi.org/10.1001/jamapsychiatry.2024.2546 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/71a5ac80-22ff-43ea-a6e2-a954de396156/study-3.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. J Psychopharmacol. 2022;36(8):965-973. https://doi.org/10.1177/02698811221084063 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/70c251d0-48a9-4941-a7dd-2623ff355da4/study-4.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Evans J, Robinson OC, Argyri EK, et al. Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLoS One. 2023;18(10):e0293349. https://doi.org/10.1371/journal.pone.0293349 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bcda7fec-2c64-448f-af98-a2764a04ac3e/study-5.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Sanacora G, Ahmed M, Brown B, et al. Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval. Am J Psychiatry. 2025;182(10):913-921. https://doi.org/10.1176/appi.ajp.20240655 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/40035597-9c13-4d83-b4a8-cc9562583749/study-6.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Vizeli P, Liechti ME. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol. 2017;31(5):576-588. https://doi.org/10.1177/0269881117691569 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b11b4e76-3eda-4192-be2e-82fb7293a31f/study-7.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Müller F, Kraus E, Holze F, et al. Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. Psychopharmacology (Berl). 2022;239(6):1933-1943. https://doi.org/10.1007/s00213-022-06066-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9aec0c89-58c6-48aa-84b7-9d6066989c27/study-8.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Holze F, Caluori TV, Vizeli P, Liechti ME. Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology (Berl). 2022;239(6):1893-1905. https://doi.org/10.1007/s00213-021-05978-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0f1d8756-3104-44be-b389-0f739310df84/study-9.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bukovsky D, Amaev A, Song J, et al. Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development. Prog Neuropsychopharmacol Biol Psychiatry. 2025;143:111541. https://doi.org/10.1016/j.pnpbp.2025.111541 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5180a068-22b8-41b9-b88a-a758e9c175fb/study-10.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: A scoping review. J Psychopharmacol. 2025;39(10):1072-1088. https://doi.org/10.1177/02698811251368360 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f3664f7f-8a6a-4873-a11a-6036bebf8872/study-11.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kwaśny A, Wilkowska A, Cubała WJ. Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials. Front Psychiatry. 2024;15:1477996. https://doi.org/10.3389/fpsyt.2024.1477996 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ba708bfa-8f4a-4f18-9939-bf0e6766a298/study-12.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Straumann I, Holze F, Becker AM, et al. Safety pharmacology of acute psilocybin administration in healthy participants. Neurosci Appl. 2024;3:104060. https://doi.org/10.1016/j.nsa.2024.104060 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/22c882c6-d7e7-424a-b6f2-29e13fb9c270/study-13.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Halman A, Kong G, Sarris J, Perkins D. Drug-drug interactions involving classic psychedelics: A systematic review. J Psychopharmacol. 2024;38(1):3-18. https://doi.org/10.1177/02698811231211219 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e1947bdd-a104-4441-b47f-1fe765f0bf91/study-14.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pleet MM, White J, Zamaria JA, Yehuda R. Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline. Psychedelic Med (New Rochelle). 2023;1(2):69-73. https://doi.org/10.1089/psymed.2022.0017 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7123f1f4-661d-4769-b080-7421ec4c4097/study-15.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bhatt M, Johnson DW, Chan J, et al. Risk Factors for Adverse Events in Emergency Department Procedural Sedation for Children. JAMA Pediatr. 2017;171(10):957-964. https://doi.org/10.1001/jamapediatrics.2017.2135 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/78aa1e37-8524-4b1b-a25b-4bd9704b350c/study-16.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Reis JAS, Ueta LZ, Bouso JC, et al. Psychedelics and psychosis: A systematic review of recent-era studies (1984-2025). J Psychopharmacol. 2026:2698811261488575. https://doi.org/10.1177/02698811261488575 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/63ac4827-c187-47a6-9a07-dbe018b6cf97/study-17.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: White E, Kennedy T, Ruffell S, et al. Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review. Int J Toxicol. 2024;43(3):327-339. https://doi.org/10.1177/10915818241230916 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8ab6074e-7af3-432b-a23a-1c7882f38e76/study-18.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Simonsson O, Carlbring P, Carhart-Harris R, et al. Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis. Psychiatry Res. 2023;327:115349. https://doi.org/10.1016/j.psychres.2023.115349 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/96d0bdd6-5190-4d9b-ae5b-2bb5890520af/study-19.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Becker AM, Humbert-Droz M, Mueller L, et al. Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial. Clin Pharmacol Ther. 2025;117(6):1784-1792. https://doi.org/10.1002/cpt.3618 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0b943aee-5e36-42c2-bdcc-a39ed1d3cecd/study-20.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Barnett BS, Ziegler K, Doblin R, Carlo AD. Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data. J Psychopharmacol. 2022;36(10):1118-1128. https://doi.org/10.1177/02698811221117536 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/edf9db5f-36a5-476e-b024-d5f9092d6614/study-21.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Sharif S, Kang J, Sadeghirad B, et al. Pharmacological agents for procedural sedation and analgesia in the emergency department and intensive care unit: a systematic review and network meta-analysis of randomised trials. Br J Anaesth. 2024;132(3):491-506. https://doi.org/10.1016/j.bja.2023.11.050 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/03313612-4cb8-4b40-9302-6f5bffcefecb/study-22.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Wasolua TT, Hardy MS, Bommersbach TJ, et al. A Systematic Review of Long-Term Safety Outcomes of Ketamine and Esketamine in Patients with Treatment-Resistant Depression. Psychother Psychosom. 2026:1. https://doi.org/10.1159/pps/aemag005 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7fc50068-75fc-491f-9e1e-06a084c39f62/study-23.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dourron HM, Bradley M, Simonsson O, et al. Naturalistic Psychedelic Use and Psychotic Symptoms: A Cross-Sectional Study of Individuals with a Personal or Family History of Psychotic or Bipolar Disorders. Psychedelic Med (New Rochelle). 2025;3(2):93-102. https://doi.org/10.1089/psymed.2024.0036 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5932df23-68cc-4c32-bac7-b178d0db8045/study-24.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zimmermann J, Friedli N, Bavato F, et al. White matter alterations in chronic MDMA use: Evidence from diffusion tensor imaging and neurofilament light chain blood levels. Neuroimage Clin. 2022;36:103191. https://doi.org/10.1016/j.nicl.2022.103191 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9d6c998b-02a0-4ef9-8983-b207fe42b62a/study-25.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Doty RL, Popova V, Wylie C, et al. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies. CNS Drugs. 2021;35(7):781-794. https://doi.org/10.1007/s40263-021-00826-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/11da28b1-f1c8-4ed8-aed1-e7c3293d2125/study-26.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dos Santos RG, Balthazar FM, Bouso JC, Hallak JE. The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. J Psychopharmacol. 2016;30(12):1230-1247. https://doi.org/10.1177/0269881116652578 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/66923a9f-9736-4da1-97cb-7499046b7e6b/study-27.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Henríquez-Hernández LA, Rojas-Hernández J, Quintana-Hernández DJ, Borkel LF. Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines. Toxics. 2023;11(2):148. https://doi.org/10.3390/toxics11020148 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c1c4ef0b-87fe-4bb4-b277-c37a043d23e6/study-28.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Khan MT, Khan AR, Rohail S, et al. Safety of procedural sedation in emergency department settings among the adult population: a systematic review and meta-analysis of randomized controlled trials. Intern Emerg Med. 2024;19(5):1385-1403. https://doi.org/10.1007/s11739-024-03697-2 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/293b6dc0-5d2b-4c9b-821e-3dd16ef1add1/study-29.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Olofsson M, Osika W, Goldberg SB, et al. Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences. Int J Drug Policy. 2026;148:105105. https://doi.org/10.1016/j.drugpo.2025.105105 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c60fac1e-64f2-4aa8-af82-d88f4a99c706/study-30.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lovell GFM, Vasudeva S, Orsini DK, et al. Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review. Gen Hosp Psychiatry. 2026;100:196-205. https://doi.org/10.1016/j.genhosppsych.2026.04.005 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5a3a6b46-27da-4118-a041-aeaf2b3b2f1d/study-31.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Makunts T, Abagyan R. Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System. Front Psychiatry. 2024;15:1414622. https://doi.org/10.3389/fpsyt.2024.1414622 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1246c798-12ea-48a3-b108-7bab948d5d4c/study-32.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Klaiber A, Humbert-Droz M, Ley L, et al. Safety pharmacology of acute mescaline administration in healthy participants. Br J Clin Pharmacol. 2024. https://doi.org/10.1111/bcp.16349 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c4bf918b-8fa4-4a52-a71c-172acf7ff258/study-33.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nomoto K, Ohtani Y, Yatomi T, et al. Association between Intravenous Ketamine Treatment and Cognitive Function in Patients with Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Trial. Pharmacopsychiatry. 2026. https://doi.org/10.1055/a-2894-5681 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/28a300ca-641f-448e-944b-a97245146f20/study-34.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Di Vincenzo JD, Lipsitz O, Rodrigues NB, et al. Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence. Psychiatry Res. 2022;307:114321. https://doi.org/10.1016/j.psychres.2021.114321 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0fc0dbd9-2768-4e5a-8d4e-b7ca8d217483/study-35.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zhou K, de Wied D, Carhart-Harris RL, Kettner H. Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use. PNAS Nexus. 2025;4(4):pgae560. https://doi.org/10.1093/pnasnexus/pgae560 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/64c155d7-a9e5-4cef-b6dd-d83c30e7f7ca/study-36.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Guo H, Tang L, He M, et al. Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis. Front Pharmacol. 2025;16:1681060. https://doi.org/10.3389/fphar.2025.1681060 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8c81546d-3202-433f-907f-60b60d5f545e/study-37.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Roncero C, Merizalde-Torres M, Szerman N, et al. Is there a risk of esketamine misuse in clinical practice? Ther Adv Drug Saf. 2025;16:20420986241310685. https://doi.org/10.1177/20420986241310685 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c93ab757-3239-4146-a6fe-2f6356eec3fb/study-38.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Gutierrez G, Vazquez G, Ravindran N, et al. Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee. Ther Adv Drug Saf. 2025;16:20420986251347360. https://doi.org/10.1177/20420986251347360 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/10389af1-bffa-4404-99cf-bf8f2319df13/study-39.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Becker AM, Klaiber A, Holze F, et al. Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants. Int J Neuropsychopharmacol. 2023;26(2):97-106. https://doi.org/10.1093/ijnp/pyac075 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5fc6b67a-f69d-48fb-a7d3-753b9c39c5f4/study-40.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Soto-Angona Ó, Fortea A, Fortea L, et al. Do classic psychedelics increase the risk of seizures? A scoping review. Eur Neuropsychopharmacol. 2024;85:35-42. https://doi.org/10.1016/j.euroneuro.2024.05.002 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e72f1e28-6251-487e-9f41-d850d17732e6/study-41.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hurst KT, Vogeley A, Greenstein DK, et al. Long-term follow-up of participants in ketamine clinical trials for mood disorders. J Affect Disord. 2024;357:134-137. https://doi.org/10.1016/j.jad.2024.04.062 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d86a9c79-1b6d-4310-9adb-ec1ba0f04e63/study-42.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Durante Í, Dos Santos RG, Bouso JC, Hallak JE. Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects. Braz J Psychiatry. 2021;43(4):362-369. https://doi.org/10.1590/1516-4446-2020-0913 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a621947d-5ea9-4269-be5c-3c21b8551e71/study-43.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Chepke C, Shelton R, Sanacora G, et al. Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression. Int J Neuropsychopharmacol. 2024;27(12):pyae058. https://doi.org/10.1093/ijnp/pyae058 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9f78cb91-ef50-47a2-b278-16959f6c26ed/study-44.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Barrios KP, Connolly DJ, Ferris JA, et al. Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment. J Psychopharmacol. 2025;39(1):8-22. https://doi.org/10.1177/02698811241273850 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4cb6a08b-22eb-4a85-a7d5-099cc5b93172/study-45.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kwan ATH, Rosenblat JD, Mansur RB, et al. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists. J Affect Disord. 2024;363:589-594. https://doi.org/10.1016/j.jad.2024.07.128 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0034c25f-65ec-4248-b8ce-42610970eac4/study-46.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, et al. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. J Affect Disord. 2020;263:568-575. https://doi.org/10.1016/j.jad.2019.11.028 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2b54f3fe-589d-49a2-b5ce-87c8f8adb554/study-47.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bailey NW, Webb SL, Fitzgibbon BM, et al. No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory study. J Psychopharmacol. 2026:2698811261464991. https://doi.org/10.1177/02698811261464991 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1d25a9fc-989f-4abf-bc4c-e1150844acd2/study-48.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Williamson D, Turkoz I, Wajs E, et al. Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD. Int J Neuropsychopharmacol. 2023;26(3):198-206. https://doi.org/10.1093/ijnp/pyac081 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/944f7f80-b208-498c-9ad0-73d435284c6d/study-49.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Weisz K, Bajaj L, Deakyne SJ, et al. Adverse Events During a Randomized Trial of Ketamine Versus Co-Administration of Ketamine and Propofol for Procedural Sedation in a Pediatric Emergency Department. J Emerg Med. 2017;53(1):1-9. https://doi.org/10.1016/j.jemermed.2017.03.024 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7dc33599-5e64-4fa5-a144-44a6ca780c52/study-50.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Novaretti N, Pessoa RMP, Hallak JEC, et al. Safety and tolerance of oral ketamine: A systematic review. Psychiatry Clin Neurosci. 2026;80(9):730-739. https://doi.org/10.1111/pcn.70091 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/74c8d4dd-7b9e-4b0b-a50c-4c493eb5b4f9/study-51.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Singh B, Leung JG, Pazdernik VK, et al. Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression: A Real-World Cohort Study. J Clin Psychopharmacol. 2026. https://doi.org/10.1097/jcp.0000000000002228 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0ea5ef55-518c-4499-a108-b336e5cba30d/study-52.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Tabaac BJ, Shinozuka K, Fadel M, et al. Psychedelic Therapy: A Primer for Primary Care Clinicians-Mescaline. Am J Ther. 2026;33(4):e318-e323. https://doi.org/10.1097/mjt.0000000000002160 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ea0d4cba-f4be-4ff9-aa4a-ce8aadf22159/study-53.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Dijkstra FM, van de Loo AJ, Abdulahad S, et al. The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder. J Psychopharmacol. 2022;36(5):614-625. https://doi.org/10.1177/02698811221078764 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/384dc3f4-40f6-478d-8465-946baa8ab96d/study-54.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dormegny-Jeanjean LC, Lenoir S, Humbert I, et al. Cardiovascular Effects of Non-Selective Monoamine Oxidase Inhibitors and Intranasal Esketamine Combination in Depression - A Quasi-Experimental Design with Bayesian Analyses. Pharmacopsychiatry. 2025;58(6):273-283. https://doi.org/10.1055/a-2590-3469 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/cbf97bcd-e3f5-40f8-b52c-24527782acd5/study-55.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Simonsson O, Hendricks PS, Chambers R, et al. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. J Affect Disord. 2023;326:105-110. https://doi.org/10.1016/j.jad.2023.01.073 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d68b1c5c-98b8-495a-8f9d-52d0cfad6727/study-56.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Jonkman K, van Rijnsoever E, Olofsen E, et al. Esketamine counters opioid-induced respiratory depression. Br J Anaesth. 2018;120(5):1117-1127. https://doi.org/10.1016/j.bja.2018.02.021 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/602f7db6-50ff-4bc6-a221-6b0df824d06c/study-57.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kerr-Gaffney J, Tröger A, Caulfield A, et al. Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review. J Psychopharmacol. 2025;39(10):1103-1113. https://doi.org/10.1177/02698811251350267 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5bc539c4-c754-4c36-a22f-a9e155b4628f/study-58.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hom B, McIntee D, Zhang YP, et al. Evaluating oral ketamine's adverse side effects in chronic pain patients. Saudi J Anaesth. 2025;19(4):546-552. https://doi.org/10.4103/sja.sja_87_25 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/50fb7b61-1d56-4e01-b195-0114c96cad76/study-59.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Buczma K, Kamińska K, Kasarełło K, et al. Psilocibin: Current Evidence, Safety Signals, and Challenges in Assessing Potential Multi-Organ Effects. Biomedicines. 2026;14(7):1516. https://doi.org/10.3390/biomedicines14071516 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d7e5a953-4719-4ad1-aa24-244ab20f1d84/study-60.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Williamson DJ, Gogate JP, Kern Sliwa JK, et al. Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression. J Clin Psychiatry. 2022;83(6):21m14318. https://doi.org/10.4088/jcp.21m14318 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c58182bf-a060-4abf-b7d4-1c9e971fc45d/study-61.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Signor A, Comai S, Pasut G, et al. Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants. Br J Clin Pharmacol. 2026. https://doi.org/10.1002/bcp.70839 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b818b8b1-caf2-4ca2-ba10-67418a837401/study-62.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Sessa B, Aday JS, O'Brien S, et al. Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMA. J Psychopharmacol. 2022;36(3):360-367. https://doi.org/10.1177/02698811211055809 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/44bc07cf-0270-4946-a041-eac0e3c4613b/study-63.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Dilip TS, Chandy GM, Hazra D, et al. The adverse effects of Ketamine on Procedural Sedation and Analgesia (PSA) in the Emergency Department. J Family Med Prim Care. 2021;10(6):2279-2283. https://doi.org/10.4103/jfmpc.jfmpc_2140_20 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3ce42985-0d78-4867-bfa9-e01968c1a712/study-64.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Qureshi M, Silman D, Gadelrab R, et al. A randomized, double-blind, placebo-controlled, Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an immediate-release oral ketamine capsule in healthy volunteers. J Psychopharmacol. 2025;39(6):545-558. https://doi.org/10.1177/02698811251340925 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/22e3433f-76d3-4938-a3f8-d674ee100335/study-65.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Shiroma PR, Velit-Salazar MR, Vorobyov Y. A Systematic Review of Neurocognitive Effects of Subanesthetic Doses of Intravenous Ketamine in Major Depressive Disorder, Post-Traumatic Stress Disorder, and Healthy Population. Clin Drug Investig. 2022;42(7):549-566. https://doi.org/10.1007/s40261-022-01169-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/69ab8538-ff79-488e-b883-242a53f1f081/study-66.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rock KL, Rees P, Morgan D, Copeland CS. The impact of antidepressant use on MDMA fatalities: A matched case-control study using a post-mortem database. J Psychopharmacol. 2026;40(9):1352-1360. https://doi.org/10.1177/02698811261436573 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3184fec8-f8ed-4aa6-8d58-a416b4bb78e7/study-67.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bouso JC, Andión Ó, Sarris JJ, et al. Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey. PLOS Glob Public Health. 2022;2(11):e0000438. https://doi.org/10.1371/journal.pgph.0000438 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/022224fb-e77b-47ac-b478-7ef1a87328a3/study-68.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Campbell K, Neul JL, Lieberman DN, et al. A randomized, placebo-controlled, cross-over trial of ketamine in Rett syndrome. J Neurodev Disord. 2025;17(1):4. https://doi.org/10.1186/s11689-025-09591-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/841b46f9-3f52-4459-beee-905065098abb/study-69.png Educational Resources - Safety and Risk Management Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Klintefors P, Bhagavan C, Kanaan R, et al. Psilocybin's kinematic effect on manual dexterity. Psychopharmacology (Berl). 2026. https://doi.org/10.1007/s00213-026-07106-8 https://www.harmreductionadvocate.com/educational-resources/set-and-setting monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793224014329-T25BOPMEQUWTQO7LMW13/illustration-set-and-setting.jpg Educational Resources - Set and Setting https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5da39aa7-107c-47db-98de-9d9bdee59285/study-1.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Strickland JC, Garcia-Romeu A, Johnson MW. Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy. ACS Pharmacol Transl Sci. 2021;4(2):472-478. https://doi.org/10.1021/acsptsci.0c00187 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c2c9b6d9-9d2f-4191-b389-30ede3c29228/study-2.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Studerus E, Gamma A, Kometer M, Vollenweider FX. Prediction of psilocybin response in healthy volunteers. PLoS One. 2012;7(2):e30800. https://doi.org/10.1371/journal.pone.0030800 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f804b451-e6c5-4852-b288-48a36ced7912/study-3.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Uthaug MV, Mason NL, Toennes SW, et al. A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology (Berl). 2021;238(7):1899-1910. https://doi.org/10.1007/s00213-021-05817-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ede54004-65f6-44f6-99b0-adead1224be1/study-4.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Estric C, Duron T, Kabani S, Lopez-Castroman J. Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review. J Psychopharmacol. 2025;39(9):910-929. https://doi.org/10.1177/02698811251338214 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/58d3904b-a149-4736-b977-16d65edf0d61/study-5.png Educational Resources - Set and Setting Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Goldy SP, Sepeda ND, Hilbert SN, et al. Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones. Psychiatry Res. 2026;359:117010. https://doi.org/10.1016/j.psychres.2026.117010 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/63cbc8fe-6ec9-4901-aa7c-2d2a64a18bb8/study-6.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Palmer M, Maynard OM. Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience. Harm Reduct J. 2022;19(1):81. https://doi.org/10.1186/s12954-022-00662-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/34db1ea3-89a7-4d17-a568-a360a66ee220/study-7.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Viljoen G, Walter H, Bendau A, et al. Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review. J Psychopharmacol. 2026;40(5):703-719. https://doi.org/10.1177/02698811251389581 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/17bee1ad-bc6c-4895-b250-d692c8375e80/study-8.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Haijen ECHM, Kaelen M, Roseman L, et al. Predicting Responses to Psychedelics: A Prospective Study. Front Pharmacol. 2018;9:897. https://doi.org/10.3389/fphar.2018.00897 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/234afca7-1be9-4bdd-99c3-3f57654b1295/study-9.png Educational Resources - Set and Setting Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: St Arnaud KO, Sharpe D. Contextual Parameters Associated with Positive and Negative Mental Health in Recreational Psychedelic Users. J Psychoactive Drugs. 2023;55(1):30-39. https://doi.org/10.1080/02791072.2022.2039815 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b1b70a10-3ef0-4818-bb3b-0314a8327edb/study-10.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wolff M, Evens R, Mertens LJ, et al. Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ). J Psychopharmacol. 2024;38(5):432-457. https://doi.org/10.1177/02698811241249698 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/239d20b6-7ba6-4111-b0a1-7e41aec7a7dc/study-11.png Educational Resources - Set and Setting Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Chwyl C, Spata A, Lucas W, Luoma JB. Mindset over molecule: comparing self-transcendent and mystical experiences across recreational psilocybin, MDMA, and cannabis use. BMC Psychol. 2026;14(1):260. https://doi.org/10.1186/s40359-025-03921-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/84614d49-160c-4ffc-b10c-311964940965/study-12.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pontual AAD, Tófoli LF, Corradi-Webster CM, et al. The influence of ceremonial settings on mystical and challenging experiences occasioned by ayahuasca: A survey among ritualistic and religious ayahuasca users. Front Psychol. 2022;13:857372. https://doi.org/10.3389/fpsyg.2022.857372 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/89648324-8159-4d08-bb83-8900752bee9c/study-13.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wolff M, Mertens LJ, Walter M, et al. The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility. J Psychopharmacol. 2022;36(3):387-408. https://doi.org/10.1177/02698811211073758 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6c651172-3d14-4152-a06e-f1ee3595c0d8/study-14.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lipson J, Kettner H, Carhart-Harris R, Miller L. Baseline Mood and "Relational Triad" Predict Acute Qualities of Psychedelic Experience. Behav Sci (Basel). 2026;16(2):310. https://doi.org/10.3390/bs16020310 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/100b66f5-f0d4-40ed-a983-31c3ed9b8f43/study-15.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Perkins D, Schubert V, Simonová H, et al. Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey. Front Pharmacol. 2021;12:623979. https://doi.org/10.3389/fphar.2021.623979 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bee98555-0a75-441d-ba57-50834df97f15/study-16.png Educational Resources - Set and Setting Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Neitzke-Spruill L, Glasser C. A Gratuitous Grace: The Influence of Religious Set and Intent on the Psychedelic Experience. J Psychoactive Drugs. 2018;50(4):314-321. https://doi.org/10.1080/02791072.2018.1494869 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/22aa2cd8-1673-462d-9351-d52c5876af79/study-17.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ley L, Liechti ME, Becker AM, et al. Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers. Psychopharmacology (Berl). 2025;242(8):1875-1892. https://doi.org/10.1007/s00213-025-06772-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ab7e7a74-0eee-4dba-b228-cb6f3b64d129/study-18.png Educational Resources - Set and Setting Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Borkel LF, Rojas-Hernández J, Henríquez-Hernández LA, et al. Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study. Expert Rev Clin Pharmacol. 2024;17(2):165-176. https://doi.org/10.1080/17512433.2023.2295997 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bc98f09f-257f-4b70-9789-9bf937c1b25c/study-19.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Gashi L, Sandberg S, Pedersen W. Making "bad trips" good: How users of psychedelics narratively transform challenging trips into valuable experiences. Int J Drug Policy. 2021;87:102997. https://doi.org/10.1016/j.drugpo.2020.102997 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6de3d859-8a7e-4644-afb5-12332c80bcb6/study-20.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Evens R, Reiche S, Marek RM, et al. Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey. Front Psychiatry. 2021;12:732028. https://doi.org/10.3389/fpsyt.2021.732028 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5971f09f-f2d2-418b-a3a6-385e2cb1c36c/study-21.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Cherniak AD, Granqvist P, Mikulincer M, Wolff M. Therapeutic-Like Context and Relational Support During Psychedelic Use Moderate Links Among Stress, Challenging Experiences, and Psychological Outcomes. J Psychoactive Drugs. 2026:1-13. https://doi.org/10.1080/02791072.2026.2644857 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bc99ba93-8c89-464e-bdd8-c6169cf687fa/study-22.png Educational Resources - Set and Setting Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Cowley-Court T, Chenhall R, Sarris J, et al. Life after Ayahuasca: A Qualitative Analysis of the Psychedelic Integration Experiences of 1630 Ayahuasca Drinkers from a Global Survey. Psychoactives. 2023. https://doi.org/10.3390/psychoactives2020014 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c21a3894-ff84-4f03-8c3c-dcd401a678f3/study-23.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Tunstad PA, Kvam TM, Uthaug MV, et al. Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample. Front Pharmacol. 2025;16:1556299. https://doi.org/10.3389/fphar.2025.1556299 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4251a804-6b17-4cbe-b4dc-4d0af6f03ab4/study-24.png Educational Resources - Set and Setting Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Mason NL, Dolder PC, Kuypers KP. Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts. Drug Science, Policy and Law. 2020. https://doi.org/10.1177/2050324519900068 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a0c8b868-2c1b-422a-a043-d573af6a24b5/study-25.png Educational Resources - Set and Setting Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Shaw L, Rea K, Lachowsky NJ, Roth EA. Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences. J Psychoactive Drugs. 2023;55(2):151-158. https://doi.org/10.1080/02791072.2022.2054746 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2791f345-25a2-46f0-acdc-c24dcb11ce11/study-26.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Elmer T, Vannoy TK, Studerus E, Lyubomirsky S. Subjective long-term emotional and social effects of recreational MDMA use: the role of setting and intentions. Sci Rep. 2024;14(1):3434. https://doi.org/10.1038/s41598-024-51355-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/76a5f820-9e4f-40d6-b1ce-0b56c9f44df0/study-27.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Grime H, Drini E. Psycholytic Therapy Using LSD: a Realist Review. Brain Behav. 2026;16(4):e71187. https://doi.org/10.1002/brb3.71187 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/48dae41a-3a7d-43b3-b1a1-5ba00f311324/study-28.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Calder AE, Rausch B, Liechti ME, et al. Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response. J Psychopharmacol. 2024;38(10):873-886. https://doi.org/10.1177/02698811241278873 https://www.harmreductionadvocate.com/educational-resources/social-connection-and-relationships monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793224001935-8JAEQ2V3VI5RMORTC01C/illustration-social-connection-and-relationships.jpg Educational Resources - Social Connection and Relationships https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e7cc8522-8f91-4d58-9962-6fdc7b5161ca/study-1.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jungwirth J, von Rotz R, Dziobek I, Vollenweider FX, Preller KH. Psilocybin increases emotional empathy in patients with major depression. Molecular psychiatry. 2025;30(6):2665-2672. https://doi.org/10.1038/s41380-024-02875-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7f92a15b-75ad-4b2d-994f-0f83935c4a8f/study-2.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L, et al. The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world. Psychopharmacology. 2022;239(11):3461-3483. https://doi.org/10.1007/s00213-022-06187-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/19de2ea4-b2b9-4459-a978-c4cbe1d92767/study-3.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Danforth AL, Grob CS, Struble C, Feduccia AA, Walker N, Jerome L, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology. 2018;235(11):3137-3148. https://doi.org/10.1007/s00213-018-5010-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1b4c3760-e4de-40e1-aa7e-bf7e5f9e7b4c/study-4.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Monson CM, Wagner AC, Mithoefer AT, Liebman RE, Feduccia AA, Jerome L, et al. MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial. European journal of psychotraumatology. 2020;11(1):1840123. https://doi.org/10.1080/20008198.2020.1840123 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/68f5c2e0-af5b-455f-9da9-907a6d016756/study-5.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Olami A, Peled-Avron L. Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task. Sci Rep. 2024;14(1):24480. https://doi.org/10.1038/s41598-024-74810-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fb4f0d65-fbd3-47fb-b821-89a800b1e080/study-6.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hysek CM, Schmid Y, Simmler LD, et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2014;9(11):1645-1652. https://doi.org/10.1093/scan/nst161 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5c7f1149-2ec7-4189-b213-c55c3aca1627/study-7.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kirkpatrick MG, Lee R, Wardle MC, et al. Effects of MDMA and Intranasal oxytocin on social and emotional processing. Neuropsychopharmacology. 2014;39(7):1654-1663. https://doi.org/10.1038/npp.2014.12 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9d0cd62c-873d-4b0d-9d93-4faaaac714fa/study-8.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hysek CM, Domes G, Liechti ME. MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions. Psychopharmacology (Berl). 2012;222(2):293-302. https://doi.org/10.1007/s00213-012-2645-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2ccdaa91-58c2-4f05-98d8-04aa836cbb2d/study-9.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Martinez RL, Radošić N, Molla H, et al. The empathogen 3,4-methylenedioxymethamphetamine, but not methamphetamine, increases feelings of global trust. J Psychopharmacol. 2026;40(9):1361-1367. https://doi.org/10.1177/02698811251370999 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4bc2eb48-f432-4ed6-8951-9ea300d39afe/study-10.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Forstmann M, Yudkin DA, Prosser AMB, et al. Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. Proc Natl Acad Sci U S A. 2020;117(5):2338-2346. https://doi.org/10.1073/pnas.1918477117 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8700ba07-f07c-4c4d-90ac-6f367c17655d/study-11.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pokorny T, Preller KH, Kometer M, et al. Effect of Psilocybin on Empathy and Moral Decision-Making. Int J Neuropsychopharmacol. 2017;20(9):747-757. https://doi.org/10.1093/ijnp/pyx047 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/27ec7f16-818d-4c58-bb00-e300e4305c5d/study-12.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Baggott MJ, Kirkpatrick MG, Bedi G, de Wit H. Intimate insight: MDMA changes how people talk about significant others. J Psychopharmacol. 2015;29(6):669-677. https://doi.org/10.1177/0269881115581962 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ea650374-5695-4b6e-a311-7b753840d341/study-13.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Schmid Y, Hysek CM, Simmler LD, et al. Differential effects of MDMA and methylphenidate on social cognition. J Psychopharmacol. 2014;28(9):847-856. https://doi.org/10.1177/0269881114542454 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/cc93c658-43cc-44c7-a5a5-08af16519236/study-14.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Vaslavski A, Gross AH, Israel S, Peled-Avron L. The effect of MDMA administration on oxytocin concentration levels: systematic review and a multilevel meta-analysis in humans. Neurosci Biobehav Rev. 2025;177:106324. https://doi.org/10.1016/j.neubiorev.2025.106324 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b337605f-907b-4818-89a4-4c7e41d130d8/study-15.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jones G, Lipson J, Wang E. Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample. Sci Rep. 2023;13(1):2466. https://doi.org/10.1038/s41598-023-29763-x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/57ab20df-230c-4755-bac5-9c7acaa0baeb/study-16.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Preller KH, Pokorny T, Hock A, et al. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci U S A. 2016;113(18):5119-5124. https://doi.org/10.1073/pnas.1524187113 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a0b80527-035c-4380-82a5-ef7fe96c4731/study-17.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bedi G, Cecchi GA, Slezak DF, et al. A window into the intoxicated mind? Speech as an index of psychoactive drug effects. Neuropsychopharmacology. 2014;39(10):2340-2348. https://doi.org/10.1038/npp.2014.80 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ca48fde8-52a3-4485-b24b-6706ade5b246/study-18.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kuypers KP, de la Torre R, Farre M, et al. No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. PLoS One. 2014;9(6):e100719. https://doi.org/10.1371/journal.pone.0100719 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c6194d78-ecf9-45f0-acc4-acb9749360e5/study-19.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hu H, Tillman AN, Fujita M, et al. Can ketamine and other glutamate receptor modulators be considered entactogens? Psychiatry Res. 2025;349:116513. https://doi.org/10.1016/j.psychres.2025.116513 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8a052624-aaeb-43d3-8342-dc40ece3710a/study-20.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kuypers KPC, Dolder PC, Ramaekers JG, Liechti ME. Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies. J Psychopharmacol. 2017;31(5):589-598. https://doi.org/10.1177/0269881117699617 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/93b15d3c-bff2-4c47-88f0-f030784d6ebf/study-21.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Gabay AS, Carhart-Harris RL, Mazibuko N, et al. Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. Sci Rep. 2018;8(1):8236. https://doi.org/10.1038/s41598-018-26656-2 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/253c5cc3-1741-4b18-b426-eb1ee0c424da/study-22.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kirkpatrick MG, Francis SM, Lee R, et al. Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans. Psychoneuroendocrinology. 2014;46:23-31. https://doi.org/10.1016/j.psyneuen.2014.04.006 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/78b671f3-2b99-43a8-9bbc-961fb7435c34/study-23.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Brooks BM, Cordero FJ, Alchermes SL, Brooks BM. Social pain: A systematic review on interventions. F1000Res. 2025;14:58. https://doi.org/10.12688/f1000research.159561.1 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/055de1e8-c363-4f43-af70-40b06b16af56/study-24.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kałużna A, Schlosser M, Gulliksen Craste E, et al. Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience. Journal of Psychedelic Studies. 2022. https://doi.org/10.1556/2054.2022.00199 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/83285ace-1621-43c8-8c05-8f85907d3fa8/study-25.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Wardle MC, de Wit H. MDMA alters emotional processing and facilitates positive social interaction. Psychopharmacology (Berl). 2014;231(21):4219-4229. https://doi.org/10.1007/s00213-014-3570-x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a05a15d7-d085-496c-8191-ebb9e532c9ef/study-26.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Stewart LH, Ferguson B, Morgan CJ, et al. Effects of ecstasy on cooperative behaviour and perception of trustworthiness: a naturalistic study. J Psychopharmacol. 2014;28(11):1001-1008. https://doi.org/10.1177/0269881114544775 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e49563b0-b1ea-4633-a407-36913da50eb7/study-27.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Smith SA, Mohammad H, Lee LHN, et al. Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review. Psychopharmacology (Berl). 2026. https://doi.org/10.1007/s00213-026-07110-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4352a836-2d09-46d5-8694-e5ffa9dbefb9/study-28.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dolder PC, Schmid Y, Müller F, et al. LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality. Neuropsychopharmacology. 2016;41(11):2638-2646. https://doi.org/10.1038/npp.2016.82 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/72a9bbe9-4d82-43df-915e-51646c85ee42/study-29.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Frye CG, Wardle MC, Norman GJ, de Wit H. MDMA decreases the effects of simulated social rejection. Pharmacol Biochem Behav. 2014;117:1-6. https://doi.org/10.1016/j.pbb.2013.11.030 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8bbb720f-6cb2-4e90-b1e8-ccdd0d320eca/study-30.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Weiss B, Nygart V, Pommerencke LM, et al. Examining Psychedelic-Induced Changes in Social Functioning and Connectedness in a Naturalistic Online Sample Using the Five-Factor Model of Personality. Front Psychol. 2021;12:749788. https://doi.org/10.3389/fpsyg.2021.749788 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/216586da-d8d3-498c-91d5-ce72e909acd3/study-31.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kirkpatrick M, Delton AW, Robertson TE, de Wit H. Prosocial effects of MDMA: A measure of generosity. J Psychopharmacol. 2015;29(6):661-668. https://doi.org/10.1177/0269881115573806 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/eb52a521-918a-4b41-94ed-b51067b70705/study-32.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: de Wit H, Hahn E, Smadi S, et al. MDMA as well as amphetamine and alcohol increase feelings of social closeness in healthy adults. Sci Rep. 2024;14(1):31312. https://doi.org/10.1038/s41598-024-82632-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/dbe115a7-5dbb-4d05-99d0-0c7cc75ed117/study-33.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Holze F, Avedisian I, Varghese N, et al. Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin. Front Pharmacol. 2021;12:711255. https://doi.org/10.3389/fphar.2021.711255 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/35685755-34cb-4992-8437-145c3c1c4e72/study-34.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dumont GJ, Sweep FC, van der Steen R, et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci. 2009;4(4):359-366. https://doi.org/10.1080/17470910802649470 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f85d0846-c003-4692-8110-2465cfb5dc42/study-35.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hogan GA, Wagner KE, Tichenor E, Barlott T. An Occupational Perspective on Psychedelic Therapy: A Scoping Review. Can J Occup Ther. 2024;91(3):272-287. https://doi.org/10.1177/00084174241228678 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/364429a5-fdf7-4713-920b-3722029c77c4/study-36.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bershad AK, Mayo LM, Van Hedger K, et al. Effects of MDMA on attention to positive social cues and pleasantness of affective touch. Neuropsychopharmacology. 2019;44(10):1698-1705. https://doi.org/10.1038/s41386-019-0402-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d1fb8d9d-c255-4e2b-8dfc-ba0032295870/study-37.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Carlyle M, Stevens T, Fawaz L, et al. Greater empathy in MDMA users. J Psychopharmacol. 2019;33(3):295-304. https://doi.org/10.1177/0269881119826594 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6ca5357a-e034-4739-8265-688d5b1ee450/study-38.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Molla H, Lee R, Lyubomirsky S, de Wit H. Drug-induced social connection: both MDMA and methamphetamine increase feelings of connectedness during controlled dyadic conversations. Sci Rep. 2023;13(1):15846. https://doi.org/10.1038/s41598-023-43156-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2f4ae192-d135-495d-8766-c9e5b0801a5c/study-39.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Roseman L, Ron Y, Saca A, et al. Relational Processes in Ayahuasca Groups of Palestinians and Israelis. Front Pharmacol. 2021;12:607529. https://doi.org/10.3389/fphar.2021.607529 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/112767a1-e713-45a1-b5b4-7d0545b5efe3/study-40.png Educational Resources - Social Connection and Relationships Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bershad AK, Hsu DT, de Wit H. MDMA enhances positive affective responses to social feedback. J Psychopharmacol. 2024;38(3):297-304. https://doi.org/10.1177/02698811231224153 https://www.harmreductionadvocate.com/educational-resources/creativity monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223994119-G2TAL9E2YUFW20KK3XLZ/illustration-creativity.jpg Educational Resources - Creativity https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/caea5957-6dbc-42fe-be65-f48b4633e55e/study-1.png Educational Resources - Creativity Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mason NL, Kuypers KPC, Reckweg JT, et al. Spontaneous and deliberate creative cognition during and after psilocybin exposure. Transl Psychiatry. 2021;11(1):209. https://doi.org/10.1038/s41398-021-01335-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/06c9335a-ed1d-480e-b2e5-7a32f4190b0c/study-2.png Educational Resources - Creativity Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wießner I, Falchi M, Maia LO, et al. LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking. J Psychopharmacol. 2022;36(3):348-359. https://doi.org/10.1177/02698811211069113 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/92f01b25-fbad-4c34-988a-42ca9fa50364/study-3.png Educational Resources - Creativity Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mason NL, Mischler E, Uthaug MV, et al. Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being. J Psychoactive Drugs. 2019;51(2):123-134. https://doi.org/10.1080/02791072.2019.1580804 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/688e9d7d-b87c-45c4-aa75-9298d356ab1e/study-4.png Educational Resources - Creativity Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Prochazkova L, Marschall J, van Elk M, et al. Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials. Neuropharmacology. 2026;284:110732. https://doi.org/10.1016/j.neuropharm.2025.110732 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1d39287a-5d5b-4873-86d9-6c81efb7e394/study-5.png Educational Resources - Creativity Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kuypers KP, Riba J, de la Fuente Revenga M, et al. Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology (Berl). 2016;233(18):3395-3403. https://doi.org/10.1007/s00213-016-4377-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c4fd93ec-b0fc-43b4-b6c7-a1ec8926b136/study-6.png Educational Resources - Creativity Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Basedow LA, Majić T, Hafiz NJ, et al. Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis. Sci Rep. 2024;14(1):14782. https://doi.org/10.1038/s41598-024-65391-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e1838d33-6e82-4076-a0c0-20f88f55da96/study-7.png Educational Resources - Creativity Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rominger C, Subow C. Feel connected to create: Self-reported psychedelic drug users exhibit higher sense of connectedness and better divergent thinking skills compared to non-users. PLoS One. 2025;20(4):e0320755. https://doi.org/10.1371/journal.pone.0320755 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/17837d40-42f3-4349-89c3-e6f460e4f90c/study-8.png Educational Resources - Creativity Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Frecska E, Móré CE, Vargha A, Luna LE. Enhancement of creative expression and entoptic phenomena as after-effects of repeated ayahuasca ceremonies. J Psychoactive Drugs. 2012;44(3):191-199. https://doi.org/10.1080/02791072.2012.703099 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6adaf15a-c1dc-47da-8edd-b0834cebe2a4/study-9.png Educational Resources - Creativity Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Sweat NW, Bates LW, Hendricks PS. The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving. J Psychoactive Drugs. 2016;48(5):344-350. https://doi.org/10.1080/02791072.2016.1234090 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7cf4e3d1-b97c-44db-845c-88466ba8fe06/study-10.png Educational Resources - Creativity Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Costa MÂ. A Dose of Creativity: An Integrative Review of the Effects of Serotonergic Psychedelics on Creativity. J Psychoactive Drugs. 2023;55(3):299-309. https://doi.org/10.1080/02791072.2022.2106805 https://www.harmreductionadvocate.com/educational-resources/inflammation-and-the-immune-system monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223981012-8AP04WNW8IF3QDWM02L2/illustration-inflammation-and-the-immune-system.jpg Educational Resources - Inflammation and the Immune System https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e4cce352-f7bc-4b18-bea8-09dcf3aa5e6f/study-1.png Educational Resources - Inflammation and the Immune System Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mason NL, Szabo A, Kuypers KPC, et al. Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study. Brain Behav Immun. 2023;114:299-310. https://doi.org/10.1016/j.bbi.2023.09.004 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fff6ffc6-3829-44be-b15f-8326f0a4555b/study-2.png Educational Resources - Inflammation and the Immune System Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Galvão-Coelho NL, de Menezes Galvão AC, de Almeida RN, et al. Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. J Psychopharmacol. 2020;34(10):1125-1133. https://doi.org/10.1177/0269881120936486 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/825e710b-9da6-4762-9ce2-f15ababdc565/study-3.png Educational Resources - Inflammation and the Immune System Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Low ZXB, Ng WS, Lim ESY, et al. The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111139. https://doi.org/10.1016/j.pnpbp.2024.111139 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/77daa31e-adb5-4c13-a19a-b4bd1460eaf4/study-4.png Educational Resources - Inflammation and the Immune System Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Qureshi O, Cowley J, Pegg A, et al. Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation? Br J Pharmacol. 2026;183(14):4006-4021. https://doi.org/10.1111/bph.70138 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c3d0a20e-591c-4e3a-bdc0-caf98b8d5238/study-5.png Educational Resources - Inflammation and the Immune System Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Garcia-Romeu A, Naudé GP, Rebman AW, et al. Pilot study of psilocybin in patients with post-treatment lyme disease. Sci Rep. 2026;16(1):7497. https://doi.org/10.1038/s41598-026-38091-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2839f6bd-939c-4cfa-8d26-d0c4a5427a94/study-6.png Educational Resources - Inflammation and the Immune System Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zhan Y, Zhou Y, Zheng W, et al. Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder. Transl Psychiatry. 2020;10(1):246. https://doi.org/10.1038/s41398-020-00933-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/105ae8dc-3085-4dcf-bcd1-a7f8c4f86471/study-7.png Educational Resources - Inflammation and the Immune System Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Chen P, Qian K, Zhu K, et al. Esketamine modulates postoperative biochemical markers of oxidative stress, inflammation, and immune dysregulation in laparoscopic colorectal cancer surgery. J Med Biochem. 2025;44(5):1020-1027. https://doi.org/10.5937/jomb0-56862 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c9d1d4c6-0a5b-4b88-9f93-5db542b55699/study-8.png Educational Resources - Inflammation and the Immune System Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Uthaug MV, Lancelotta R, Szabo A, et al. Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology (Berl). 2020;237(3):773-785. https://doi.org/10.1007/s00213-019-05414-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6cd6d187-e908-44e7-abe5-5ea1d3caf569/study-9.png Educational Resources - Inflammation and the Immune System Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Jones GH, Gilbert JR, Johnston JN, et al. Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics. Mol Psychiatry. 2026. https://doi.org/10.1038/s41380-026-03777-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/11ceeafa-00e8-4d9a-a085-d28a24222831/study-10.png Educational Resources - Inflammation and the Immune System Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dawson KL, Carangan AMJM, Klunder J, et al. Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study. Transl Psychiatry. 2025;15(1):452. https://doi.org/10.1038/s41398-025-03683-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/828bcd4f-1f20-4279-a5ba-1bb2c2ccdd14/study-11.png Educational Resources - Inflammation and the Immune System Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Semple MG, Mennenga SE, Smith R, et al. Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA. Transl Psychiatry. 2026;16(1):524. https://doi.org/10.1038/s41398-026-04191-3 https://www.harmreductionadvocate.com/educational-resources/brain-imaging-research monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223973603-M4T4OEMNF416PP9TP3DR/illustration-brain-imaging-research.jpg Educational Resources - Brain Imaging Research https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/39e62725-7faf-4fb7-abb7-9289f867d1af/study-1.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wall MB, Demetriou L, Giribaldi B, Roseman L, Ertl N, Erritzoe D, et al. Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression. The American journal of psychiatry. 2025;182(6):569-582. https://doi.org/10.1176/appi.ajp.20230751 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b506bb6b-5316-4bcf-b474-bb37a0b4117e/study-2.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Siegel JS, Subramanian S, Perry D, Kay BP, Gordon EM, Laumann TO, et al. Psilocybin desynchronizes the human brain. Nature. 2024;632(8023):131-138. https://doi.org/10.1038/s41586-024-07624-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5f0851bf-568d-4b55-8db8-3caaf15b568b/study-3.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Timmermann C, Roseman L, Haridas S, Rosas FE, Luan L, Kettner H, et al. Human brain effects of DMT assessed via EEG-fMRI. Proceedings of the National Academy of Sciences of the United States of America. 2023;120(13):e2218949120. https://doi.org/10.1073/pnas.2218949120 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ff06d9c4-4aff-489b-b7fa-ca2f708bda5d/study-4.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44(7):1328-1334. https://doi.org/10.1038/s41386-019-0324-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6e46b5e2-89d6-4bb9-86d3-074768635fbd/study-5.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Girn M, Doss MK, Roseman L, et al. An international mega-analysis of psychedelic drug effects on brain circuit function. Nat Med. 2026;32(4):1543-1554. https://doi.org/10.1038/s41591-026-04287-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/afb8d4fd-a15d-4acc-876e-591a822105c1/study-6.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kraehenmann R, Preller KH, Scheidegger M, et al. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biol Psychiatry. 2015;78(8):572-581. https://doi.org/10.1016/j.biopsych.2014.04.010 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9385e85a-3d5d-4a01-9c6b-b69db58152cf/study-7.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012;109(6):2138-2143. https://doi.org/10.1073/pnas.1119598109 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b461d989-1762-4296-a45f-3ade5a4b2bbf/study-8.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Tagliazucchi E, Carhart-Harris R, Leech R, et al. Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum Brain Mapp. 2014;35(11):5442-5456. https://doi.org/10.1002/hbm.22562 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/241e4f8b-c375-49ff-ae70-dba42aa35098/study-9.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Stoliker D, Novelli L, Khajehnejad M, et al. Psychedelics align brain activity with context. Nature. 2026;656(8129):936-947. https://doi.org/10.1038/s41586-026-10910-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8d4bd0e7-5240-4e21-b0b1-b028cc0e322a/study-10.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Yu Z, Burback L, Winkler O, et al. Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review. Front Psychiatry. 2024;15:1386321. https://doi.org/10.3389/fpsyt.2024.1386321 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e0c3bebf-4514-4fcb-85f4-981ba5940ff1/study-11.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lyons T, Spriggs M, Kerkelä L, et al. Human brain changes after first psilocybin use. Nat Commun. 2026;17(1):3977. https://doi.org/10.1038/s41467-026-71962-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c73b13b6-e7dc-4bf4-b8e8-87b97a78594b/study-12.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Barrett FS, Doss MK, Sepeda ND, et al. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10(1):2214. https://doi.org/10.1038/s41598-020-59282-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/510c72d0-311f-43df-9fee-5546e2bf792e/study-13.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Silva-Costa N, Pessoa JA, Andrade KC, et al. Predicting and exploring ayahuasca effects: Perception, mind-wandering, and EEG oscillations. J Psychopharmacol. 2026;40(8):1305-1320. https://doi.org/10.1177/02698811251389563 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a25f69fc-e14c-490e-8379-4e7e1b0792e0/study-14.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Singleton SP, Luppi AI, Carhart-Harris RL, et al. Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape. Nat Commun. 2022;13(1):5812. https://doi.org/10.1038/s41467-022-33578-1 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3ad1aac7-abdc-49bf-8c89-f49a34c5f96e/study-15.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Mallaroni P, Singleton SP, Mason NL, et al. Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin. Mol Psychiatry. 2026;31(6):3295-3307. https://doi.org/10.1038/s41380-026-03447-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/16a11ff7-12d8-4a53-bf44-898f5c78d962/study-16.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Vohryzek J, Luppi AI, Atasoy S, et al. N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences. Neuropsychopharmacology. 2025;50(12):1768-1776. https://doi.org/10.1038/s41386-025-02190-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/38601240-30cb-4691-892a-d4119e5934d4/study-17.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Abdallah CG, Ahn KH, Averill LA, et al. A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants. Neuropsychopharmacology. 2021;46(2):478-485. https://doi.org/10.1038/s41386-020-00864-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c78dc8ec-601b-4534-8932-1d97ac599e65/study-18.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mueller F, Lenz C, Dolder PC, et al. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry. 2017;7(4):e1084. https://doi.org/10.1038/tp.2017.54 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a4aad9c5-76c7-47c0-86cb-57f8580e1625/study-19.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pasquini L, Vohryzek J, Escrichs A, et al. Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits. Hum Brain Mapp. 2026;47(10):e70596. https://doi.org/10.1002/hbm.70596 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/49a9ad38-877b-4a3f-bae8-29aaab7a1cfe/study-20.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Timmermann C, Roseman L, Schartner M, et al. Neural correlates of the DMT experience assessed with multivariate EEG. Sci Rep. 2019;9(1):16324. https://doi.org/10.1038/s41598-019-51974-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2d65dcf9-3ea6-44ce-a60f-5030d85a853d/study-21.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Egger K, Bozsak R, Aicher HD, et al. Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomized [18F]FDG-PET study. J Cereb Blood Flow Metab. 2026;46(9):2411-2425. https://doi.org/10.1177/0271678x261454172 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8113f87f-1650-4684-8e3d-4c4a020668a6/study-22.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Soares C, Lima G, Pais ML, et al. Increased functional connectivity between brain regions involved in social cognition, emotion and affective-value in psychedelic states induced by N,N-Dimethyltryptamine (DMT). Front Pharmacol. 2024;15:1454628. https://doi.org/10.3389/fphar.2024.1454628 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/112de440-23c6-4afa-a4b6-6ba3ec9c8833/study-23.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zhang X, Hack LM, Bertrand C, et al. Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial. JAMA Netw Open. 2025;8(4):e257803. https://doi.org/10.1001/jamanetworkopen.2025.7803 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/eb254164-2d6d-40de-85d2-c0be6244e04e/study-24.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lebedev AV, Kaelen M, Lövdén M, et al. LSD-induced entropic brain activity predicts subsequent personality change. Hum Brain Mapp. 2016;37(9):3203-3213. https://doi.org/10.1002/hbm.23234 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e3c8a763-c34c-4a76-95a2-c92b82545db7/study-25.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Abdallah CG, De Feyter HM, Averill LA, et al. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology. 2018;43(10):2154-2160. https://doi.org/10.1038/s41386-018-0136-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3a1e755d-3535-471a-b1ea-aaf1b109c806/study-26.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Meiering MS, Weigner D, Gärtner M, et al. Ketamine's impact on rumination-related brain dynamics: insights from a randomized controlled fMRI trial. Transl Psychiatry. 2026;16(1):417. https://doi.org/10.1038/s41398-026-04392-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c8f8af91-4a04-4e32-ae00-611573a92ca5/study-27.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zhang L, Shi W, Zhao Z, et al. Lysergic acid diethylamide-derived excitatory/inhibitory ratio change enhances global synchrony in functional brain dynamics. PLoS Comput Biol. 2025;21(12):e1013822. https://doi.org/10.1371/journal.pcbi.1013822 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/10124741-f487-43e0-a344-1d27d0b35975/study-28.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Calder AE, Diehl VJ, Lietz MP, et al. Acute and post-acute neurobehavioral responses to lysergic acid diethylamide in healthy subjects: a randomized controlled study. Neuropsychopharmacology. 2026;51(9):1577-1587. https://doi.org/10.1038/s41386-026-02454-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ba7e6fc3-afeb-4f9e-90eb-5298a5f7818c/study-29.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sampedro F, de la Fuente Revenga M, Valle M, et al. Assessing the Psychedelic "After-Glow" in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities. Int J Neuropsychopharmacol. 2017;20(9):698-711. https://doi.org/10.1093/ijnp/pyx036 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/38f4bbfc-487e-4b09-9fd0-c7b4e6b6381a/study-30.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Pines AR, Zhang X, Kochalka J, et al. Psychedelics disrupt hierarchical cortical propagations in the default mode network of humans and mice. Proc Natl Acad Sci U S A. 2026;123(24):e2522000123. https://doi.org/10.1073/pnas.2522000123 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ef57039a-9969-4b57-93f7-6466918e2ff8/study-31.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Scheidegger M, Henning A, Walter M, et al. Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation. Hum Brain Mapp. 2016;37(5):1941-1952. https://doi.org/10.1002/hbm.23148 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/56ac26bd-5824-4830-8891-9f5542153aeb/study-32.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Soares C, Lima G, Teixeira M, et al. Ayahuasca enhances functional connectivity in the third visual pathway and mirror neuron networks: a crossover, multiple-dose functional MRI study. Soc Cogn Affect Neurosci. 2026;21(1):nsag004. https://doi.org/10.1093/scan/nsag004 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2eef1aab-0935-45c0-96f1-249391c87c4f/study-33.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Melani A, Bonaso M, Biso L, et al. Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications. Pharmaceuticals (Basel). 2025;18(1):130. https://doi.org/10.3390/ph18010130 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0e37d92b-92e2-4f0b-8cfe-e5e56d4d4ae8/study-34.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bedford P, Hauke DJ, Wang Z, et al. The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity. Neuropsychopharmacology. 2023;48(8):1175-1183. https://doi.org/10.1038/s41386-023-01574-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f6ee0e16-8fb5-42cd-939f-24fe02fb9697/study-35.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Carhart-Harris RL, Wall MB, Erritzoe D, et al. The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol. 2014;17(4):527-540. https://doi.org/10.1017/s1461145713001405 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c11e32d0-66ad-41da-9bfe-b4c36bf5ffb0/study-36.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kroupi E, Araujo H, Oosterveld C, et al. Higher signal diversity, network dysregulation, and increased well-being under DMT administration: An EEG study. Brain Res. 2026;1892:150530. https://doi.org/10.1016/j.brainres.2026.150530 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f8c00cd8-294d-4eae-81ad-259f0f5b5c17/study-37.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Niesters M, Khalili-Mahani N, Martini C, et al. Effect of subanesthetic ketamine on intrinsic functional brain connectivity: a placebo-controlled functional magnetic resonance imaging study in healthy male volunteers. Anesthesiology. 2012;117(4):868-877. https://doi.org/10.1097/aln.0b013e31826a0db3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/08c42504-f85a-4c9f-b061-168916841a61/study-38.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Molla H, Novembre G, Bershad A, et al. MDMA modulates human sensorimotor cortical pathways during gentle touch. Imaging Neurosci (Camb). 2024;2:imag-2-00316. https://doi.org/10.1162/imag_a_00316 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/153eb759-e83b-46cb-8939-ec35cf61dfe9/study-39.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Coverdale NS, Cook DJ. Mechanisms of integration in psychedelic-assisted therapy. J Mil Veteran Fam Health. 2023;9(5):38-55. https://doi.org/10.3138/jmvfh-2023-0014 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/58a55ecc-d1e7-41a9-8838-7f9ee0fa4bb7/study-40.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nikolič M, Froese T, Mediano PAM, et al. Psilocybin-induced changes in electroencephalography link acute and long-term effects. J Psychopharmacol. 2026:2698811261473445. https://doi.org/10.1177/02698811261473445 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e8b6b1e8-acd6-4608-9f67-51b2774114bb/study-41.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Carhart-Harris RL, Muthukumaraswamy S, Roseman L, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A. 2016;113(17):4853-4858. https://doi.org/10.1073/pnas.1518377113 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b8d0fab1-8979-4e80-a74b-447a2bac9d99/study-42.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dai R, Jang H, Hudetz AG, et al. Opposite network patterns of integration-segregation in psychedelic and sedated states of consciousness. Cell Rep. 2026;45(8):117830. https://doi.org/10.1016/j.celrep.2026.117830 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/da959631-e2ae-4bac-9ee0-cf5197bfd7b2/study-43.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Shaw AD, Saxena N, E Jackson L, et al. Ketamine amplifies induced gamma frequency oscillations in the human cerebral cortex. Eur Neuropsychopharmacol. 2015;25(8):1136-1146. https://doi.org/10.1016/j.euroneuro.2015.04.012 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/923389c8-dd18-4d53-b3d1-9cd6db73333c/study-44.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zang Z, Li A, Zhang Z, et al. Intranasal (R)-ketamine modulates depression symptom and neurotransmitters-associated human brain connectivity. Neurotherapeutics. 2026;23(1):e00790. https://doi.org/10.1016/j.neurot.2025.e00790 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7f453c2f-d164-49db-9a97-ad7a624d0348/study-45.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Höflich A, Kraus C, Pfeiffer RM, et al. Translating the immediate effects of S-Ketamine using hippocampal subfield analysis in healthy subjects-results of a randomized controlled trial. Transl Psychiatry. 2021;11(1):200. https://doi.org/10.1038/s41398-021-01318-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/18febcc3-1067-4eb8-8d05-b6675a56eb76/study-46.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Tagliazucchi E, Roseman L, Kaelen M, et al. Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. Curr Biol. 2016;26(8):1043-1050. https://doi.org/10.1016/j.cub.2016.02.010 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/31be17c6-1318-4236-84e9-e85490d0b63c/study-47.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Orłowski P, Domagalik A, Bola M. Investigating Emotional Reactivity in Experienced Users of Psychedelics: A Cross-Sectional fMRI Study. Hum Brain Mapp. 2026;47(5):e70522. https://doi.org/10.1002/hbm.70522 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/766eaa62-1f92-4bdf-a380-d597cfb94a31/study-48.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lima G, Soares C, Teixeira M, et al. Inhaled N, N-dimethyltryptamine diminishes connectivity between the ventral tegmental area and the nucleus accumbens: relevance to pathologies of mesolimbic and mesocortical pathways. Sci Rep. 2025;16(1):1744. https://doi.org/10.1038/s41598-025-31431-1 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4a7308c9-4647-4056-af85-cf0322dabe8c/study-49.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Schartner MM, Carhart-Harris RL, Barrett AB, et al. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Sci Rep. 2017;7:46421. https://doi.org/10.1038/srep46421 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e7918649-26b4-4620-8d9b-6159e4e09551/study-50.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Haggarty CJ, Bershad AK, Kumar MK, et al. The 3,4-methylenedioxymethamphetamine enhances early visual processing for salient socio-emotional stimuli. Eur J Neurosci. 2024;59(12):3224-3235. https://doi.org/10.1111/ejn.16346 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/20c2b8bd-e52b-407d-b255-94d978b91b50/study-51.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Castelhano J, Lima G, Teixeira M, et al. The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies. Front Pharmacol. 2021;12:739053. https://doi.org/10.3389/fphar.2021.739053 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/358b56cb-da6a-4f51-9ceb-23c3ca9db6c5/study-52.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Mäki-Marttunen V. Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptors. Commun Biol. 2026;9(1):672. https://doi.org/10.1038/s42003-026-09912-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/237dc6e2-a708-45e7-9916-1b3a104b0d16/study-53.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rocha JM, Osório FL, Crippa JAS, et al. Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature. Ther Adv Psychopharmacol. 2019;9:2045125319845774. https://doi.org/10.1177/2045125319845774 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a52f86b6-3961-4ee7-bde3-efed765d235c/study-54.png Educational Resources - Brain Imaging Research Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Holze F, Larsen K, Ozenne B, et al. LSD treatment affects working memory-related brain function in patients with major depressive disorder. Translational Psychiatry. 2026. https://doi.org/10.1038/s41398-026-04522-4 https://www.harmreductionadvocate.com/educational-resources/premenstrual-dysphoric-disorder monthly 0.5 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223966336-DV6KFXLPHDB4C6XN0FYV/illustration-premenstrual-dysphoric-disorder.jpg Educational Resources - Premenstrual Dysphoric Disorder https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9fe8077d-4322-4f4f-ba77-4d7b3e3d41f9/study-1.png Educational Resources - Premenstrual Dysphoric Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Nazareth M, Paone V, Yaden ME, et al. Cannabis, Psychedelics, and Other Substance Use to Manage Premenstrual Symptoms: A Survey Study. J Womens Health (Larchmt). 2026;35(10):994-1003. https://doi.org/10.1177/15409996261459360 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/069e0cf5-889c-4731-a232-83da6e523052/study-2.png Educational Resources - Premenstrual Dysphoric Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Gukasyan N, Narayan SK. Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series. J Psychoactive Drugs. 2024;56(1):50-55. https://doi.org/10.1080/02791072.2022.2157350 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4fce93d2-9dad-4b74-8acd-c1b20d8306b7/study-3.png Educational Resources - Premenstrual Dysphoric Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fadiman J, Korb S. Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. J Psychoactive Drugs. 2019;51(2):118-122. https://doi.org/10.1080/02791072.2019.1593561 https://www.harmreductionadvocate.com/educational-resources/pregnancy-and-postpartum monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223960156-FURX3HQ3PSTNC5QK36CA/illustration-pregnancy-and-postpartum.jpg Educational Resources - Pregnancy and Postpartum https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1f7f9805-f9d1-4ddc-8cbf-1619e1f1b38a/study-1.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wang S, Deng CM, Zeng Y, et al. Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial. BMJ. 2024;385:e078218. https://doi.org/10.1136/bmj-2023-078218 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bbb2874c-db34-4508-a72b-8c2c7b0dba13/study-2.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Chen Y, Guo Y, Wu H, et al. Perioperative Adjunctive Esketamine for Postpartum Depression Among Women Undergoing Elective Cesarean Delivery: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(3):e240953. https://doi.org/10.1001/jamanetworkopen.2024.0953 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7b96b705-453d-46d7-9eda-38fe48868bfd/study-3.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ma JH, Wang SY, Yu HY, et al. Prophylactic use of ketamine reduces postpartum depression in Chinese women undergoing cesarean section. Psychiatry Res. 2019;279:252-258. https://doi.org/10.1016/j.psychres.2019.03.026 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/902be9db-ce02-455e-b627-da94b6979cd1/study-4.png Educational Resources - Pregnancy and Postpartum Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Li Q, Wang S, Mei X. A single intravenous administration of a sub-anesthetic ketamine dose during the perioperative period of cesarean section for preventing postpartum depression: A meta-analysis. Psychiatry Res. 2022;310:114396. https://doi.org/10.1016/j.psychres.2022.114396 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d2f92394-7f92-4d90-becd-f3f770728a8f/study-5.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Darwish MY, Helal AA, Othman YA, et al. Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis. BMC Pregnancy Childbirth. 2025;25(1):125. https://doi.org/10.1186/s12884-025-07186-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e4653639-8e85-47e5-8083-31a307a4b28b/study-6.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Shi H, Zheng C, Shou H, Zhu B. Prophylactic esketamine for postpartum depression after cesarean section: a systematic review and meta-analysis. J Affect Disord. 2025;388:119631. https://doi.org/10.1016/j.jad.2025.119631 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/24205a00-4280-4140-8a24-49cea5279ae2/study-7.png Educational Resources - Pregnancy and Postpartum Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Jiang Q, Qi Y, Zhou M, et al. Effect of esketamine on serum neurotransmitters in patients with postpartum depression: a randomized controlled trial. BMC Anesthesiol. 2024;24(1):293. https://doi.org/10.1186/s12871-024-02681-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ff76b80b-a55b-48b7-b090-a178ba1e2b93/study-8.png Educational Resources - Pregnancy and Postpartum Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Frivaldszky L, Lőrincz K, Hoferica J, et al. Esketamine reduces the risk of postpartum depression in women undergoing cesarean section: A systematic review and meta-analysis. J Psychiatr Res. 2025;183:164-173. https://doi.org/10.1016/j.jpsychires.2025.02.021 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d0646aca-f940-4dfb-8dd5-5183b9c3b83b/study-9.png Educational Resources - Pregnancy and Postpartum Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Parsaei M, Hasehmi SM, Seyedmirzaei H, et al. Perioperative esketamine administration for prevention of postpartum depression after the cesarean section: A systematic review and meta-analysis. J Affect Disord. 2024;361:564-580. https://doi.org/10.1016/j.jad.2024.06.080 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2e0c20d0-fa94-455b-9362-5195248268b1/study-10.png Educational Resources - Pregnancy and Postpartum Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zhang XQ, Li S, Qin XL. Impact of esketamine intravenous analgesic pump on pain and depression post-cesarean. BMC Surg. 2025;25(1):144. https://doi.org/10.1186/s12893-025-02868-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b8bc4d4f-066b-49dd-9a92-71a1cbb0b134/study-11.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Alipoor M, Loripoor M, Kazemi M, et al. The effect of ketamine on preventing postpartum depression. J Med Life. 2021;14(1):87-92. https://doi.org/10.25122/jml-2020-0116 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b3c3a904-c705-43bd-a6e4-e25231f4a783/study-12.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Li S, Zhuo Z, Li R, Guo K. Efficacy of esketamine for the treatment of postpartum depression and pain control following cesarean section: a randomized, double-blind, controlled clinical trial. BMC Anesthesiol. 2024;24(1):52. https://doi.org/10.1186/s12871-024-02436-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3a2490be-88f0-4dc8-b237-d8589450f8f1/study-13.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zhang B, Zhou Q, Zhou Q. Esketamine for postoperative analgesia after cesarean section: Effects on pain, mood, sleep quality, and safety. Medicine (Baltimore). 2025;104(37):e44432. https://doi.org/10.1097/md.0000000000044432 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6f07780c-067b-422e-a2a2-0e1e3f5c8459/study-14.png Educational Resources - Pregnancy and Postpartum Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Jing R, Tu Y. Single low-dose esketamine improves postpartum depression symptoms and recovery quality in cesarean section women. Am J Transl Res. 2026;18(2):1287-1297. https://doi.org/10.62347/euok7911 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c7c25563-973e-48bf-982e-2bb900520db9/study-15.png Educational Resources - Pregnancy and Postpartum Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ma S, Dou Y, Wang W, et al. Association between esketamine interventions and postpartum depression and analgesia following cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2024;6(3):101241. https://doi.org/10.1016/j.ajogmf.2023.101241 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7ce30c82-d8ac-4030-b8fa-826112410408/study-16.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jiang T, Zhao R. Efficacy and safety of esketamine for pain control after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2025;16:1708221. https://doi.org/10.3389/fphar.2025.1708221 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/72687e6c-1381-41c8-960c-d486f2e4dabd/study-17.png Educational Resources - Pregnancy and Postpartum Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Chu T, Peng X, Wan K, et al. Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial. Eur J Anaesthesiol. 2026;43(7):584-593. https://doi.org/10.1097/eja.0000000000002348 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/edb91c37-7afc-4bfd-8d9a-e5e24cbe837b/study-18.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ren L, Zhang T, Zou B, et al. Intraoperative Esketamine and Postpartum Depression Among Women With Cesarean Delivery: A Randomized Clinical Trial. JAMA Netw Open. 2025;8(2):e2459331. https://doi.org/10.1001/jamanetworkopen.2024.59331 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/caea2c9c-1b50-4758-892b-b94819037cb3/study-19.png Educational Resources - Pregnancy and Postpartum Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Xue-Song, Xu YY, Xiong HP, et al. Efficacy of esketamine after cesarean section for women with symptoms of prenatal depression: A randomized controlled trial. Psychiatry Res. 2026;355:116849. https://doi.org/10.1016/j.psychres.2025.116849 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5629c5e1-c05c-4b88-848c-43d6b661bd60/study-20.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zhang H, Jiang YA, Fu H, et al. Association of multimodal analgesic protocol with postpartum depression incidence and sleep quality in high-risk parturients. Front Med (Lausanne). 2026;13:1828838. https://doi.org/10.3389/fmed.2026.1828838 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a029488c-f08a-4b6b-a26a-ba09f73c71ad/study-21.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Yang J, Yan Q, Zhang T, et al. Bolus versus Continuous Infusion of Esketamine for Prevention of Postpartum Depression After Caesarean Delivery: A Randomized, Double-Blind, Controlled Trial. Drug Des Devel Ther. 2026;20:601347. https://doi.org/10.2147/dddt.s601347 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5a5a6a9e-641b-49d2-b589-6eab926045fb/study-22.png Educational Resources - Pregnancy and Postpartum Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Li Y, Zhao K, Cao P, et al. Perioperative use of esketamine for the prevention of postpartum depression after cesarean section: a meta-analysis. BMC Pregnancy Childbirth. 2025;25(1):775. https://doi.org/10.1186/s12884-025-07809-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3b21270a-29b8-4f73-8191-e64f281fd3bc/study-23.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wang Y, Lin X, Zou X, et al. Effects of esketamine on postoperative pain, anxiety, depression, sleep, and inflammation in pregnancies undergoing cesarean section: A randomized controlled trial. PLoS One. 2026;21(1):e0328585. https://doi.org/10.1371/journal.pone.0328585 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/497a5098-6ac0-4e70-9bb5-f88425b4404e/study-24.png Educational Resources - Pregnancy and Postpartum Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nayyer MA, Khan SM, Umer M, et al. Efficacy and safety of peri-partum Esketamine for prevention of post-partum depression in women undergoing caesarian section: A meta-analysis and systematic review of randomized controlled trials. Asian J Psychiatr. 2024;97:104090. https://doi.org/10.1016/j.ajp.2024.104090 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/517799ad-cf4b-4e1a-ac8c-c18ff8747ece/study-25.png Educational Resources - Pregnancy and Postpartum Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Wen Y, Mao M, Wang X, et al. Efficacy and safety of perioperative application of esketamine on postpartum depression: A meta-analysis of randomized controlled studies. Psychiatry Res. 2024;333:115765. https://doi.org/10.1016/j.psychres.2024.115765 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c5785985-ca34-4507-869c-bce84caf38e3/study-26.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Siu S, Hsin P, Simon S, et al. Effect of Perioperative Ketamine on Early Postpartum Depressive Symptoms Following Cesarean Section: A Meta-Analysis. Cureus. 2026;18(4):e107180. https://doi.org/10.7759/cureus.107180 https://www.harmreductionadvocate.com/educational-resources/older-adults monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223929258-2E585YOQFR22ULTQO945/illustration-older-adults.jpg Educational Resources - Older Adults https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6c5237ef-98f1-422e-9c27-b56f71e1f252/study-1.png Educational Resources - Older Adults Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Family N, Maillet EL, Williams LTJ, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology (Berl). 2020;237(3):841-853. https://doi.org/10.1007/s00213-019-05417-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7d2ef792-6984-4099-9f9c-8a206ab86713/study-2.png Educational Resources - Older Adults Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bradley ER, Sakai K, Fernandes-Osterhold G, et al. Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial. Neuropsychopharmacology. 2025;50(8):1200-1209. https://doi.org/10.1038/s41386-025-02097-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/691c61d2-4d0a-4ea5-a8e9-8ff6676bf552/study-3.png Educational Resources - Older Adults Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Anderson BT, Danforth A, Daroff PR, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020;27:100538. https://doi.org/10.1016/j.eclinm.2020.100538 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7a36fbc9-d33b-4fd9-969d-b94084f380ed/study-4.png Educational Resources - Older Adults Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kettner H, Roseman L, Gazzaley A, et al. Effects of Psychedelics in Older Adults: A Prospective Cohort Study. Am J Geriatr Psychiatry. 2024;32(9):1047-1059. https://doi.org/10.1016/j.jagp.2024.05.007 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f38945ed-b0fd-4946-aba9-70eb7a451d30/study-5.png Educational Resources - Older Adults Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Huang C, Yang R, Xie X, et al. Effect of small dose esketamine on perioperative neurocognitive disorder and postoperative depressive symptoms in elderly patients undergoing major elective noncardiac surgery for malignant tumors: A randomized clinical trial. Medicine (Baltimore). 2024;103(42):e40028. https://doi.org/10.1097/md.0000000000040028 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/47ae811f-4cef-44fe-8e93-a16e3be91861/study-6.png Educational Resources - Older Adults Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zhang T, Yan S, Wang H, Wang L. Efficacy and Safety of Intravenous Esketamine in Elderly Patients Undergoing Laparoscopic Radical Prostatectomy. J Vis Exp. 2026(227). https://doi.org/10.3791/69250 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5c6eb37e-c9eb-4415-9c6c-bc49e0b6c467/study-7.png Educational Resources - Older Adults Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zhao Y, Ye C, He Y, et al. Effect of Esketamine for Patient-Controlled Intravenous Analgesia on Postoperative Sleep Disturbance in the Elderly After Total Hip or Knee Arthroplasty: A Prospective, Randomized, Double-Blind, and Controlled Trial. J Arthroplasty. 2026;41(1):81-89. https://doi.org/10.1016/j.arth.2025.06.009 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4aaa891e-f763-45d6-a0eb-e67ee504ebd1/study-8.png Educational Resources - Older Adults Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Jia X, Liao X, Zhou M. Effects of Esketamine on Haemodynamics and Inflammatory Stress Response in Elderly Patients Undergoing Proximal Femoral Surgery. J Coll Physicians Surg Pak. 2025;35(2):141-146. https://doi.org/10.29271/jcpsp.2025.02.141 https://www.harmreductionadvocate.com/educational-resources/veterans monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223922185-OWMHZS56A1KWVG2XNUND/illustration-veterans.jpg Educational Resources - Veterans https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b3a7d4da-beb8-46b8-8cf7-353330f77db2/study-1.png Educational Resources - Veterans Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mithoefer MC, Mithoefer AT, Feduccia AA, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018;5(6):486-497. https://doi.org/10.1016/s2215-0366(18)30135-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2b686f84-428c-475c-b381-1a468c94d8ab/study-2.png Educational Resources - Veterans Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Abdallah CG, Roache JD, Gueorguieva R, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022;47(8):1574-1581. https://doi.org/10.1038/s41386-022-01266-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/530eba81-d41a-4294-bd53-675903245539/study-3.png Educational Resources - Veterans Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Cherian KN, Keynan JN, Anker L, et al. Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nat Med. 2024;30(2):373-381. https://doi.org/10.1038/s41591-023-02705-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/05e26e25-7822-4cd6-b1fb-9e424f7c0744/study-4.png Educational Resources - Veterans Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Armstrong SB, Levin AW, Sepeda ND, et al. Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial. Commun Med (Lond). 2026;6(1):411. https://doi.org/10.1038/s43856-026-01767-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/af7e9854-5698-4ed9-9710-50fcf6c6db73/study-5.png Educational Resources - Veterans Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Calnan M, Blest-Hopley G, Busch C, et al. Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings. Brain Behav. 2025;15(7):e70660. https://doi.org/10.1002/brb3.70660 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8af3dab4-2b03-4a64-97bf-3d74063b819c/study-6.png Educational Resources - Veterans Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Davis AK, Xin Y, Sepeda N, Averill LA. Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico. Am J Drug Alcohol Abuse. 2023;49(5):587-596. https://doi.org/10.1080/00952990.2023.2220874 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b2374745-f362-434d-bc1e-10d74f4f38da/study-7.png Educational Resources - Veterans Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Titone MK, Hunt C, Bismark A, et al. The effect of obstructive sleep apnea severity on PTSD symptoms during the course of esketamine treatment: a retrospective clinical study. J Clin Sleep Med. 2023;19(12):2043-2051. https://doi.org/10.5664/jcsm.10746 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/69ffc0ed-0a66-4629-aad6-9a9a36520874/study-8.png Educational Resources - Veterans Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Morland LA, Khalifian CE, Perivoliotis D, et al. Healing together: Results from a pilot trial of 3,4-Methylenedioxymethamphetamine-enhanced cognitive-behavioral conjoint therapy for posttraumatic stress disorder. J Trauma Stress. 2026. https://doi.org/10.1002/jts.70126 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/43e75ba2-1a4b-42c0-95ba-45d572b0367d/study-9.png Educational Resources - Veterans Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Mangini P, Averill LA, Davis AK. Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans. Journal of Psychedelic Studies. 2022. https://doi.org/10.1556/2054.2021.00176 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b8a80dab-4447-44f1-bdda-a549b8b93cfa/study-10.png Educational Resources - Veterans Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: McGhee LL, Maani CV, Garza TH, et al. The correlation between ketamine and posttraumatic stress disorder in burned service members. J Trauma. 2008;64(2 Suppl):S195-8; Discussion S197-8. https://doi.org/10.1097/ta.0b013e318160ba1d https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/64dc38cd-5b1e-4a60-90a5-a159dc95f8ca/study-11.png Educational Resources - Veterans Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Sridhar M, Azeez A, Geoly AD, et al. Neural Correlates of Ibogaine: Evidence From Functional Neuroimaging of Military Veterans. Biol Psychiatry Cogn Neurosci Neuroimaging. 2026;11(6):624-633. https://doi.org/10.1016/j.bpsc.2026.02.001 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2ee4b8ea-efac-4a85-8951-f30176c5199d/study-12.png Educational Resources - Veterans Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ross C, Jain R, Bonnett CJ, Wolfson P. High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Ann Clin Psychiatry. 2019;31(4):271-279. https://doi.org/10.1177/154733251903100411 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1b458050-1e20-48fc-8111-aa3785ad1c61/study-13.png Educational Resources - Veterans Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Olash C, Buchanan DM, Brown R, et al. Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders. Npj Ment Health Res. 2026;5(1):8. https://doi.org/10.1038/s44184-026-00185-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fd506075-0d37-43f9-a15b-4f2319ce7c61/study-14.png Educational Resources - Veterans Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Barone W, Beck J, Mitsunaga-Whitten M, Perl P. Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction: Qualitative Follow-Up Study of a Clinical Trial for Individuals with Treatment-Resistant PTSD. J Psychoactive Drugs. 2019;51(2):199-208. https://doi.org/10.1080/02791072.2019.1580805 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5e6e5d07-2854-4230-8846-b5e67873034f/study-15.png Educational Resources - Veterans Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Albott CS, Lim KO, Erbes C, et al. Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder. J Affect Disord. 2022;308:289-297. https://doi.org/10.1016/j.jad.2022.04.066 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7a57ecb4-4236-48fa-9e81-532be13e8926/study-16.png Educational Resources - Veterans Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Weiss B, Dinh-Williams LL, Beller N, et al. Ayahuasca in the treatment of posttraumatic stress disorder: Mixed-methods case series evaluation in military combat veterans. Psychol Trauma. 2024;16(Suppl 3):S718-S722. https://doi.org/10.1037/tra0001625 https://www.harmreductionadvocate.com/educational-resources/neurological-injury monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223916411-EJ3FQ4IZTYJNY4SX83HT/illustration-neurological-injury.jpg Educational Resources - Neurological Injury https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d07ff34f-4e42-452e-a659-de5a93706198/study-1.png Educational Resources - Neurological Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Burman S, Chouhan RS, Kumar N, Mahajan C. Effect of Ketamine Analgosedation on Neurological Outcome in patients with Severe Traumatic Brain Injury: A Randomized Controlled Pilot Study. Neurocritical care. 2026;44(1):9-17. https://doi.org/10.1007/s12028-025-02274-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a03a0722-2c7d-4d3d-bf97-001c61c36ef2/study-2.png Educational Resources - Neurological Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Cherian KN, Keynan JN, Anker L, Faerman A, Brown RE, Shamma A, et al. Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature medicine. 2024;30(2):373-381. https://doi.org/10.1038/s41591-023-02705-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0d0762f4-9571-405f-a7dc-664a85a9dce1/study-3.png Educational Resources - Neurological Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Blest-Hopley G, Pasculli G, Ruffell SGD, Tsang W, Emmanuel O, Pate KM, et al. Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat. Frontiers in psychiatry. 2025;16:1594307. https://doi.org/10.3389/fpsyt.2025.1594307 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9ce19cf4-7a48-4f37-b3be-542710be43c2/study-4.png Educational Resources - Neurological Injury Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Carlson AP, Abbas M, Alunday RL, et al. Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial. J Neurosurg. 2019;130(5):1513-1519. https://doi.org/10.3171/2017.12.jns171665 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8a38529e-f6cc-498b-a118-c6bd212ff25c/study-5.png Educational Resources - Neurological Injury Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hertle DN, Dreier JP, Woitzik J, et al. Effect of analgesics and sedatives on the occurrence of spreading depolarizations accompanying acute brain injury. Brain. 2012;135(Pt 8):2390-2398. https://doi.org/10.1093/brain/aws152 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d51be8c2-588d-478e-b00e-ef9d30564b44/study-6.png Educational Resources - Neurological Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Beretta S, Pozzi M, Tagliabue S, et al. Dual Antiglutamate Therapy in Super-Refractory Status Epilepticus After Cardiac Arrest (SUPER-CAT Study). Neurology. 2026;107(8):e218565. https://doi.org/10.1212/wnl.0000000000218565 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/066bfa50-ba38-427c-83f7-883e46ce213d/study-7.png Educational Resources - Neurological Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Qin X, Chen X, Yao L, et al. Esketamine Preserves Network Connectivity and Promotes Recovery in Consciousness Disorders. CNS Neurosci Ther. 2026;32(5):e70890. https://doi.org/10.1002/cns.70890 https://www.harmreductionadvocate.com/educational-resources/traumatic-brain-injury monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223910598-2AAX9E7MOWT1MQOCFDJY/illustration-traumatic-brain-injury.jpg Educational Resources - Traumatic Brain Injury https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3eb68350-96e3-4817-84a3-9984b738c780/study-1.png Educational Resources - Traumatic Brain Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Cherian KN, Keynan JN, Anker L, et al. Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nat Med. 2024;30(2):373-381. https://doi.org/10.1038/s41591-023-02705-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3d8dc1e2-1713-487a-aa47-6b0124dea72e/study-2.png Educational Resources - Traumatic Brain Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Blest-Hopley G, Pasculli G, Ruffell SGD, et al. Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat. Front Psychiatry. 2025;16:1594307. https://doi.org/10.3389/fpsyt.2025.1594307 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3a2a8d5d-b05a-4548-98df-5e8dcd6b0a3b/study-3.png Educational Resources - Traumatic Brain Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Gray JC, Murphy M, Carter SE, et al. Beliefs and Perceived Barriers Regarding Psychedelic-assisted Therapy in a Pilot Study of Service Members and Veterans With a History of Traumatic Brain Injury. Mil Med. 2023;188(11-12):e3356-e3362. https://doi.org/10.1093/milmed/usac400 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0a6b1298-ee20-48af-9a94-d9671b14eecc/study-4.png Educational Resources - Traumatic Brain Injury Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lipov E, Rolain H, Neufeld T. Treating Post-Traumatic Stress Disorder in Canadian Special Operation Forces Command With Ketamine Plus Cervical Sympathetic Blockade. Mil Med. 2025;190(11-12):e2246-e2249. https://doi.org/10.1093/milmed/usaf051 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/adb5674f-075e-4177-b78d-f574335f3383/study-5.png Educational Resources - Traumatic Brain Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Geoly AD, Coetzee JP, Buchanan DM, et al. Increased cortical thickness and decreased brain age among special operations veterans with blast TBI after a magnesium-ibogaine protocol. iScience. 2026;29(3):115121. https://doi.org/10.1016/j.isci.2026.115121 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2356ed98-5a52-49c7-8bb4-66753ed0f0f1/study-6.png Educational Resources - Traumatic Brain Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Reed O. Exploring the potential of psychedelics in brain injury recovery: a thematic analysis of participant narratives. Front Neurol. 2026;17:1880026. https://doi.org/10.3389/fneur.2026.1880026 https://www.harmreductionadvocate.com/educational-resources/dementia-and-neurocognitive-disorders monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223903820-1E5V95YPQN7W53CKQRV6/illustration-dementia-and-neurocognitive-disorders.jpg Educational Resources - Dementia and Neurocognitive Disorders https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c4ad30e9-aa08-46f8-b17a-75e3c8973ae7/study-1.png Educational Resources - Dementia and Neurocognitive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Family N, Maillet EL, Williams LTJ, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology (Berl). 2020;237(3):841-853. https://doi.org/10.1007/s00213-019-05417-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b03d9496-cce1-4e50-a196-e05b2dbda8fd/study-2.png Educational Resources - Dementia and Neurocognitive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bradley ER, Sakai K, Fernandes-Osterhold G, et al. Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial. Neuropsychopharmacology. 2025;50(8):1200-1209. https://doi.org/10.1038/s41386-025-02097-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a783ef03-3acf-4a62-8f89-07e34440393b/study-3.png Educational Resources - Dementia and Neurocognitive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kettner H, Roseman L, Gazzaley A, Carhart-Harris RL, Pasquini L. Effects of Psychedelics in Older Adults: A Prospective Cohort Study. Am J Geriatr Psychiatry. 2024;32(9):1047-1059. https://doi.org/10.1016/j.jagp.2024.05.007 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3bfd5ee7-4ba6-42fc-bce8-6fdf8495b30a/study-4.png Educational Resources - Dementia and Neurocognitive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Fremont R, Karim A, Estevez TP, et al. KET-MCI: A Pilot Safety and Tolerability Study of Single Infusion Intravenous Ketamine for Older Adults with Depression and Mild Cognitive Impairment. Am J Geriatr Psychiatry. 2026;34(7):899-910. https://doi.org/10.1016/j.jagp.2026.02.005 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/06545def-5474-41c2-b2f9-cdc4456de420/study-5.png Educational Resources - Dementia and Neurocognitive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Abd Ellatif SE, Mowafy SMS, Shahin MA. Ketofol versus Dexmedetomidine for preventing postoperative delirium in elderly patients undergoing intestinal obstruction surgeries: a randomized controlled study. BMC Anesthesiol. 2024;24(1):1. https://doi.org/10.1186/s12871-023-02378-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6ce2e145-0f86-4406-a61d-120de57ee8a4/study-6.png Educational Resources - Dementia and Neurocognitive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hou J, Wang J, Li Y, et al. Subanesthetic S-ketamine prevents postoperative delirium and reduces inflammatory cytokines in older patients receiving hip fracture surgery: a randomized, controlled study. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(6):8463-8471. https://doi.org/10.1007/s00210-025-04945-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2cf985b2-5c03-43df-9bb9-e3b9b86316b3/study-7.png Educational Resources - Dementia and Neurocognitive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Han C, Ji H, Guo Y, et al. Effect of Subanesthetic Dose of Esketamine on Perioperative Neurocognitive Disorders in Elderly Undergoing Gastrointestinal Surgery: A Randomized Controlled Trial. Drug Des Devel Ther. 2023;17:863-873. https://doi.org/10.2147/dddt.s401161 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f152e5d4-60fc-4b04-a073-15ffca82670b/study-8.png Educational Resources - Dementia and Neurocognitive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Tang X, Luo G, He Q, et al. Effect of perioperative esketamine administration on the incidence of postoperative delirium: a systematic review and meta-analysis. BMC Anesthesiol. 2026;26(1):296. https://doi.org/10.1186/s12871-026-03785-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8f5c21f3-fd54-48e7-a734-c56e3fdb528f/study-9.png Educational Resources - Dementia and Neurocognitive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Li X, Mao H, Luo J, et al. Effects of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Pulmonary Lobectomy: A Randomised, Single-Blind Controlled Clinical Trial. Actas Esp Psiquiatr. 2025;53(6):1320-1331. https://doi.org/10.62641/aep.v53i6.2044 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2779c375-eed4-448f-937a-8bf6101612b4/study-10.png Educational Resources - Dementia and Neurocognitive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Qi R, Wu Y, Zhang L, et al. Perioperative esketamine-containing strategies and postoperative neurocognitive outcomes in older surgical patients: a systematic review and meta-analysis of randomized controlled trials with certainty assessment. BMC Geriatr. 2026;26(1):1171. https://doi.org/10.1186/s12877-026-08201-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0ac2501d-067b-4b04-ab08-07a828b8d4ec/study-11.png Educational Resources - Dementia and Neurocognitive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lu Y, Wang X, Zou H, et al. A comprehensive review and meta-analysis on the safety and efficacy of esketamine for emerging delirium in elderly patients. Front Med (Lausanne). 2026;13:1752055. https://doi.org/10.3389/fmed.2026.1752055 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/84ddd3ac-77d3-4ad2-aad1-a3ad5b03eb6f/study-12.png Educational Resources - Dementia and Neurocognitive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ju LY, Liu GQ, Yuan L, et al. Effect of Esketamine on Postoperative Delirium and Inflammatory Response in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting: A Randomized Controlled Study. J Cardiothorac Vasc Anesth. 2025;39(8):2079-2087. https://doi.org/10.1053/j.jvca.2025.04.013 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0312f10f-d8de-4ce3-90a6-eef77a9f180e/study-13.png Educational Resources - Dementia and Neurocognitive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Fu H, Hu J, Zhang X, et al. The effects of esketamine on postoperative delirium in older patients with fragile brain function during the non-acute phase following lung cancer surgery: a randomized controlled trial. BMC Geriatr. 2025;25(1):608. https://doi.org/10.1186/s12877-025-06268-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8989d2ad-0626-4384-b8a2-5a40be7765c5/study-14.png Educational Resources - Dementia and Neurocognitive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Santos Neto NCD, Montenegro Neto RP, Gomes EF, et al. Ketamine and Esketamine for the Prevention of Delirium in Surgical Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. J Intensive Care Med. 2026;41(8):765-775. https://doi.org/10.1177/08850666251410471 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/84787e09-2349-4305-8018-3cfb573185b8/study-15.png Educational Resources - Dementia and Neurocognitive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wang ZY, Yuan WJ, Pu J, Yin YB. Perioperative dexmedetomidine plus esketamine for postoperative neurocognitive outcomes: a systematic review and meta-analysis. Front Med (Lausanne). 2026;13:1909826. https://doi.org/10.3389/fmed.2026.1909826 https://www.harmreductionadvocate.com/educational-resources/parkinsons-disease monthly 0.5 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223897820-A3BZ3J9OWZO7DPJI4R8F/illustration-parkinsons-disease.jpg Educational Resources - Parkinson’s Disease https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f798cb8e-cdfe-493f-a30c-f4dfd5aead52/study-1.png Educational Resources - Parkinson’s Disease Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bradley ER, Sakai K, Fernandes-Osterhold G, et al. Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial. Neuropsychopharmacology. 2025;50(8):1200-1209. https://doi.org/10.1038/s41386-025-02097-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e42536cf-02ed-4e27-9f15-b6c6ff7dbb5e/study-2.png Educational Resources - Parkinson’s Disease Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sherman SJ, Estevez M, Magill AB, et al. Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing l-DOPA-Induced Dyskinesias. Case Rep Neurol. 2016;8(1):53-58. https://doi.org/10.1159/000444278 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/78ffba88-f9d1-404b-8713-d588f8bb7ef7/study-3.png Educational Resources - Parkinson’s Disease Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fleury V, Tomkova E, Catalano Chiuvé S, et al. Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report. J Parkinsons Dis. 2025;15(2):440-444. https://doi.org/10.1177/1877718x241312604 https://www.harmreductionadvocate.com/educational-resources/fibromyalgia monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223891835-6CDJCHL0QM2ZSGJX6A8J/illustration-fibromyalgia.jpg Educational Resources - Fibromyalgia https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5d660552-f5a9-415e-a612-964ad93471e6/study-1.png Educational Resources - Fibromyalgia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Aday JS, McAfee J, Conroy DA, et al. Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial. Front Pain Res (Lausanne). 2025;6:1527783. https://doi.org/10.3389/fpain.2025.1527783 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0e552692-1c4a-4fa3-b26c-d02d08229f7d/study-2.png Educational Resources - Fibromyalgia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Noppers I, Niesters M, Swartjes M, et al. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial. Eur J Pain. 2011;15(9):942-949. https://doi.org/10.1016/j.ejpain.2011.03.008 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/00871d7d-b824-423d-bb47-b092dffe3bc2/study-3.png Educational Resources - Fibromyalgia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Glynos NG, Pierce J, Davis AK, et al. Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia. J Psychoactive Drugs. 2023;55(1):73-84. https://doi.org/10.1080/02791072.2021.2022817 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7a3c568a-2da7-4054-83f4-afa7d6bfc5ef/study-4.png Educational Resources - Fibromyalgia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kapural L, Choi S, Rogers EJ, et al. A Single-Day Intravenous Ketamine Infusions for Fibromyalgia, a Large Retrospective Study with a Long-Term Assessment. J Pain Res. 2026;19:629157. https://doi.org/10.2147/jpr.s629157 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5c31ea96-a792-4943-bb7b-172d78300cfc/study-5.png Educational Resources - Fibromyalgia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: de Carvalho JF, de Sena EP. Ketamine in fibromyalgia: a systematic review. Adv Rheumatol. 2024;64(1):54. https://doi.org/10.1186/s42358-024-00393-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4e746732-aa4d-425b-ae31-16c10d6c5a46/study-6.png Educational Resources - Fibromyalgia Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Treillet E, Hadjiat Y, Pickering G, et al. Hospital-Compounded Oral Ketamine as Maintenance Therapy After Intravenous Induction for Fibromyalgia: A Retrospective Real-World Study, Off-Label Pharmacotherapy. J Pain Palliat Care Pharmacother. 2026;40(1):63-71. https://doi.org/10.1080/15360288.2025.2596159 https://www.harmreductionadvocate.com/educational-resources/cluster-headache-and-migraine monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223885338-LXSII8SA1URA73PDQEV9/illustration-cluster-headache-and-migraine.jpg Educational Resources - Cluster Headache and Migraine https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5b4771db-7eba-40fc-b8f0-811b0f7546a7/study-1.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics. 2021;18(1):534-543. https://doi.org/10.1007/s13311-020-00962-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2d6ec131-5956-4774-8822-8fd92e2481eb/study-2.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Schindler EAD, Sewell RA, Gottschalk CH, et al. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. J Neurol Sci. 2024;460:122993. https://doi.org/10.1016/j.jns.2024.122993 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/edf8b959-09a7-43a8-a830-690d74de000a/study-3.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sewell RA, Halpern JH, Pope HG. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920-1922. https://doi.org/10.1212/01.wnl.0000219761.05466.43 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/98156c41-9b85-48ea-a790-9618418dac4f/study-4.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Madsen MK, Petersen AS, Stenbaek DS, et al. CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity. Headache. 2024;64(1):55-67. https://doi.org/10.1111/head.14656 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e1b0c393-2d16-4bbd-acec-8a5468ad48e7/study-5.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rusanen SS, De S, Schindler EAD, et al. Self-Reported Efficacy of Treatments in Cluster Headache: a Systematic Review of Survey Studies. Curr Pain Headache Rep. 2022;26(8):623-637. https://doi.org/10.1007/s11916-022-01063-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2f6f816d-604c-4582-8e3a-3da292aaacab/study-6.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ray JC, Cheng S, Tsan K, et al. Intravenous Lidocaine and Ketamine Infusions for Headache Disorders: A Retrospective Cohort Study. Front Neurol. 2022;13:842082. https://doi.org/10.3389/fneur.2022.842082 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ea71953b-f776-46c6-8277-11905b129117/study-7.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bjurenfalk Z, Cosmo A, Simonsson O, Ran C. Lifetime classic psychedelic use and headaches: A cross-sectional study. J Psychopharmacol. 2025;39(9):968-975. https://doi.org/10.1177/02698811251324372 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4f07f3a2-eea4-4997-bbfd-ed9f368edc07/study-8.png Educational Resources - Cluster Headache and Migraine Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Afridi SK, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology. 2013;80(7):642-647. https://doi.org/10.1212/wnl.0b013e3182824e66 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0213960f-ed0c-4aba-97d0-c21374dc9e5e/study-9.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lauritsen C, Mazuera S, Lipton RB, Ashina S. Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. J Headache Pain. 2016;17(1):106. https://doi.org/10.1186/s10194-016-0700-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e0fc698f-560b-4930-a102-85e8785616cb/study-10.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Neumann J, Bornemann-Cimenti H, Rumpold-Seitlinger G, et al. Ketamine as Treatment for Cluster Headache: A Systematic Review of Literature and a Case Series. Pain Ther. 2024;13(3):651-662. https://doi.org/10.1007/s40122-024-00606-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e02016ad-a676-4f86-9583-706e8278ff4d/study-11.png Educational Resources - Cluster Headache and Migraine Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Schindler EA, Gottschalk CH, Weil MJ, et al. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. J Psychoactive Drugs. 2015;47(5):372-381. https://doi.org/10.1080/02791072.2015.1107664 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5f2e1d0f-d3f4-4b77-8531-a2ba2c3f20d0/study-12.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Shiju S, Tirumala R, Marseille E. Self-medication with psychedelics: a scoping review and narrative synthesis of review-level evidence. Explor Res Clin Soc Pharm. 2026;21:100709. https://doi.org/10.1016/j.rcsop.2026.100709 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ad304bf2-c4fb-46d0-9154-5ba902492f88/study-13.png Educational Resources - Cluster Headache and Migraine Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Schwenk ES, Dayan AC, Rangavajjula A, et al. Ketamine for Refractory Headache: A Retrospective Analysis. Reg Anesth Pain Med. 2018;43(8):875-879. https://doi.org/10.1097/aap.0000000000000827 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4cce68aa-b1d2-4e57-8046-af55587ae3cb/study-14.png Educational Resources - Cluster Headache and Migraine Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Brendstrup-Brix K, Ozenne B, Fisher PM, et al. Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache. J Psychopharmacol. 2026:2698811261449380. https://doi.org/10.1177/02698811261449380 https://www.harmreductionadvocate.com/educational-resources/pain monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223879279-0R1K4FM8QI8ETFBOZ5I3/illustration-pain.jpg Educational Resources - Pain https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5b6b2138-6fc7-4708-b709-e0ea9d8dc494/study-1.png Educational Resources - Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sigtermans MJ, van Hilten JJ, Bauer MCR, et al. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain. 2009;145(3):304-311. https://doi.org/10.1016/j.pain.2009.06.023 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/968f426b-7052-4220-a226-1e360f205bd7/study-2.png Educational Resources - Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Christie D, Yazar-Klosinski B, Nosova E, et al. MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder. Front Psychiatry. 2022;13:939302. https://doi.org/10.3389/fpsyt.2022.939302 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/21d1a996-69a8-4fff-92d3-8432d3ed908e/study-3.png Educational Resources - Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bonnelle V, Smith WJ, Mason NL, et al. Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey. Br J Pain. 2022;16(6):619-631. https://doi.org/10.1177/20494637221114962 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/25cf5cc8-600f-4d1c-979c-61ffda6a4b91/study-4.png Educational Resources - Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bornemann J, Close JB, Spriggs MJ, et al. Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research. Front Psychiatry. 2021;12:735427. https://doi.org/10.3389/fpsyt.2021.735427 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0bd3dfb8-14d0-4be2-95b2-6a363f9902dc/study-5.png Educational Resources - Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Koppert W, Sittl R, Scheuber K, et al. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology. 2003;99(1):152-159. https://doi.org/10.1097/00000542-200307000-00025 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f7648899-f318-4198-b099-3d6f5e7ff70f/study-6.png Educational Resources - Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Gitlin J, Chamadia S, Locascio JJ, et al. Dissociative and Analgesic Properties of Ketamine Are Independent. Anesthesiology. 2020;133(5):1021-1028. https://doi.org/10.1097/aln.0000000000003529 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/56ef5c4c-ac82-49c5-8210-e039028636ec/study-7.png Educational Resources - Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bossard AE, Guirimand F, Fletcher D, et al. Interaction of a combination of morphine and ketamine on the nociceptive flexion reflex in human volunteers. Pain. 2002;98(1-2):47-57. https://doi.org/10.1016/s0304-3959(01)00472-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/80d483c0-d339-4c70-8755-bc4d624cda22/study-8.png Educational Resources - Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kern D, Pelle-Lancien E, Luce V, Bouhassira D. Pharmacological dissection of the paradoxical pain induced by a thermal grill. Pain. 2008;135(3):291-299. https://doi.org/10.1016/j.pain.2007.12.001 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e6536c34-c88d-4cb8-8e34-3319cb665b98/study-9.png Educational Resources - Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Guirimand F, Dupont X, Brasseur L, et al. The effects of ketamine on the temporal summation (wind-up) of the R(III) nociceptive flexion reflex and pain in humans. Anesth Analg. 2000;90(2):408-414. https://doi.org/10.1097/00000539-200002000-00031 https://www.harmreductionadvocate.com/educational-resources/chronic-pain monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223865432-JJT2E7EOZD09QBF83IY7/illustration-chronic-pain.jpg Educational Resources - Chronic Pain https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/148201bd-8363-4208-a03e-249c5aa4587d/study-1.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Schindler EAD, Sewell RA, Gottschalk CH, et al. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. J Neurol Sci. 2024;460:122993. https://doi.org/10.1016/j.jns.2024.122993 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3151ab21-a047-43bc-bc00-0522d3caed72/study-2.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics. 2021;18(1):534-543. https://doi.org/10.1007/s13311-020-00962-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bbfa21cb-e513-4163-8885-c51258e50c1d/study-3.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sewell RA, Halpern JH, Pope HG. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920-1922. https://doi.org/10.1212/01.wnl.0000219761.05466.43 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3fb750d6-d961-4a36-a5ac-8cf45bceed7c/study-4.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Aday JS, McAfee J, Conroy DA, et al. Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial. Front Pain Res (Lausanne). 2025;6:1527783. https://doi.org/10.3389/fpain.2025.1527783 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/40f2ff24-03bb-482b-b27e-eaee49ec31c6/study-5.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dahan A, Olofsen E, Sigtermans M, et al. Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain. 2011;15(3):258-267. https://doi.org/10.1016/j.ejpain.2010.06.016 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8d20a3ac-9dac-4ec4-bf4f-886e3c1dc693/study-6.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kvarnström A, Karlsten R, Quiding H, et al. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol Scand. 2003;47(7):868-877. https://doi.org/10.1034/j.1399-6576.2003.00187.x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e64bf23c-75ef-4029-99de-ee30cfaf75f6/study-7.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lemming D, Sörensen J, Graven-Nielsen T, et al. The responses to pharmacological challenges and experimental pain in patients with chronic whiplash-associated pain. Clin J Pain. 2005;21(5):412-421. https://doi.org/10.1097/01.ajp.0000126155.82815.fc https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5e61ae84-cc3a-4579-95da-7aa3b31e63c1/study-8.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Orhurhu V, Orhurhu MS, Bhatia A, Cohen SP. Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Anesth Analg. 2019;129(1):241-254. https://doi.org/10.1213/ane.0000000000004185 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4097a129-e97c-47b6-86a4-d9044c24e059/study-9.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Wang QY, Zhang JY, Gu JQ, et al. Effects of perioperative esketamine infusion on chronic pain after video-assisted thoracoscopic lung resection: a multicentre, randomised, double-blind clinical trial. Br J Anaesth. 2026:S0007-0912(26)00693-8. https://doi.org/10.1016/j.bja.2026.08.039 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7170e5a4-4a8f-4ffc-b562-d035f66e6260/study-10.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Robinson CL, Fonseca ACG, Diejomaoh EM, et al. Scoping Review: The Role of Psychedelics in the Management of Chronic Pain. J Pain Res. 2024;17:965-973. https://doi.org/10.2147/jpr.s439348 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/52a3afd8-e889-49b8-bc06-80e6e2ee09af/study-11.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Rigo FK, Trevisan G, Godoy MC, et al. Management of Neuropathic Chronic Pain with Methadone Combined with Ketamine: A Randomized, Double Blind, Active-Controlled Clinical Trial. Pain Physician. 2017;20(3):207-215. https://doi.org/10.36076/ppj.2017.215 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/35a20802-926d-4f7e-8594-783daf1b6689/study-12.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Schwartzman RJ, Alexander GM, Grothusen JR, et al. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 2009;147(1-3):107-115. https://doi.org/10.1016/j.pain.2009.08.015 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ebc78be7-1ee1-42d8-a283-b9dc919e7093/study-13.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Huge V, Lauchart M, Magerl W, et al. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur J Pain. 2010;14(4):387-394. https://doi.org/10.1016/j.ejpain.2009.08.002 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/dfdeb9f0-043d-4ca1-8bf5-f176d8d192f5/study-14.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Chaparro LE, Smith SA, Moore RA, et al. Pharmacotherapy for the prevention of chronic pain after surgery in adults. Cochrane Database Syst Rev. 2013(7):CD008307. https://doi.org/10.1002/14651858.cd008307.pub2 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e0568a1f-382b-40ca-867a-39105d3dfec2/study-15.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain. 2004;108(1-2):17-27. https://doi.org/10.1016/j.pain.2003.07.001 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7420a60c-6b07-444c-87b2-ce9084ceca16/study-16.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Max MB, Byas-Smith MG, Gracely RH, Bennett GJ. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clin Neuropharmacol. 1995;18(4):360-368. https://doi.org/10.1097/00002826-199508000-00008 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e45193b2-5c45-471a-b057-a28e8a6e1c96/study-17.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Voute M, Lambert C, Pereira B, Pickering G. Assessment of Initial Depressive State and Pain Relief With Ketamine in Patients With Chronic Refractory Pain. JAMA Netw Open. 2023;6(5):e2314406. https://doi.org/10.1001/jamanetworkopen.2023.14406 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4159e0cc-b7a3-4a30-9b52-e5ecc248a1b0/study-18.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Glynos NG, Baker A, Aday JS, et al. Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use. Br J Pain. 2025;19(3):187-199. https://doi.org/10.1177/20494637251319497 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d258b0c4-0f72-44be-97c3-ec0f1a2b9bf5/study-19.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Corriger A, Voute M, Lambert C, et al. Ketamine for refractory chronic pain: a 1-year follow-up study. Pain. 2022;163(4):690-701. https://doi.org/10.1097/j.pain.0000000000002403 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a3073bcd-3f1d-4eb4-85f5-2f58f2a0f80e/study-20.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Amr YM. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. Pain Physician. 2010;13(3):245-249. https://doi.org/10.36076/ppj.2010/13/245 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/381295d7-134b-4ac5-9e4b-4a750f5eda5f/study-21.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Batievsky D, Weiner M, Kaplan SB, et al. Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches. Front Pain Res (Lausanne). 2023;4:1127863. https://doi.org/10.3389/fpain.2023.1127863 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7dd419e2-17eb-4525-937b-ad6005017be8/study-22.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bosma RL, Cheng JC, Rogachov A, et al. Brain Dynamics and Temporal Summation of Pain Predicts Neuropathic Pain Relief from Ketamine Infusion. Anesthesiology. 2018;129(5):1015-1024. https://doi.org/10.1097/aln.0000000000002417 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f8ec0c54-edf4-4088-8d59-d4dd81aaafb9/study-23.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Jafarinia M, Afarideh M, Tafakhori A, et al. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. J Affect Disord. 2016;204:1-8. https://doi.org/10.1016/j.jad.2016.05.076 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d1617638-8569-4604-a560-5598f90d673c/study-24.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Felsby S, Nielsen J, Arendt-Nielsen L, Jensen TS. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain. 1996;64(2):283-291. https://doi.org/10.1016/0304-3959(95)00113-1 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9af759ea-37d3-4a73-9661-fd8c7239e494/study-25.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77(2):357-367. https://doi.org/10.1111/bcp.12094 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9ee3d22c-5d57-4f3a-b27c-d3bc574cc0d8/study-26.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Cavarra M, Mason NL, Kuypers KPC, et al. Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study. Eur J Pain. 2024;28(1):153-165. https://doi.org/10.1002/ejp.2171 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7656c47c-8d77-463c-8f59-4a3cc8868a85/study-27.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nikolajsen L, Nikolajsen L, Hansen CL, et al. The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. Pain. 1996;67(1):69-77. https://doi.org/10.1016/0304-3959(96)03080-1 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/248ca146-51e9-49b6-accb-d9dbc82bf81c/study-28.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Leung A, Wallace MS, Ridgeway B, Yaksh T. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001;91(1-2):177-187. https://doi.org/10.1016/s0304-3959(00)00433-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e973c018-33b6-4a17-8e12-4b8f937b28db/study-29.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pickering G, Voute M, Sorel M, et al. Sex and Age Differences in Ketamine Efficacy and Safety in Chronic Pain Alleviation. J Clin Med. 2025;14(12):4269. https://doi.org/10.3390/jcm14124269 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d9e0d22e-d180-4829-a4fd-e88a5dd0de6a/study-30.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zekry O, Gibson SB, Aggarwal A. Subanesthetic, Subcutaneous Ketamine Infusion Therapy in the Treatment of Chronic Nonmalignant Pain. J Pain Palliat Care Pharmacother. 2016;30(2):91-98. https://doi.org/10.3109/15360288.2016.1161690 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0549d55d-70a3-4edc-8fde-751d1d798475/study-31.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Gottrup H, Bach FW, Juhl G, Jensen TS. Differential effect of ketamine and lidocaine on spontaneous and mechanical evoked pain in patients with nerve injury pain. Anesthesiology. 2006;104(3):527-536. https://doi.org/10.1097/00000542-200603000-00021 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b946dc2b-e1c9-4e6e-b714-4d8c53fff9ac/study-32.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg. 2003;97(6):1730-1739. https://doi.org/10.1213/01.ane.0000086618.28845.9b https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a59838c8-17c5-42e2-842c-ca66a4e0dff1/study-33.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zaki C. Beyond Anesthesia: Ketamine's Expanding Role in Chronic Pain and Psychiatric Disorders. J Integr Neurosci. 2025;24(7):26766. https://doi.org/10.31083/jin26766 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1ac2fff1-070d-4d5d-aaa4-811abb60b3fd/study-34.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Winegarden J, Brose A, Storm A, et al. Oral Ketamine for Chronic Pain: Towards an Evidence-Based Dosing Regimen. J Pain Res. 2026;19:545221. https://doi.org/10.2147/jpr.s545221 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0fcefabe-cfa4-4aeb-aa7c-d04a582c96c4/study-35.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Jørum E, Warncke T, Stubhaug A. Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine--a double-blind, cross-over comparison with alfentanil and placebo. Pain. 2003;101(3):229-235. https://doi.org/10.1016/s0304-3959(02)00122-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/66ca6214-e34d-43ef-89ec-4f91fb43d65b/study-36.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sucu MG, Yavuz Mollavelioğlu T, Akyüz Yildirim A, Çelebi N. Short- and Midterm Analgesic Outcomes of Ketamine Versus Lidocaine Infusion in Chronic Peripheral Neuropathic Pain: A Retrospective Study. Pain Res Manag. 2026;2026(1):e7897619. https://doi.org/10.1155/prm/7897619 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/210c146e-9847-4af6-bae2-a207164ed479/study-37.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Patil S, Anitescu M. Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5-year retrospective analysis. Pain Med. 2012;13(2):263-269. https://doi.org/10.1111/j.1526-4637.2011.01241.x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e17d9307-1364-4fe1-87d4-30d196b59dec/study-38.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Striebel J, Ruppen W, Schneider T. Simultaneous application of lidocaine and ketamine during ambulatory infusion therapy: a retrospective analysis. Pain Manag. 2023;13(9):539-553. https://doi.org/10.2217/pmt-2023-0037 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/989a81ed-5841-42d3-986e-0a0c0d289983/study-39.png Educational Resources - Chronic Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Mills EP, Bosma RL, Rogachov A, et al. Pretreatment Brain White Matter Integrity Associated With Neuropathic Pain Relief and Changes in Temporal Summation of Pain Following Ketamine. J Pain. 2024;25(9):104536. https://doi.org/10.1016/j.jpain.2024.104536 https://www.harmreductionadvocate.com/educational-resources/opioid-use-disorder monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223858430-8XT11WOOU7904E69L12W/illustration-opioid-use-disorder.jpg Educational Resources - Opioid Use Disorder https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c4d7a7a1-2848-47af-9eb4-5f5543328957/study-1.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Krupitsky E, Burakov A, Romanova T, et al. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat. 2002;23(4):273-283. https://doi.org/10.1016/s0740-5472(02)00275-1 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c542e288-da05-4a5b-8460-8efe64c1c793/study-2.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Krupitsky EM, Burakov AM, Dunaevsky IV, et al. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39(1):13-19. https://doi.org/10.1080/02791072.2007.10399860 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/785cb5f7-885b-44d5-a722-93164579a63b/study-3.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36. https://doi.org/10.1080/00952990.2017.1320802 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/cb6a8fff-72ff-448e-bdf5-27e7d5c3538b/study-4.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Argento E, Socias ME, Hayashi K, et al. Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting. Int J Drug Policy. 2022;100:103518. https://doi.org/10.1016/j.drugpo.2021.103518 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6c6eb799-dc9b-4ed1-ac63-690a941993a3/study-5.png Educational Resources - Opioid Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Malcolm BJ, Polanco M, Barsuglia JP. Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine. J Psychoactive Drugs. 2018;50(3):256-265. https://doi.org/10.1080/02791072.2018.1447175 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0c52b431-0662-40ff-b500-809f0dc9ef15/study-6.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jones G. Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder. PLoS One. 2025;20(5):e0321461. https://doi.org/10.1371/journal.pone.0321461 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/cc15235d-789d-4e2d-a138-21b6f887df7e/study-7.png Educational Resources - Opioid Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Pisano VD, Putnam NP, Kramer HM, et al. The association of psychedelic use and opioid use disorders among illicit users in the United States. J Psychopharmacol. 2017;31(5):606-613. https://doi.org/10.1177/0269881117691453 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/24356959-6979-46df-9800-c397a4f311c6/study-8.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Engeriser JL, Hutch T, Smith CL, et al. Buprenorphine initiation from fentanyl using low-dose intramuscular ketamine: a pilot study. Addict Sci Clin Pract. 2026;21(1):23. https://doi.org/10.1186/s13722-026-00649-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ba4b620f-4296-4c0c-b304-48839dfc7be8/study-9.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jones G, Ricard JA, Lipson J, Nock MK. Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. Sci Rep. 2022;12(1):4099. https://doi.org/10.1038/s41598-022-08085-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/541e5bd6-e8c4-4b8a-b59c-dbf43975881c/study-10.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Grande LA, Hutch T, Jack K, et al. Ketamine-assisted buprenorphine initiation: a pilot case series. Addict Sci Clin Pract. 2024;19(1):60. https://doi.org/10.1186/s13722-024-00494-2 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c489a4b2-9bbf-4301-aa51-e7ef8bcee5b9/study-11.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mash DC, Duque L, Page B, Allen-Ferdinand K. Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes. Front Pharmacol. 2018;9:529. https://doi.org/10.3389/fphar.2018.00529 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f6eb42d5-e8b5-44c9-8e39-e739b9887a5d/study-12.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Shen MR, Campbell DE, Kopczynski A, et al. Ketamine in treating opioid use disorder and opioid withdrawal: a scoping review. Front Psychiatry. 2025;16:1552084. https://doi.org/10.3389/fpsyt.2025.1552084 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e05cea76-f902-41fd-a4b4-bef5c987b382/study-13.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Davis AK, Barsuglia JP, Windham-Herman AM, et al. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. J Psychedelic Stud. 2017;1(2):65-73. https://doi.org/10.1556/2054.01.2017.009 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b65a81f8-55cd-46a9-93dc-4c01f63c90f9/study-14.png Educational Resources - Opioid Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46. https://doi.org/10.1080/00952990.2017.1310218 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5e27dfed-be01-430e-aac1-34e4210e4b16/study-15.png Educational Resources - Opioid Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Alper KR, Lotsof HS, Frenken GM, et al. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999;8(3):234-242. https://doi.org/10.1080/105504999305848 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5da75525-f90a-4e62-a7fc-97993c9d9f1d/study-16.png Educational Resources - Opioid Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ahmadi J, Mansoori A, Mosavat SH, Bazrafshan A. Comparison of ketamine with buprenorphine as adjunctive therapy in the treatment of comorbid major depressive disorder and opium use disorders: A randomized controlled trial. Int J Psychiatry Med. 2024;59(5):521-535. https://doi.org/10.1177/00912174231225087 https://www.harmreductionadvocate.com/educational-resources/tobacco-and-nicotine-use-disorder monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223852087-448S3V8MWB0BYUYP6U8G/illustration-tobacco-and-nicotine-use-disorder.jpg Educational Resources - Tobacco and Nicotine Use Disorder https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/410f09bb-6bda-476d-9f4d-bad1f40f5f0b/study-1.png Educational Resources - Tobacco and Nicotine Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Johnson MW, Naudé GP, Hendricks PS, et al. Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial. JAMA Netw Open. 2026;9(3):e260972. https://doi.org/10.1001/jamanetworkopen.2026.0972 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d2422a33-ff43-40cb-a66d-ca9fb90aa801/study-2.png Educational Resources - Tobacco and Nicotine Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983-992. https://doi.org/10.1177/0269881114548296 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/29e62207-fcfa-4d8a-90e4-f03b92b67a48/study-3.png Educational Resources - Tobacco and Nicotine Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Johnson MW, Garcia-Romeu A, Johnson PS, et al. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. J Psychopharmacol. 2017;31(7):841-850. https://doi.org/10.1177/0269881116684335 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bf3d613e-2905-41e1-8dc6-e6d1228f243c/study-4.png Educational Resources - Tobacco and Nicotine Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hong X, Xu S, Sun G, et al. Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial. J Affect Disord. 2025;383:1-10. https://doi.org/10.1016/j.jad.2025.04.077 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7f35eba9-353b-4a1c-9020-75570e45348c/study-5.png Educational Resources - Tobacco and Nicotine Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017;43(1):55-60. https://doi.org/10.3109/00952990.2016.1170135 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/30089d0a-4609-44e0-a14b-07f559f7b23f/study-6.png Educational Resources - Tobacco and Nicotine Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jones G, Lipson J, Nock MK. Associations between classic psychedelics and nicotine dependence in a nationally representative sample. Sci Rep. 2022;12(1):10578. https://doi.org/10.1038/s41598-022-14809-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/eef50cbe-0e87-4a8b-9f09-adb8364910a0/study-7.png Educational Resources - Tobacco and Nicotine Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Barbosa PCR, Tófoli LF, Bogenschutz MP, et al. Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca. Front Psychiatry. 2018;9:136. https://doi.org/10.3389/fpsyt.2018.00136 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e5129d42-31ae-4ff1-adad-07a165761a94/study-8.png Educational Resources - Tobacco and Nicotine Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Daldegan-Bueno D, Maia LO, Massarentti CM, Tófoli LF. Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil. Psychopharmacology (Berl). 2022;239(6):1767-1782. https://doi.org/10.1007/s00213-022-06063-2 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/26206c7c-6b54-40cd-963f-826c68490693/study-9.png Educational Resources - Tobacco and Nicotine Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Romeo B, Fauvel B, Dejean S, et al. Impact of a Naturalistic Psychedelic Experience on Smoking: A Retrospective Survey. J Psychoactive Drugs. 2023;55(5):640-649. https://doi.org/10.1080/02791072.2023.2227171 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0f371499-b570-4b7d-9bd2-9d4905ad0965/study-10.png Educational Resources - Tobacco and Nicotine Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Noorani T, Garcia-Romeu A, Swift TC, et al. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. J Psychopharmacol. 2018;32(7):756-769. https://doi.org/10.1177/0269881118780612 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/786ed988-c49d-43a9-82ff-0ea58e379492/study-11.png Educational Resources - Tobacco and Nicotine Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Jones J, Redding J, Amador E. Ketamine-enhanced psychotherapy for smoking cessation: A pilot study of feasibility, safety, and clinical outcomes. J Psychopharmacol. 2026:2698811261488486. https://doi.org/10.1177/02698811261488486 https://www.harmreductionadvocate.com/educational-resources/schizophrenia monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223837708-4DTAOXVE1V89G1U1YZNN/illustration-schizophrenia.jpg Educational Resources - Schizophrenia https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/66fe4569-7842-4076-a3f9-d76b430cab41/study-1.png Educational Resources - Schizophrenia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sabé M, Sulstarova A, Glangetas A, et al. Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Mol Psychiatry. 2025;30(3):1223-1255. https://doi.org/10.1038/s41380-024-02800-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3d0e1f07-a4d8-49b8-836c-a4cec8830aa0/study-2.png Educational Resources - Schizophrenia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Steinle JT, Shankar S, Siegel JS, et al. Hallucinogen-Psychosis Associations Are Confounded by Baseline Psychiatric History. J Clin Psychiatry. 2026;87(3):25m16034. https://doi.org/10.4088/jcp.25m16034 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/323ea6a9-5285-4766-8497-47bf4b2c1ad4/study-3.png Educational Resources - Schizophrenia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Brar PS, Price RB, Ross S, et al. The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential. J Psychopharmacol. 2026;40(7):1037-1053. https://doi.org/10.1177/02698811261456191 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7cc51429-9dc6-45de-ba03-5c54b10c9290/study-4.png Educational Resources - Schizophrenia Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: La Torre JT, Gallo J, Mahammadli M, et al. Experiences of psychedelic drug use among people with psychotic symptoms and disorders: Personal growth and mystical experiences. Journal of Psychedelic Studies. 2024. https://doi.org/10.1556/2054.2024.00348 https://www.harmreductionadvocate.com/educational-resources/eating-disorders monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223830532-5HC6EULGNUEGH6HWKLJB/illustration-eating-disorders.jpg Educational Resources - Eating Disorders https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4acdee9a-e01f-4707-a4de-51253e5a2cc0/study-1.png Educational Resources - Eating Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Brewerton TD, Wang JB, Lafrance A, et al. MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. J Psychiatr Res. 2022;149:128-135. https://doi.org/10.1016/j.jpsychires.2022.03.008 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c05c8097-ee20-4422-a879-a8fd82b1e9c6/study-2.png Educational Resources - Eating Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Douglass HM, Spriggs MJ, Godfrey K, et al. Psilocybin therapy for adult females with anorexia nervosa: pilot study. Br J Psychiatry. Published online July 8, 2026:1-9. https://doi.org/10.1192/bjp.2026.10687 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0f1f9058-6935-4dea-a6af-655b04fb2f43/study-3.png Educational Resources - Eating Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023;29(8):1947-1953. https://doi.org/10.1038/s41591-023-02455-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/612a7bc7-b67d-4771-bb41-835a293d4532/study-4.png Educational Resources - Eating Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Dallery J, Miller JL, Boissoneault J, et al. An open-label pilot study of psilocybin-assisted therapy for binge eating disorder. J Eat Disord. 2026;14(1):41. https://doi.org/10.1186/s40337-025-01508-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d16362c0-0500-4077-8f2c-adf17d17de2a/study-5.png Educational Resources - Eating Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Calabrese L, Scolnick B, Zupec-Kania B, et al. Ketogenic diet and ketamine infusion treatment to target chronic persistent eating disorder psychopathology in anorexia nervosa: a pilot study. Eat Weight Disord. 2022;27(8):3751-3757. https://doi.org/10.1007/s40519-022-01455-x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ec9956bc-0a33-4bd9-8449-9e5fa8e54e37/study-6.png Educational Resources - Eating Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rodan SC, Maguire S, Meez N, et al. Prescription and Nonprescription Drug Use Among People With Eating Disorders. JAMA Netw Open. 2025;8(7):e2522406. https://doi.org/10.1001/jamanetworkopen.2025.22406 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ccc41d8b-f059-403a-af5b-7fb06c1e2345/study-7.png Educational Resources - Eating Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Spriggs MJ, Kettner H, Carhart-Harris RL. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eat Weight Disord. 2021;26(4):1265-1270. https://doi.org/10.1007/s40519-020-01000-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1c984b8d-f705-4865-b1df-762b31707b2a/study-8.png Educational Resources - Eating Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Escobedo-Aedo PJ, Serrand C, Kabani S, Estric C. Ketamine as adjuvant treatment in eating disorders: an exploratory study of a case series and retrospective analysis. J Eat Disord. 2025;13(1):48. https://doi.org/10.1186/s40337-025-01232-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ed3e3be7-8676-4681-9cb0-29ece124ac63/study-9.png Educational Resources - Eating Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lafrance A, Loizaga-Velder A, Fletcher J, et al. Nourishing the Spirit: Exploratory Research on Ayahuasca Experiences along the Continuum of Recovery from Eating Disorders. J Psychoactive Drugs. 2017;49(5):427-435. https://doi.org/10.1080/02791072.2017.1361559 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/62420920-20d0-4a6c-84cd-5cbc1d13eeb2/study-10.png Educational Resources - Eating Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: van Beers E, de Vries I, Planting C, et al. Biological treatments for co-occurring eating disorders and psychological trauma: a systematic review. Front Psychiatry. 2025;16:1523269. https://doi.org/10.3389/fpsyt.2025.1523269 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ccd738fa-53e8-425b-ba29-db0ccdfe4d73/study-11.png Educational Resources - Eating Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Renelli M, Fletcher J, Tupper KW, et al. An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. Eat Weight Disord. 2020;25(2):437-444. https://doi.org/10.1007/s40519-018-0619-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/06345fad-ca7d-4cd8-80ea-4abedb8126a2/study-12.png Educational Resources - Eating Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Rodan SC, Meez N, Lloyd-Hurwitz S, et al. Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey. J Eat Disord. 2025;13(1):152. https://doi.org/10.1186/s40337-025-01328-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b87c07ff-1803-457a-8549-bc160f655012/study-13.png Educational Resources - Eating Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Väyrynen H, Strid N, Ylönen E, et al. Body image phenomenology in reports of psychedelic and meditative experiences: main themes and associations with body attitudes. Neurosci Conscious. 2026;2026(1):niag062. https://doi.org/10.1093/nc/niag062 https://www.harmreductionadvocate.com/educational-resources/personality-disorders monthly 0.5 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223824181-JK44I4Q7A8964GFKTDB7/illustration-personality-disorders.jpg Educational Resources - Personality Disorders https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f078c671-7472-49ff-9d60-b37edcf9d966/study-1.png Educational Resources - Personality Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fineberg SK, Choi EY, Shapiro-Thompson R, et al. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology. 2023;48(7):991-999. https://doi.org/10.1038/s41386-023-01540-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c37b88ed-8c60-4b3a-a293-08fc5dbf3827/study-2.png Educational Resources - Personality Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Grant JE, Boutouis S, O'Brien M, et al. An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder. Clin Neuropharmacol. 2026;49(4):163-169. https://doi.org/10.1097/wnf.0000000000000683 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/55e62796-7648-4330-8295-c5a7bf7a86ca/study-3.png Educational Resources - Personality Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Raffone F, Mazzoni F, De Ciechi A, et al. Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A real-world longitudinal study of suicidal ideation and self-harm. Asian J Psychiatr. 2026;120:104983. https://doi.org/10.1016/j.ajp.2026.104983 https://www.harmreductionadvocate.com/educational-resources/suicidality monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223811785-8FIY05GLGZO83KW132XQ/illustration-suicidality.jpg Educational Resources - Suicidality https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d918174c-7d13-4dae-b60c-acf5cbbb5cda/study-1.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648. https://doi.org/10.1056/nejmoa2206443 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ce5570fe-f832-4558-a41d-3b897d4a5233/study-2.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zeifman RJ, Palhano-Fontes F, Hallak J, Arcoverde E, Maia-Oliveira JP, Araujo DB. The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial. Front Pharmacol. 2019;10:1325. https://doi.org/10.3389/fphar.2019.01325 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/815790ad-46e9-4b53-a783-37bdd30ca1a3/study-3.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024;81(12):1225-1235. https://doi.org/10.1001/jamapsychiatry.2024.2546 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fd56ebab-39fe-44e8-ada6-63aedb80627a/study-4.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Meshkat S, Malik T, Zeifman R, et al. Psychedelics and Suicide-Related Outcomes: A Systematic Review. J Clin Med. 2025;14(5):1416. https://doi.org/10.3390/jcm14051416 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bf4b6070-ee49-4020-8d32-a95032365911/study-5.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zeifman RJ, Yu D, Singhal N, et al. Decreases in Suicidality Following Psychedelic Therapy: A Meta-Analysis of Individual Patient Data Across Clinical Trials. J Clin Psychiatry. 2022;83(2):21r14057. https://doi.org/10.4088/jcp.21r14057 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1f34c929-df60-48b6-becb-ce418aae63dd/study-6.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fu DJ, Zhang Q, Shi L, et al. Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality. BMC Psychiatry. 2023;23(1):587. https://doi.org/10.1186/s12888-023-05017-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a024c9d6-616c-47f2-bddf-8cd5851f2d43/study-7.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Can AT, Hermens DF, Dutton M, et al. Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study. Transl Psychiatry. 2021;11(1):101. https://doi.org/10.1038/s41398-021-01230-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2b282567-4104-44b8-975d-2cb0765feea0/study-8.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry. 2020;54(1):29-45. https://doi.org/10.1177/0004867419883341 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1cad140d-341a-488a-8f3f-9abc8f1c52b8/study-9.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Shah A, Sawaira FNU, Misbahuddin, et al. Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials. Brain Behav. 2026;16(2):e71255. https://doi.org/10.1002/brb3.71255 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ee16f77a-a66a-45f1-a468-c545127613b6/study-10.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Abbar M, Demattei C, El-Hage W, et al. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ. 2022;376:e067194. https://doi.org/10.1136/bmj-2021-067194 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b59b2efe-c06d-404f-8cad-1598ff532151/study-11.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Turkoz I, Lopena O, Salvadore G, et al. Treatment response to esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior without evidence of early response: a pooled post hoc analysis of ASPIRE. CNS Spectr. 2023;28(4):482-488. https://doi.org/10.1017/s1092852922000931 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7215dbcd-4ef1-4e40-bfb4-22149e7108ea/study-12.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry. 2018;175(7):620-630. https://doi.org/10.1176/appi.ajp.2018.17060720 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/eb478e63-9400-414e-979d-17e363cc4caf/study-13.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Liu TH, Shen HS, Wu JY, et al. Sustained effectiveness and safety of esketamine for major depressive disorder: a target trial simulation of real-world data. Transl Psychiatry. 2026;16(1):254. https://doi.org/10.1038/s41398-026-04032-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/dd0fb6e5-f3d1-4510-923f-abf665ad61d0/study-14.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Waszak PM, Opalko J, Olszańska N, Zagożdżon P. Anti-Suicidal Effects of Lithium, Ketamine, and Clozapine-A 10-Year Systematic Review. Pharmaceuticals (Basel). 2025;18(5):742. https://doi.org/10.3390/ph18050742 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fa00e025-a7cb-4fff-87cd-b77a9ed86e60/study-15.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Wilkinson ST, Ballard ED, Bloch MH, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018;175(2):150-158. https://doi.org/10.1176/appi.ajp.2017.17040472 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/895f697c-35a9-4933-b969-4c0d6889686f/study-16.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ross S, Agin-Liebes G, Lo S, et al. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacol Transl Sci. 2021;4(2):553-562. https://doi.org/10.1021/acsptsci.1c00020 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a0fa2bdd-8b21-4a51-a162-8a11278f6146/study-17.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kaur S, Parmar C, Gaur V, et al. The efficacy of oral ketamine in severely depressed patients at high risk of suicide. Asian J Psychiatr. 2023;86:103678. https://doi.org/10.1016/j.ajp.2023.103678 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ee87b033-94ee-481e-89d6-6075415bc8ff/study-18.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry. 2018;175(4):327-335. https://doi.org/10.1176/appi.ajp.2017.17060647 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/791d2d22-499c-4ef1-8842-c5e3cf9386ee/study-19.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014;31(4):335-343. https://doi.org/10.1002/da.22253 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f8260578-a41c-4ae5-a474-7c834a8a068e/study-20.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Shivanekar S, Shivanekar S, Gopalan P, et al. A Pilot Study of Ketamine Infusion after Suicide Attempt: New Frontiers in Treating Acute Suicidality in a Real-World Medical Setting. Int J Environ Res Public Health. 2022;19(21):13792. https://doi.org/10.3390/ijerph192113792 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5eb3b40d-0ed6-499a-a2ef-db95047aaafb/study-21.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Dadiomov D, Lee K. The effects of ketamine on suicidality across various formulations and study settings. Ment Health Clin. 2019;9(1):48-60. https://doi.org/10.9740/mhc.2019.01.048 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3f1d1d5e-aef6-41b6-b435-ad8205174e44/study-22.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Menon T, Lu A, Arulmozhi A, et al. The use of repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), ketamine, and esketamine in reducing suicidality in major depressive disorder: A comprehensive narrative review. Psychiatry Res. 2026;359:117036. https://doi.org/10.1016/j.psychres.2026.117036 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/90911f95-8bff-4674-ab86-70629c20472d/study-23.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: van der Vaart A, LaPratt J, Swartz K, et al. Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial. J Clin Psychiatry. 2026;87(2):26m16338. https://doi.org/10.4088/jcp.26m16338 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d5fc423c-fb27-491e-8d9d-823a8619b945/study-24.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Keilp JG, Madden SP, Marver JE, et al. Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation. J Clin Psychiatry. 2021;82(6):21m13921. https://doi.org/10.4088/jcp.21m13921 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5a52a2db-0045-4f6f-97ea-efe7ed33186e/study-25.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zhou Y, Wang C, Lan X, et al. Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation. Front Psychiatry. 2022;13:779326. https://doi.org/10.3389/fpsyt.2022.779326 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f77272c5-72d6-403b-873c-ad50627d9de8/study-26.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ballard ED, Lally N, Nugent AC, et al. Neural correlates of suicidal ideation and its reduction in depression. Int J Neuropsychopharmacol. 2014;18(1):pyu069. https://doi.org/10.1093/ijnp/pyu069 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/15966aed-89f1-44a9-821d-97fcbb2a98f9/study-27.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Baryshnikov I, Demattei C, Abbar M, et al. Intravenous Ketamine reduces psychological pain in suicidal inpatients: A secondary analysis of a six-week randomized placebo-controlled trial. J Affect Disord. 2026;414:122366. https://doi.org/10.1016/j.jad.2026.122366 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b4bfb245-f9db-4c57-aa47-bedc95557aed/study-28.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zhou Y, Lan X, Wang C, et al. Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial. J Am Acad Child Adolesc Psychiatry. 2024;63(5):507-518. https://doi.org/10.1016/j.jaac.2023.05.031 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ba27ac9e-3b7e-4a5e-8884-95514f9886d9/study-29.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fan W, Yang H, Sun Y, et al. Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. Oncotarget. 2017;8(2):2356-2360. https://doi.org/10.18632/oncotarget.13743 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c16180ef-c563-4603-969e-2fd8174f290a/study-30.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Tucciarone JM, Bandeira ID, Blasey C, et al. Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Am J Psychiatry. 2026;183(6):409-419. https://doi.org/10.1176/appi.ajp.20250840 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/63191cde-2071-4185-ac85-fb1ee6ec04de/study-31.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ionescu DF, Fu DJ, Qiu X, et al. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). Int J Neuropsychopharmacol. 2021;24(1):22-31. https://doi.org/10.1093/ijnp/pyaa068 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/767b5bc5-776e-43bd-866f-0cee6237e54f/study-32.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Domany Y, McCullumsmith CB. Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial. Arch Suicide Res. 2022;26(3):1250-1265. https://doi.org/10.1080/13811118.2021.1878078 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0fb13662-007e-400f-8ea2-ea0f7e071fd7/study-33.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Anzolin AP, Baldez DP, Montezano BB, et al. Subcutaneous ketamine reduces suicide risk and improves functioning in depression: A proof-of-concept study. Psychiatry Res. 2024;337:115915. https://doi.org/10.1016/j.psychres.2024.115915 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/525ff80b-a855-40c8-8ecb-fe236985266d/study-34.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sexton JD, Nichols CD, Hendricks PS. Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics. Front Psychiatry. 2019;10:896. https://doi.org/10.3389/fpsyt.2019.00896 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/97a1b935-7d37-4604-92f5-fd82bbba83e4/study-35.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kutz CJ, Mistry AM, Dukes CH. Expanding Ketamine Application for Treatment of Acute Suicidality in Long-Duration Spaceflight. Aerosp Med Hum Perform. 2025;96(6):509-519. https://doi.org/10.3357/amhp.6619.2025 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/532eefdb-2444-4512-a1fa-c7b55a2ff214/study-36.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Fu DJ, Ionescu DF, Li X, et al. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). J Clin Psychiatry. 2020;81(3):19m13191. https://doi.org/10.4088/jcp.19m13191 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9c1fff4d-e8ab-420f-8303-f4cf2ed12dda/study-37.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Wilkinson ST, Kitay BM, Macaluso M, et al. Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial. J Clin Psychiatry. 2026;87(2):25m16285. https://doi.org/10.4088/jcp.25m16285 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/057a41c0-783d-4319-b1f9-564d71e9b67b/study-38.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Sajid S, Mann JJ, Grunebaum MF. Clinical trials since 2020 of rapid anti-suicidal ideation effects of ketamine and its enantiomers: a systematic review. Transl Psychiatry. 2025;15(1):44. https://doi.org/10.1038/s41398-025-03255-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/15c28f6d-7e41-4959-8c0a-0f57a5c85fbf/study-39.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Canuso CM, Ionescu DF, Li X, et al. Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior. J Clin Psychopharmacol. 2021;41(5):516-524. https://doi.org/10.1097/jcp.0000000000001465 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/90dc2cef-3998-4548-b34b-c3a00f1a8a75/study-40.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Jones GM, Nock MK. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. J Psychopharmacol. 2022;36(1):46-56. https://doi.org/10.1177/02698811211058923 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/aabd69f2-cb82-4ce8-814c-b8c4f9bcab86/study-41.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hochschild A, Keilp JG, Madden SP, et al. Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression. J Affect Disord. 2022;300:10-16. https://doi.org/10.1016/j.jad.2021.12.055 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/56158fc5-2756-4282-a07a-e10cd1a361e8/study-42.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Seraj A, Reyazuddin M, Gaur RK, Andrade C. Oral ketamine for rapid reduction of suicidal ideation in major depressive disorder: A midazolam-controlled randomized clinical trial. Asian J Psychiatr. 2025;106:104413. https://doi.org/10.1016/j.ajp.2025.104413 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/19eefb12-8506-4172-8cda-e212c9d7580b/study-43.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jamieson C, Canuso CM, Ionescu DF, et al. Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II). Qual Life Res. 2023;32(11):3053-3061. https://doi.org/10.1007/s11136-023-03451-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ad7af936-6d94-4538-b6df-b4068d368131/study-44.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dutton M, Can AT, Beaudequin D, et al. Oral ketamine reduces the experience of stress in people with chronic suicidality. J Affect Disord. 2022;300:410-417. https://doi.org/10.1016/j.jad.2022.01.018 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5757be7f-2fe6-4ed5-920b-0bd65674df15/study-45.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Amerio A, Venturini E, Capanna M, et al. Exploring the effects of pharmacological treatments on suicidality in children and adolescents: a structured review of the literature and narrative synthesis. EClinicalMedicine. 2026;91:103748. https://doi.org/10.1016/j.eclinm.2025.103748 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b8fda960-8037-4b2c-ac25-668e18ad4ff8/study-46.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Pastre M, Chancel R, Malestroit M, et al. Early Response to Ketamine for Suicidal Crisis Reduces Suicidal Events at 3 Months. J Clin Psychiatry. 2025;86(3):25m15829. https://doi.org/10.4088/jcp.25m15829 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/be8cb17d-5f41-44a8-8c88-aebb20c3665e/study-47.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Shamabadi A, Ahmadzade A, Hasanzadeh A. Ketamine for suicidality: An umbrella review. Br J Clin Pharmacol. 2022;88(9):3990-4018. https://doi.org/10.1111/bcp.15360 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5df2edbe-5767-4313-98bd-04751490eed0/study-48.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Rizk MM, Mann JJ. An Update on Somatic Treatments for Suicide Risk. Am J Psychiatry. 2026;183(6):382-400. https://doi.org/10.1176/appi.ajp.20260287 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b76b0dc6-b2f3-4c04-b6ae-ff51a34cb181/study-49.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Seth L, Biswal J, Sahoo S, et al. A Randomised Controlled Trial on the Efficacy of Ketamine versus Electroconvulsive Therapy in Severe Depression with Suicidal Ideation. Neuropsychobiology. 2026;85(3):156-167. https://doi.org/10.1159/000550863 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d6ec9a59-656d-49af-a13b-f44d8e9d50cc/study-50.png Educational Resources - Suicidality Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: O'Brien B, Lee J, Kim S, et al. Anti-suicidal effects of IV ketamine in a real-world setting. Psychiatry Res. 2024;331:115604. https://doi.org/10.1016/j.psychres.2023.115604 https://www.harmreductionadvocate.com/educational-resources/adhd monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223947299-NJLG4UDJ33M1IC4V1L6G/illustration-adhd.jpg Educational Resources - ADHD https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/68e18ba7-34d6-42a9-9364-5801d01ca59b/study-1.png Educational Resources - ADHD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mueller L, Santos de Jesus J, Schmid Y, et al. Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(6):555-562. https://doi.org/10.1001/jamapsychiatry.2025.0044 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/17307d14-d3c2-4095-8d83-1c99a7005273/study-2.png Educational Resources - ADHD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Haijen-Bongers ECHM, Hurks PPM, Schepers J, et al. Effects of repeated low-dose LSD on neuropsychological functioning in adults with ADHD: a randomized placebo-controlled study. Psychopharmacology (Berl). 2026. https://doi.org/10.1007/s00213-026-07107-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ec12b366-d1f7-4395-9682-67bed94fad12/study-3.png Educational Resources - ADHD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Haijen ECHM, Hurks PPM, Kuypers KPC. Effects of psychedelic microdosing versus conventional ADHD medication use on emotion regulation, empathy, and ADHD symptoms in adults with severe ADHD symptoms: A naturalistic prospective comparison study. Eur Psychiatry. 2024;67(1):e18. https://doi.org/10.1192/j.eurpsy.2024.8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1c4e02ba-d03e-4c17-849e-2c4d4c8237cd/study-4.png Educational Resources - ADHD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Haijen ECHM, Hurks PPM, Kuypers KPC. Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study. Front Psychiatry. 2023;14:1233585. https://doi.org/10.3389/fpsyt.2023.1233585 https://www.harmreductionadvocate.com/educational-resources/autism monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223940854-X72N36YZTUTEWAB2PHIB/illustration-autism.jpg Educational Resources - Autism https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e4dbfc44-01e4-4160-a300-b3f4ab24951b/study-1.png Educational Resources - Autism Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Danforth AL, Grob CS, Struble C, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl). 2018;235(11):3137-3148. https://doi.org/10.1007/s00213-018-5010-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a2a88c23-a49a-4593-aca3-881026ad9a3f/study-2.png Educational Resources - Autism Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Stroud J, Rice C, Orsini A, et al. Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey. Psychopharmacology (Berl). 2025;242(2):373-387. https://doi.org/10.1007/s00213-024-06685-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e1c0b58f-83d3-4ea8-9b7d-ba62fef8bea1/study-3.png Educational Resources - Autism Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Afsharnia S, Liang V, Lunsky Y, et al. Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey. PLOS Ment Health. 2025;2(12):e0000514. https://doi.org/10.1371/journal.pmen.0000514 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e6d1cb90-2805-417d-a9bf-ed87d5ac3dc3/study-4.png Educational Resources - Autism Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Danforth AL. Embracing Neurodiversity in Psychedelic Science: A Mixed-Methods Inquiry into the MDMA Experiences of Autistic Adults. J Psychoactive Drugs. 2019;51(2):146-154. https://doi.org/10.1080/02791072.2019.1587116 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/df553174-8dc6-45de-858e-64d4833722e6/study-5.png Educational Resources - Autism Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Miao Y, Zheng M, Li Q, et al. Comparison of propofol-esketamine versus propofol-sufentanil for deep sedation and analgesia in children with autism: A randomized double-blind clinical trial. Autism Res. 2024;17(7):1356-1364. https://doi.org/10.1002/aur.3172 https://www.harmreductionadvocate.com/educational-resources/adolescents monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223934789-9STEH46JNH3MAXF1F29F/illustration-adolescents.jpg Educational Resources - Adolescents https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/af898289-f826-43af-b769-bceea076ad17/study-1.png Educational Resources - Adolescents Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pardossi S, Fagiolini A, Scheggi S, et al. A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope? Children (Basel). 2024;11(7):801. https://doi.org/10.3390/children11070801 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e8a2b8f2-00b2-4edf-b11b-e7a055428418/study-2.png Educational Resources - Adolescents Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Simonsson O, Mosing MA, Osika W, et al. Adolescent Psychedelic Use and Psychotic or Manic Symptoms. JAMA Psychiatry. 2024;81(6):579-585. https://doi.org/10.1001/jamapsychiatry.2024.0047 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e64c7979-f883-4028-8a64-8f708c0b2488/study-3.png Educational Resources - Adolescents Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Cullen KR, Amatya P, Roback MG, et al. Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study. J Child Adolesc Psychopharmacol. 2018;28(7):437-444. https://doi.org/10.1089/cap.2018.0030 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8534cc7c-aa58-465b-85b8-f9178fe6cd1f/study-4.png Educational Resources - Adolescents Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kosik-Gonzalez C, Fu DJ, Chen LN, et al. Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study. Focus (Am Psychiatr Publ). 2026;24(2):223-235. https://doi.org/10.1176/appi.focus.26024113 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/253ad056-52a9-4749-9212-880c2afae8ea/study-5.png Educational Resources - Adolescents Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sheehy KA, Muller EA, Lippold C, et al. Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. BMC Pediatr. 2015;15:198. https://doi.org/10.1186/s12887-015-0515-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e76fb953-16ba-4aa5-90ed-22af824cac46/study-6.png Educational Resources - Adolescents Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Li Y, Zhao K, Cao P, et al. Investigation of Esketamine Administration During Surgical Procedures for the Alleviation of Postoperative Anxiety and Depression in Adolescent Patients: A Randomized Controlled Trial. Drug Des Devel Ther. 2026;20:587626. https://doi.org/10.2147/dddt.s587626 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3d27f251-f606-4652-9bc5-8a404463e0c2/study-7.png Educational Resources - Adolescents Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Meshkat S, Rosenblat JD, Ho RC, et al. Ketamine use in pediatric depression: A systematic review. Psychiatry Res. 2022;317:114911. https://doi.org/10.1016/j.psychres.2022.114911 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/43044ab2-aa69-47c7-8b86-921411e72543/study-8.png Educational Resources - Adolescents Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bruton AM, Wesemann DG, Machingo TA, et al. Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review. Eur Child Adolesc Psychiatry. 2025;34(1):141-157. https://doi.org/10.1007/s00787-024-02458-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/383709e6-e6d2-4fc5-aefc-e343eb3c14f7/study-9.png Educational Resources - Adolescents Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Da Silveira DX, Grob CS, de Rios MD, et al. Ayahuasca in adolescence: a preliminary psychiatric assessment. J Psychoactive Drugs. 2005;37(2):129-133. https://doi.org/10.1080/02791072.2005.10399792 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/efb95a83-bb70-4de5-bf73-845ec29df512/study-10.png Educational Resources - Adolescents Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Wolfson P, Carroll C. A longitudinal analysis of the clinical practice of ketamine assisted psychotherapy with adolescents and young adults. Front Psychiatry. ;17. https://doi.org/10.3389/fpsyt.2026.1886833 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b1ba9a4c-cf57-4c56-92ee-5ee556d53d3b/study-11.png Educational Resources - Adolescents Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Doering-Silveira E, Grob CS, de Rios MD, et al. Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J Psychoactive Drugs. 2005;37(2):141-144. https://doi.org/10.1080/02791072.2005.10399794 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/68c8b795-4eb9-46ea-af76-2c92336444e0/study-12.png Educational Resources - Adolescents Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bredlau AL, McDermott MP, Adams HR, et al. Oral ketamine for children with chronic pain: a pilot phase 1 study. J Pediatr. 2013;163(1):194-200.e1. https://doi.org/10.1016/j.jpeds.2012.12.077 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2357ee4e-4be4-487a-8a47-c7ece8c84d83/study-13.png Educational Resources - Adolescents Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: van Vugt AS, Zijlmans J, Lindauer R, van Dam L. MDMA-assisted psychotherapy with adolescents suffering from PTSD: Do or don’t? a qualitative study with youth, parents, and clinicians. Drug Science, Policy and Law. 2023. https://doi.org/10.1177/20503245231198477 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f36f877e-101c-4008-a0da-d396d4613590/study-14.png Educational Resources - Adolescents Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: de Rios MD, Grob CS, Lopez E, et al. Ayahuasca in adolescence: Qaualitative results. J Psychoactive Drugs. 2005;37(2):135-139. https://doi.org/10.1080/02791072.2005.10399793 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b63f76df-c426-4d9f-b7ef-22cd3cf80c1f/study-15.png Educational Resources - Adolescents Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Mathai DS, McCathern AG, Guzick AG, et al. Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality. J Child Adolesc Psychopharmacol. 2021;31(8):553-561. https://doi.org/10.1089/cap.2021.0078 https://www.harmreductionadvocate.com/educational-resources/acute-pain monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223872284-4EQHGU8BYFNMIOC2T5WU/illustration-acute-pain.jpg Educational Resources - Acute Pain https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8b338e65-8333-4045-9519-7276c59a6137/study-1.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Smyth MA, Noordali H, Starr K, et al. Paramedic analgesia comparing ketamine and morphine in trauma (PACKMaN): a randomised, double-blind, phase 3 trial. Lancet Reg Health Eur. 2025;53:101265. https://doi.org/10.1016/j.lanepe.2025.101265 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5ecfefac-f757-4ace-8996-737d28cfbded/study-2.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Motov S, Rockoff B, Cohen V, et al. Intravenous Subdissociative-Dose Ketamine Versus Morphine for Analgesia in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2015;66(3):222-229.e1. https://doi.org/10.1016/j.annemergmed.2015.03.004 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/390418d9-6c9b-4062-804b-b833a7c8ebd9/study-3.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ramaekers JG, Hutten N, Mason NL, et al. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. J Psychopharmacol. 2021;35(4):398-405. https://doi.org/10.1177/0269881120940937 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d6530331-89db-467e-859b-a04e8b5243dc/study-4.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Beaudoin FL, Lin C, Guan W, Merchant RC. Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial. Acad Emerg Med. 2014;21(11):1193-1202. https://doi.org/10.1111/acem.12510 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7bc82f7a-5220-48fd-a01e-828464654166/study-5.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Le Cornec C, Le Pottier M, Broch H, et al. Ketamine Compared With Morphine for Out-of-Hospital Analgesia for Patients With Traumatic Pain: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(1):e2352844. https://doi.org/10.1001/jamanetworkopen.2023.52844 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/97fbaadf-e761-442c-8e01-22b475893697/study-6.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Park KM, Max MB, Robinovitz E, et al. Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Pain. 1995;63(2):163-172. https://doi.org/10.1016/0304-3959(95)00029-r https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2bd32b19-4808-43a5-bded-ff00a3d44b60/study-7.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Andolfatto G, Innes K, Dick W, et al. Prehospital Analgesia With Intranasal Ketamine (PAIN-K): A Randomized Double-Blind Trial in Adults. Ann Emerg Med. 2019;74(2):241-250. https://doi.org/10.1016/j.annemergmed.2019.01.048 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4cb7053e-ec84-4b83-aced-bea90370fa12/study-8.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nielsen RV, Fomsgaard JS, Siegel H, et al. Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial. Pain. 2017;158(3):463-470. https://doi.org/10.1097/j.pain.0000000000000782 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7280a1f8-b11a-4b77-830e-979f1c461491/study-9.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Sobieraj DM, Martinez BK, Miao B, et al. Comparative Effectiveness of Analgesics to Reduce Acute Pain in the Prehospital Setting. Prehosp Emerg Care. 2020;24(2):163-174. https://doi.org/10.1080/10903127.2019.1657213 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2609bc4a-41e6-4ccb-bc71-b9e956a6ffe8/study-10.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Majeed E, Rafique I, Inam K, Majeed F. Efficacy of intraoperative low dose intravenous Esketamine for acute postoperative pain control: Meta-analysis of randomized controlled trials. J Clin Anesth. 2026;114:112278. https://doi.org/10.1016/j.jclinane.2026.112278 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8353e9ae-4d72-4507-ad86-93d06cc48ae9/study-11.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Akram U, Fatima E, Ashraf H, et al. Perioperative ketamine or esketamine for acute postoperative pain after laparoscopic cholecystectomy: A systematic review and meta-analysis with meta-regression. Anaesth Crit Care Pain Med. 2026;45(3):101762. https://doi.org/10.1016/j.accpm.2026.101762 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4b38fa64-9d0f-429d-bded-289602d4e498/study-12.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Li M, Wu D, Zhang H, et al. Effectiveness of adding esketamine to dexmedetomidine for sedation and analgesia during radiofrequency ablation and saphenous vein stripping: a randomized controlled trial. Minerva Anestesiol. 2026;92(3):155-164. https://doi.org/10.23736/s0375-9393.26.19169-x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bd36484e-b427-4aa5-bca0-d8a8e491c968/study-13.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sarvari HR, Baigrezaii H, Nazarianpirdosti M, et al. Comparison of the efficacy of intranasal ketamine versus intravenous ketorolac on acute non-traumatic headaches: a randomized double-blind clinical trial. Head Face Med. 2022;18(1):1. https://doi.org/10.1186/s13005-021-00303-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/aa9f5dd0-31cc-498d-8f18-f24a97806535/study-14.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Warncke T, Stubhaug A, Jørum E. Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo. Pain. 1997;72(1-2):99-106. https://doi.org/10.1016/s0304-3959(97)00006-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/14e56e94-8852-49b3-8c5a-e87ff771dc06/study-15.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Guo J, Zhao F, Bian J, et al. Low-dose ketamine versus morphine in the treatment of acute pain in the emergency department: A meta-analysis of 15 randomized controlled trials. Am J Emerg Med. 2024;76:140-149. https://doi.org/10.1016/j.ajem.2023.11.056 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/00af3afd-d75b-499c-a24e-c392ddba2b3b/study-16.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bowers KJ, McAllister KB, Ray M, Heitz C. Ketamine as an Adjunct to Opioids for Acute Pain in the Emergency Department: A Randomized Controlled Trial. Acad Emerg Med. 2017;24(6):676-685. https://doi.org/10.1111/acem.13172 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b8d83096-f59d-4d33-9209-9b3daeddf002/study-17.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Oliveira J E Silva L, Lee JY, Bellolio F, et al. Intranasal ketamine for acute pain management in children: A systematic review and meta-analysis. Am J Emerg Med. 2020;38(9):1860-1866. https://doi.org/10.1016/j.ajem.2020.05.094 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e305ffb5-5719-45bb-99e8-22b092cda72d/study-18.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Li J, Wang X. Esketamine for Postoperative Multimodal Analgesia in Laparoscopic Surgery: A Systematic Review and Meta-Analysis. J Pain Res. 2026;19:597557. https://doi.org/10.2147/jpr.s597557 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9797f522-86a5-4486-b2f7-1707b83909d5/study-19.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Abo Zeid M, Abou Elezz AM, Khalefa K, et al. Ketamine Immediate Analgesia and Opioid-Sparing Benefits in Laparoscopic Cholecystectomy: A Meta-Analysis of Time Points, Anesthesia Protocols, and Bolus/Infusion Strategies. Clin J Pain. 2026;42(6):e1382. https://doi.org/10.1097/ajp.0000000000001382 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/cd8ee4ec-8796-46f3-8324-6a0dc2093473/study-20.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Li Y, Wang L, Liu K, et al. Esketamine combined with hydromorphone versus hydromorphone for post-operative patient-controlled intravenous analgesia in children: a randomized controlled trial. Eur J Med Res. 2026;31(1):209. https://doi.org/10.1186/s40001-025-03806-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/07cdbab8-e406-41f1-8266-91829b35dcc2/study-21.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Andolfatto G, Willman E, Joo D, et al. Intranasal ketamine for analgesia in the emergency department: a prospective observational series. Acad Emerg Med. 2013;20(10):1050-1054. https://doi.org/10.1111/acem.12229 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ba372064-29e2-4263-92b9-70da6b8ad2e7/study-22.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Segerdahl M, Ekblom A, Sollevi A. The influence of adenosine, ketamine, and morphine on experimentally induced ischemic pain in healthy volunteers. Anesth Analg. 1994;79(4):787-791. https://doi.org/10.1213/00000539-199410000-00029 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ef8735a1-6140-4dee-8e48-b4c1fb1059cc/study-23.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fjendbo Galili S, Nikolajsen L, Papadomanolakis-Pakis N. Subanaesthetic single-dose ketamine as an adjunct to opioid analgesics for acute pain management in the emergency department: a systematic review and meta-analysis. BMJ Open. 2023;13(3):e066444. https://doi.org/10.1136/bmjopen-2022-066444 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6e717f8c-5428-4f57-842d-6dc4b3e78ef5/study-24.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Eddie EA, Zahedi AZBA, Jamaluddin SFB, Noor JM. Low-dose short infusion ketamine as adjunct to morphine for acute long bone fracture in the emergency department: a randomized controlled trial. BMC Emerg Med. 2024;24(1):80. https://doi.org/10.1186/s12873-024-00997-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/06ddc796-96bc-48d8-8984-d5dab0e73a88/study-25.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Wheeler KE, Grilli R, Centofanti JE, et al. Adjuvant Analgesic Use in the Critically Ill: A Systematic Review and Meta-Analysis. Crit Care Explor. 2020;2(7):e0157. https://doi.org/10.1097/cce.0000000000000157 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ddd5ab47-41f6-46f9-9c99-42649c8f5575/study-26.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zhu X, Bao W, Wang L, et al. Esketamine as an Adjuvant to Ropivacaine in Genicular Nerve and IPACK Blocks for Total Knee Arthroplasty: A Double-Blind Randomized Trial. Drug Des Devel Ther. 2025;19:11047-11056. https://doi.org/10.2147/dddt.s579720 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e862a73e-ace4-4362-9c38-42e3905e32fb/study-27.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wang S, Hao W, Fan H, et al. Effectiveness and safety of esketamine in laparoscopic surgery patients: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2025;16:1663348. https://doi.org/10.3389/fphar.2025.1663348 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5c9b6bc0-d3b7-449f-b5d5-e9447baab363/study-28.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Liu H, Xing X, Jiang F, et al. Esketamine-Based Opioid-Free versus Opioid-Based Anesthesia for Recovery Quality After Laparoscopic Transabdominal Preperitoneal Repair: A Randomized Noninferiority Trial. Drug Des Devel Ther. 2026;20:572431. https://doi.org/10.2147/dddt.s572431 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d25231b0-f180-40ec-8f1c-34d912d71f76/study-29.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Watso JC, Huang M, Moralez G, et al. Low dose ketamine reduces pain perception and blood pressure, but not muscle sympathetic nerve activity, responses during a cold pressor test. J Physiol. 2021;599(1):67-81. https://doi.org/10.1113/jp280706 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6510b36d-7d4d-4733-aadd-a12d0513bb8d/study-30.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Warncke T, Jørum E, Stubhaug A. Local treatment with the N-methyl-D-aspartate receptor antagonist ketamine, inhibit development of secondary hyperalgesia in man by a peripheral action. Neurosci Lett. 1997;227(1):1-4. https://doi.org/10.1016/s0304-3940(97)00263-2 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/28204201-53ab-4cec-bc8a-0e162ad9cad0/study-31.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Graudins A, Meek R, Egerton-Warburton D, et al. The PICHFORK (Pain in Children Fentanyl or Ketamine) trial: a randomized controlled trial comparing intranasal ketamine and fentanyl for the relief of moderate to severe pain in children with limb injuries. Ann Emerg Med. 2015;65(3):248-254.e1. https://doi.org/10.1016/j.annemergmed.2014.09.024 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/69918ce5-ccad-4029-b2bf-2d117cb7d11d/study-32.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Jahanian F, Hosseininejad SM, Amini Ahidashti H, et al. Efficacy and Safety of Morphine and Low Dose Ketamine for Pain Control of Patients with Long Bone Fractures: A Randomized, Double-Blind, Clinical Trial. Bull Emerg Trauma. 2018;6(1):31-36. https://doi.org/10.29252/beat-060105 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/13c1ecc4-4d9c-49ee-98a1-f0d7a5a46c2d/study-33.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zhou J, Wen Y, Xu S, et al. Efficacy and safety of N-methyl-d-aspartate receptor antagonists for preventing acute postoperative pain: A systematic review and network meta-analysis of randomized controlled trials. J Clin Anesth. 2026;112:112233. https://doi.org/10.1016/j.jclinane.2026.112233 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1d2985ee-8ce6-4c34-98d1-91160cccae45/study-34.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zhong L, Zhong R, Xie B, et al. Ketamine/esketamine for preventing rebound pain after peripheral nerve block: a systematic review and meta-analysis of randomized controlled trials. Minerva Anestesiol. 2026;92(5):480-488. https://doi.org/10.23736/s0375-9393.25.19528-x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/14a35f80-08cd-4d78-ba2f-7c5a11eb2310/study-35.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wu Y, Wu H, Dong J, et al. Effect of Subanesthetic Doses of Esketamine on Early Postoperative Pain Sensitivity in Patients Undergoing Salpingectomy: A Randomized Clinical Trial. Drug Des Devel Ther. 2026;20:596251. https://doi.org/10.2147/dddt.s596251 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/79265ab6-848f-4027-8b3d-ae6771507105/study-36.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Takada M, Fukusaki M, Terao Y, et al. Preadministration of low-dose ketamine reduces tourniquet pain in healthy volunteers. J Anesth. 2005;19(2):180-182. https://doi.org/10.1007/s00540-005-0306-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e5454228-57ea-472a-921a-d735f3c08b01/study-37.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nguyen T, Mai M, Choudhary A, et al. Comparison of Nebulized Ketamine to Intravenous Subdissociative Dose Ketamine for Treating Acute Painful Conditions in the Emergency Department: A Prospective, Randomized, Double-Blind, Double-Dummy Controlled Trial. Ann Emerg Med. 2024;84(4):354-362. https://doi.org/10.1016/j.annemergmed.2024.03.024 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/143679c7-ce14-4161-8e2e-ecc62e09a2bb/study-38.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Shimonovich S, Gigi R, Shapira A, et al. Intranasal ketamine for acute traumatic pain in the Emergency Department: a prospective, randomized clinical trial of efficacy and safety. BMC Emerg Med. 2016;16(1):43. https://doi.org/10.1186/s12873-016-0107-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/006d0ed8-1c59-4bf6-871c-da15551771eb/study-39.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sotoodehnia M, Farmahini-Farahani M, Safaie A, et al. Low-dose intravenous ketamine versus intravenous ketorolac in pain control in patients with acute renal colic in an emergency setting: a double-blind randomized clinical trial. Korean J Pain. 2019;32(2):97-104. https://doi.org/10.3344/kjp.2019.32.2.97 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5130a4f4-c874-46c4-b18a-7f2ffff96c8b/study-40.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Makkar JK, Khurana BJK, Singh PM, Singh NP. Role of perioperative ketamine on the incidence of rebound pain after regional nerve block in the adult surgical population: A systematic review and meta-analysis of randomised controlled trials. Indian J Anaesth. 2026;70(7):797-805. https://doi.org/10.4103/ija.ija_100_26 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4e76f419-a6e9-4661-88f6-3d193ea1c5f5/study-41.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Heikal Y, Wagdy M, Alkheder A, et al. Prophylactic esketamine for postoperative sore throat: a meta-analysis of randomized evidence. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(13):21725-21735. https://doi.org/10.1007/s00210-026-05694-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1e99f230-db20-4f4c-9be6-60eb75b09104/study-42.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Warncke T, Stubhaug A, Jørum E. Preinjury treatment with morphine or ketamine inhibits the development of experimentally induced secondary hyperalgesia in man. Pain. 2000;86(3):293-303. https://doi.org/10.1016/s0304-3959(00)00260-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bdbffe05-cf75-4ad7-a48b-5709aeea86b4/study-43.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Frey TM, Florin TA, Caruso M, et al. Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children: The PRIME Randomized Clinical Trial. JAMA Pediatr. 2019;173(2):140-146. https://doi.org/10.1001/jamapediatrics.2018.4582 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a425a209-5c1e-4ea7-b51c-cd671b32d3b9/study-44.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Esfahani H, Khazaeipour Z, Safaie A, Aghili SM. Ketamine Sub-Dissociative Dose Vs. Morphine Sulfate for Acute Pain Control in Patients with Isolated Limb Injuries in the Emergency Department: A Randomized, Double-blind, Clinical Trial. Bull Emerg Trauma. 2021;9(2):73-79. https://doi.org/10.30476/beat.2021.85949 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8ac5028a-d1df-4a05-bb1b-f313570030ac/study-45.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zhou M, Qi Y, Zhou F, et al. Esketamine-based PCIA combined with intercostal nerve block for acute pain after lobectomy: a randomized controlled trial. Front Pharmacol. 2026;17:1746121. https://doi.org/10.3389/fphar.2026.1746121 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/441aa82c-f09b-4ad4-8749-46cc33a284f7/study-46.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Xu Y, Zhou L, Tang Q, et al. Lidocaine combined with low-dose esketamine for movement-evoked pain after hepatectomy: a double-blind randomised controlled trial. Anaesthesia. 2026;81(9):1209-1218. https://doi.org/10.1111/anae.70215 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/24c68fa1-2771-4c1e-a6c8-a8c4de20e291/study-47.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Sprenger T, Valet M, Woltmann R, et al. Imaging pain modulation by subanesthetic S-(+)-ketamine. Anesth Analg. 2006;103(3):729-737. https://doi.org/10.1213/01.ane.0000231635.14872.40 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/80cee03e-de74-4786-ae7a-1a9ff40ff5d6/study-48.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Alshahrani MS, AlSulaibikh AH, ElTahan MR, et al. Ketamine administration for acute painful sickle cell crisis: A randomized controlled trial. Acad Emerg Med. 2022;29(2):150-158. https://doi.org/10.1111/acem.14382 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/769542dd-064e-4ce6-9c94-677fd54eeda2/study-49.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Häske D, Dorau W, Heinemann N, et al. Efficacy and safety in ketamine-guided prehospital analgesia for abdominal pain. Intern Emerg Med. 2022;17(8):2291-2297. https://doi.org/10.1007/s11739-022-03091-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2c58fe46-0abe-4bdf-8462-3cde3c92d4ce/study-50.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Motov S, Mann S, Drapkin J, et al. Intravenous subdissociative-dose ketamine versus morphine for acute geriatric pain in the Emergency Department: A randomized controlled trial. Am J Emerg Med. 2019;37(2):220-227. https://doi.org/10.1016/j.ajem.2018.05.030 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6e6c1342-2cba-4b7c-bcf7-76ce0ca612fd/study-51.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Fu D, Shen Y, Xiao H, Jia J. Dose-dependent effects of esketamine on the prevention of propofol-induced injection pain: a randomized controlled trial. BMC Anesthesiol. 2026;26(1):115. https://doi.org/10.1186/s12871-026-03636-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ae07cafa-954a-4a14-8449-0b1977e34475/study-52.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zhao H, Liu Z, Zhang Y, et al. Effects of Intravenous Subanesthetic-Dose Esketamine on Early Postoperative Pain in Elderly Patients Undergoing Thoracoscopic Lung Surgery: A Randomized Double-Blind Controlled Trial. Drug Des Devel Ther. 2025;19:11289-11305. https://doi.org/10.2147/dddt.s565937 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/27bac8b4-a7c7-44c1-a6a5-e7bd3bc9dfbb/study-53.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Beaudrie-Nunn AN, Wieruszewski ED, Woods EJ, et al. Efficacy of analgesic and sub-dissociative dose ketamine for acute pain in the emergency department. Am J Emerg Med. 2023;70:133-139. https://doi.org/10.1016/j.ajem.2023.05.026 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fe51a416-e340-48c5-bdbe-84effcda4e75/study-54.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wei LY, Luo MC, He JX, et al. Analgesic Efficacy of Different Doses of Esketamine as an Adjuvant to Ropivacaine for Thoracoscopy-Guided Thoracic Paravertebral Block After Thoracoscopic Radical Resection for Lung Cancer: A Prospective Randomized Controlled Trial. Drug Des Devel Ther. 2026;20:641176. https://doi.org/10.2147/dddt.s641176 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/28ff0e8f-9f0f-416d-afda-2243b766a1e8/study-55.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ren Y, Li YT, Yin QL, et al. Opioid-free analgesia with esketamine-dexmedetomidine versus opioid-based analgesia after gynaecological laparoscopic surgery: a double-blind, randomized, controlled trial. Ann Med. 2026;58(1):2732292. https://doi.org/10.1080/07853890.2026.2732292 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d9ce1cd9-1610-4576-a1a0-a635cb500be4/study-56.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hosseininejad SM, Jahanian F, Erfanian Irankar S, et al. Comparing the analgesic efficacy of morphine plus ketamine versus morphine plus placebo in patients with acute renal colic: A double-blinded randomized controlled trial. Am J Emerg Med. 2019;37(6):1118-1123. https://doi.org/10.1016/j.ajem.2018.09.004 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d9e71f60-d271-4723-954c-1f83a4f4d13d/study-57.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Groth CM, Droege CA, Connor KA, et al. Multicenter Retrospective Review of Ketamine Use in the ICU. Crit Care Explor. 2022;4(2):e0633. https://doi.org/10.1097/cce.0000000000000633 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b69ef435-50a0-4427-9754-e4865948c103/study-58.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Guthrie AM, Baum RA, Carter C, et al. Use of Intranasal Ketamine in Pediatric Patients in the Emergency Department. Pediatr Emerg Care. 2021;37(12):e1001-e1007. https://doi.org/10.1097/pec.0000000000001863 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/64ed55e2-7e90-4903-aa86-e01c9d61b7b2/study-59.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Huang C, Guan Z, Wang S, et al. Dual benefit of esketamine-based opioid-free anesthesia on postoperative pain and mental health outcomes in patients undergoing bariatric surgery: a randomized controlled trial. Transl Psychiatry. 2026;16(1):570. https://doi.org/10.1038/s41398-026-04241-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/05cec586-8dd7-490e-8eda-d9bf3f7fc5c8/study-60.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Cheng CX, Wang K, Jiang YX, et al. Opioid-free anesthesia with quadratus lumborum block and Esketamine enhances postoperative recovery in laparoscopic colon cancer surgery: A randomized controlled trial. Sci Rep. 2025;15(1):38848. https://doi.org/10.1038/s41598-025-22688-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c7010832-2d0d-47fd-b4ef-d322fc88bf80/study-61.png Educational Resources - Acute Pain Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Olejnik L, Lima JP, Sadeghirad B, et al. Pharmacologic Management of Acute Pain in Children: A Systematic Review and Network Meta-Analysis. JAMA Pediatr. 2025;179(4):407-417. https://doi.org/10.1001/jamapediatrics.2024.5920 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/124bcfd9-6f58-4581-b0c0-3fa6b0798715/study-62.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Häske D, Eppler F, Heinemann N, Schempf B. Patient-reported side effects and satisfaction of pre-hospital analgesia with low-dose esketamine: a cross-sectional study. BMC Emerg Med. 2023;23(1):130. https://doi.org/10.1186/s12873-023-00898-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f9ec6c3e-9086-4db9-88d3-f560cd144e92/study-63.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Motov S, Drapkin J, Likourezos A, et al. Continuous Intravenous Sub-Dissociative Dose Ketamine Infusion for Managing Pain in the Emergency Department. West J Emerg Med. 2018;19(3):559-566. https://doi.org/10.5811/westjem.2017.12.36174 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e33a2bcf-a91f-4927-bed1-d6ad904664bc/study-64.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Du J, Li C, Huang M, Qin X. Comparison of the Effective Dose 90 (ED90) and Clinical Outcomes of Fentanyl Versus Esketamine for Analgesia in Hysteroscopy: A Two-Part, Randomized, Double-Blind Trial. Drug Des Devel Ther. 2026;20:574516. https://doi.org/10.2147/dddt.s574516 https://www.harmreductionadvocate.com/educational-resources/alcohol-use-disorder monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223844424-INU41K48X6CJ4YOACULW/illustration-alcohol-use-disorder.jpg Educational Resources - Alcohol Use Disorder https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fe0f9633-901c-46b2-a7bf-1b2c49933aed/study-1.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(10):953-962. https://doi.org/10.1001/jamapsychiatry.2022.2096 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/220ba00d-b5e4-4cd5-b350-c9fc69a102d7/study-2.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Florineth GA, Boeker AL, Bracht T, et al. Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: a systematic review and meta-analysis. J Psychopharmacol. Published online October 8, 2026. https://doi.org/10.1177/02698811261490221 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1515ad61-3d03-442c-80e9-054f8367c2c3/study-3.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Luquiens A, Belahda D, Graux C, et al. Psilocybin in alcohol use disorder and comorbid depressive symptoms: results from a feasibility randomized clinical trial. Addiction. Published online July 24, 2025. https://doi.org/10.1111/add.70152 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a7aeb29c-081e-4476-b518-e564e6c514db/study-4.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26(7):994-1002. https://doi.org/10.1177/0269881112439253 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/72c2bcf8-dc6a-4f76-bc15-dc8c352e6b49/study-5.png Educational Resources - Alcohol Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Sicignano D, Hernandez AV, Schiff B, et al. The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis. Curr Med Res Opin. 2024;40(2):293-302. https://doi.org/10.1080/03007995.2023.2296968 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7654852a-4007-4804-9f7a-bf7545e23f36/study-6.png Educational Resources - Alcohol Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Jensen ME, Stenbæk DS, Messell CD, et al. Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study. J Psychopharmacol. 2025;39(5):463-473. https://doi.org/10.1177/02698811251319457 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c831b2ff-8fca-454b-a70d-2b164614bfa7/study-7.png Educational Resources - Alcohol Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Rathore BS, Singh S, Gupta M, Verma P. Safety and efficacy of ketamine for the treatment of patients with alcohol use disorder: a systematic review. Am J Drug Alcohol Abuse. 2025;51(5):563-576. https://doi.org/10.1080/00952990.2025.2535559 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2df80560-5fff-4281-a990-2e0fb3a4c466/study-8.png Educational Resources - Alcohol Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs. 1997;29(2):165-183. https://doi.org/10.1080/02791072.1997.10400185 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a6a2d2a6-2bd9-41d6-bff4-a9f4033651e3/study-9.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Calleja-Conde J, Morales-García JA, Echeverry-Alzate V, et al. Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies. Addict Biol. 2022;27(6):e13229. https://doi.org/10.1111/adb.13229 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ed4a83e1-5d28-42aa-bfb3-bdc4997dcb2c/study-10.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Goldfine CE, Tom JJ, Im DD, et al. The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review. Front Psychiatry. 2023;14:1141836. https://doi.org/10.3389/fpsyt.2023.1141836 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1fbcdeb1-63da-46d8-8b79-3c3c0dbc75b4/study-11.png Educational Resources - Alcohol Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dakwar E, Levin F, Hart CL, et al. A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. Am J Psychiatry. 2020;177(2):125-133. https://doi.org/10.1176/appi.ajp.2019.19070684 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/87e786e6-848b-4570-8ff0-69b4142e79db/study-12.png Educational Resources - Alcohol Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Thurgur H, Sessa B, Higbed L, et al. MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up. Alcohol Alcohol. 2025;60(4):agaf031. https://doi.org/10.1093/alcalc/agaf031 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c0b082fe-0256-492c-9cf2-b4c505ea3d28/study-13.png Educational Resources - Alcohol Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zech JM, Richard J, Jones GM. The Relationship Between Psychedelic Use and Alcohol Use Disorder in a Nationally Representative Sample. J Psychoactive Drugs. 2025:1-11. https://doi.org/10.1080/02791072.2025.2583967 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/58586243-0789-4b33-b477-488b37a0924f/study-14.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Gent EM, Bryan JW, Cleary MA, et al. Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems. J Psychopharmacol. 2024;38(6):541-550. https://doi.org/10.1177/02698811241254834 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1a2de89e-f704-49ad-abf5-4e5da8ce7297/study-15.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kelson M, Burnett JM, Matthews A, Juneja T. Ketamine Treatment for Alcohol Use Disorder: A Systematic Review. Cureus. 2023;15(5):e38498. https://doi.org/10.7759/cureus.38498 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/135c060a-1964-4882-addd-d1859d8163f5/study-16.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Das RK, Gale G, Walsh K, et al. Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories. Nat Commun. 2019;10(1):5187. https://doi.org/10.1038/s41467-019-13162-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9196c873-f95a-4272-9828-9e4b6ffc5208/study-17.png Educational Resources - Alcohol Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kervadec E, Fauvel B, Strika-Bruneau L, et al. Reduction of alcohol use and increase in psychological flexibility after a naturalistic psychedelic experience: a retrospective survey. Alcohol Alcohol. 2024;59(2):agad078. https://doi.org/10.1093/alcalc/agad078 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e776c9a0-97e6-46de-a66e-a813853332ea/study-18.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Marsden J, Kelleher M, Dunbar F, et al. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial. Addiction. 2025. https://doi.org/10.1111/add.70260 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1b07e158-58ab-41a8-b17d-087019bcec75/study-19.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pagni BA, Petridis PD, Podrebarac SK, et al. Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study. Sci Rep. 2024;14(1):3159. https://doi.org/10.1038/s41598-024-52967-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e479c33e-e06c-4a8b-ade1-204b82e375ad/study-20.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fuentes JJ, Fonseca F, Elices M, et al. Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. Front Psychiatry. 2019;10:943. https://doi.org/10.3389/fpsyt.2019.00943 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5f630e85-26db-46c7-8a25-8d6bc323bd10/study-21.png Educational Resources - Alcohol Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Agin-Liebes G, Nielson EM, Zingman M, et al. Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis. Psychol Addict Behav. 2024;38(1):101-113. https://doi.org/10.1037/adb0000935 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7d3a1899-f370-43b7-bbb9-67a36c7af36a/study-22.png Educational Resources - Alcohol Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nicholas CR, Wang JB, Coker A, et al. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 2022;233:109356. https://doi.org/10.1016/j.drugalcdep.2022.109356 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ebb81db3-c12f-48fb-8ee5-32ccf9c16857/study-23.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mollaahmetoglu OM, Keeler J, Ashbullby KJ, et al. "This Is Something That Changed My Life": A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders. Front Psychiatry. 2021;12:695335. https://doi.org/10.3389/fpsyt.2021.695335 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2d29f8dd-4462-4530-ac76-a57e98f6658d/study-24.png Educational Resources - Alcohol Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Rothberg RL, Azhari N, Haug NA, Dakwar E. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. J Psychopharmacol. 2021;35(2):150-158. https://doi.org/10.1177/0269881120970879 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/160c5795-c703-4de0-b754-2fa518e1dc47/study-25.png Educational Resources - Alcohol Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Seynaeve M, Dunbar F, Ermakova AO, et al. Psychological change processes in alcohol use disorder: A qualitative study of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) with cognitive behavioural therapy. Addiction. 2026. https://doi.org/10.1111/add.70555 https://www.harmreductionadvocate.com/educational-resources/borderline-personality-disorder monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223818273-SUYUJSTCTFVUULQT5GXL/illustration-borderline-personality-disorder.jpg Educational Resources - Borderline Personality Disorder https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d79e0bfb-9a62-4df9-ab6e-4383913f0afd/study-1.png Educational Resources - Borderline Personality Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fineberg SK, Choi EY, Shapiro-Thompson R, et al. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology. 2023;48(7):991-999. https://doi.org/10.1038/s41386-023-01540-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ef7dfe9c-c088-4387-b989-04701c0a94d1/study-2.png Educational Resources - Borderline Personality Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Grant JE, Boutouis S, O'Brien M, et al. An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder. Clin Neuropharmacol. 2026;49(4):163-169. https://doi.org/10.1097/wnf.0000000000000683 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/52f1d89e-12a9-40f2-8ae7-19fbc6097736/study-3.png Educational Resources - Borderline Personality Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Danayan K, Chisamore N, Rodrigues NB, et al. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Res. 2023;323:115133. https://doi.org/10.1016/j.psychres.2023.115133 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/906d9b72-06d4-4c32-a8d3-a32713c64fd7/study-4.png Educational Resources - Borderline Personality Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Raffone F, Mazzoni F, De Ciechi A, et al. Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A real-world longitudinal study of suicidal ideation and self-harm. Asian J Psychiatr. 2026;120:104983. https://doi.org/10.1016/j.ajp.2026.104983 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1f7c358d-33dd-4b77-97d1-52513aa2343f/study-5.png Educational Resources - Borderline Personality Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Domínguez-Clavé E, Soler J, Pascual JC, et al. Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits. Psychopharmacology (Berl). 2019;236(2):573-580. https://doi.org/10.1007/s00213-018-5085-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/871492a4-aa66-4641-abb9-b94296f26b1f/study-6.png Educational Resources - Borderline Personality Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Chen KS, Dwivedi Y, Shelton RC. The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder. J Affect Disord. 2022;315:13-16. https://doi.org/10.1016/j.jad.2022.07.054 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1833c29d-7cf1-4ed5-b271-fb711201813c/study-7.png Educational Resources - Borderline Personality Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Mazzoni F, Raffone F, De Ciechi A, et al. Intranasal esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A multicenter real-world longitudinal study. Psychiatry Res. 2026;364:117288. https://doi.org/10.1016/j.psychres.2026.117288 https://www.harmreductionadvocate.com/educational-resources/anxiety-disorders monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223795217-M8AXC916BQWYD8X1R9X6/illustration-anxiety-disorders.jpg Educational Resources - Anxiety Disorders https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1204c6c2-d11a-44c3-94be-8b938e83c396/study-1.png Educational Resources - Anxiety Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Robison R, Barrow R, Conant C, et al. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA. 2025;334(15):1358-1372. https://doi.org/10.1001/jama.2025.13481 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b67aa0de-27f6-4277-a2c4-c1395e2a198e/study-2.png Educational Resources - Anxiety Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Holze F, Gasser P, Müller F, et al. Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biol Psychiatry. 2023;93(3):215-223. https://doi.org/10.1016/j.biopsych.2022.08.025 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d905c573-2ff4-4a9a-b713-9d796c79d353/study-3.png Educational Resources - Anxiety Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Danforth AL, Grob CS, Struble C, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl). 2018;235(11):3137-3148. https://doi.org/10.1007/s00213-018-5010-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2b7803db-7b00-48f3-8bdf-da011c63dab3/study-4.png Educational Resources - Anxiety Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Dos Santos RG, Osório FL, Rocha JM, et al. Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder: A Pilot, Proof-of-Concept, Randomized, Placebo-Controlled Trial. J Clin Psychopharmacol. 2021;41(5):540-550. https://doi.org/10.1097/jcp.0000000000001428 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a83664ca-30bb-49d0-85e4-693971efce4e/study-5.png Educational Resources - Anxiety Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Leger RF, Unterwald EM. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. J Psychopharmacol. 2022;36(1):20-30. https://doi.org/10.1177/02698811211044688 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/719a1c9e-538f-4e8c-8eba-93f5c3f7836b/study-6.png Educational Resources - Anxiety Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Glue P, Medlicott NJ, Harland S, et al. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol. 2017;31(10):1302-1305. https://doi.org/10.1177/0269881117705089 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9b524b28-a43b-44b6-93bb-484da193a30c/study-7.png Educational Resources - Anxiety Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: McNaughton N, Beaglehole B, Glue P. Ketamine Dose and Duration Effects in Internalizing Disorders. J Clin Pharmacol. 2026;66(9):e70299. https://doi.org/10.1002/jcph.70299 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5a177ce7-992f-460a-b47d-a5a3f09934cc/study-8.png Educational Resources - Anxiety Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Goldberg SB, Pace BT, Nicholas CR, et al. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Res. 2020;284:112749. https://doi.org/10.1016/j.psychres.2020.112749 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4ba61069-74a8-4595-bf55-79534f7cf85a/study-9.png Educational Resources - Anxiety Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Santos RG, Landeira-Fernandez J, Strassman RJ, et al. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol. 2007;112(3):507-513. https://doi.org/10.1016/j.jep.2007.04.012 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1d4a5d62-8588-4a94-8944-6f934e715183/study-10.png Educational Resources - Anxiety Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Masdrakis VG, Tebbs Z, Natsis V, Baldwin DS. Ketamine/esketamine pharmacotherapy for treatment of anxiety disorders and anxiety symptoms in depression: Systematic review. J Psychopharmacol. 2026;40(6):877-899. https://doi.org/10.1177/02698811251389583 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c6d42242-3ad5-4bd8-9747-20567db7d3f2/study-11.png Educational Resources - Anxiety Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hull TD, Malgaroli M, Gazzaley A, et al. At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. J Affect Disord. 2022;314:59-67. https://doi.org/10.1016/j.jad.2022.07.004 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/995c82f6-777e-4b88-98bf-e625bb003711/study-12.png Educational Resources - Anxiety Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hartland H, Mahdavi K, Jelen LA, et al. A transdiagnostic systematic review and meta-analysis of ketamine's anxiolytic effects. J Psychopharmacol. 2023;37(8):764-774. https://doi.org/10.1177/02698811231161627 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/40ad29fd-5ff4-4d35-a445-42e066a0e0f4/study-13.png Educational Resources - Anxiety Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Taylor JH, Landeros-Weisenberger A, Coughlin C, et al. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology. 2018;43(2):325-333. https://doi.org/10.1038/npp.2017.194 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c0a977c8-c450-4e40-9ea8-92c04181b0f5/study-14.png Educational Resources - Anxiety Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Holze F, Gasser P, Müller F, et al. LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up. Br J Psychiatry. 2024;225(3):362-370. https://doi.org/10.1192/bjp.2024.99 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/208c7e93-e2e6-4083-a3ec-68288ca0edb8/study-15.png Educational Resources - Anxiety Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Glue P, Neehoff S, Sabadel A, et al. Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. J Psychopharmacol. 2020;34(3):267-272. https://doi.org/10.1177/0269881119874457 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/22f8a541-5774-4b69-8f33-ee97b65a01c6/study-16.png Educational Resources - Anxiety Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Glue P, Neehoff SM, Medlicott NJ, et al. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. J Psychopharmacol. 2018;32(6):663-667. https://doi.org/10.1177/0269881118762073 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ce3503ee-3d8d-48b2-a97f-9e3d742b1e11/study-17.png Educational Resources - Anxiety Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kiraga MK, Kuypers KPC, Uthaug MV, et al. Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees. Front Psychiatry. 2022;13:883869. https://doi.org/10.3389/fpsyt.2022.883869 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/837c70cc-1843-4a73-87f6-cd4f3eae98cf/study-18.png Educational Resources - Anxiety Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Davis AK, Barrett FS, Griffiths RR. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Contextual Behav Sci. 2020;15:39-45. https://doi.org/10.1016/j.jcbs.2019.11.004 https://www.harmreductionadvocate.com/educational-resources/bipolar-disorder monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223787487-5A0ZXWIKIU1NRDZDLMAD/illustration-bipolar-disorder.jpg Educational Resources - Bipolar Disorder https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b7649282-386c-4c3e-a518-317a5d585a86/study-1.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Eskinazi M, Nasserdine R, Cusin RM, et al. Psychedelic-induced hypomania and mania: a systematic review and meta-analysis. Mol Psychiatry. 2026;31(10):5749-5763. https://doi.org/10.1038/s41380-026-03657-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e3bba15a-d61b-47b4-bed7-88687e8cb494/study-2.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Downey AE, Szigeti B, Bradley ER, et al. An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression. J Clin Psychiatry. 2026;87(4):25m16227. https://doi.org/10.4088/jcp.25m16227 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/55bc0396-1cb9-41d3-98c4-00739f06c801/study-3.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Aaronson ST, van der Vaart A, Miller T, et al. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial. JAMA Psychiatry. 2024;81(6):555-562. https://doi.org/10.1001/jamapsychiatry.2023.4685 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4de44b92-17a4-4aa3-84ba-30a1dddddead/study-4.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. J Psychopharmacol. 2023;37(1):49-60. https://doi.org/10.1177/02698811221131997 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4493244f-038f-48ba-8df2-f3e28b2e4d19/study-5.png Educational Resources - Bipolar Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Orsini DK, Di Luch S, Tomlinson G, et al. Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2026. https://doi.org/10.1001/jamapsychiatry.2026.2658 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2e406921-1070-4528-ad87-855dda07054c/study-6.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Xu AJ, Niciu MJ, Lundin NB, et al. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. Neural Plast. 2015;2015:858251. https://doi.org/10.1155/2015/858251 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8805d0b3-ffb6-40e6-8781-3078f86b38e8/study-7.png Educational Resources - Bipolar Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939-946. https://doi.org/10.1016/j.biopsych.2011.12.010 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e051bc0d-fb1a-4028-a9d5-85f5c91ee2e7/study-8.png Educational Resources - Bipolar Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Liu TH, Wu JY, Huang PY, et al. Risk of manic switch and suicidal outcomes in bipolar depression treated with esketamine: A one-year retrospective cohort study of 2126 patients. Eur Neuropsychopharmacol. 2025;99:3-12. https://doi.org/10.1016/j.euroneuro.2025.07.006 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4d617319-5fc7-4b23-9ee3-d0b14f425088/study-9.png Educational Resources - Bipolar Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793-802. https://doi.org/10.1001/archgenpsychiatry.2010.90 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3becce01-ef90-4cf2-bdc7-cd5fe25abd06/study-10.png Educational Resources - Bipolar Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bandeira ID, Leal GC, Correia-Melo FS, et al. Arketamine for bipolar depression: Open-label, dose-escalation, pilot study. J Psychiatr Res. 2023;164:229-234. https://doi.org/10.1016/j.jpsychires.2023.06.028 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e5f373bc-115a-4c2e-96a0-667a2af63c20/study-11.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bahji A, Zarate CA, Vazquez GH. Ketamine for Bipolar Depression: A Systematic Review. Int J Neuropsychopharmacol. 2021;24(7):535-541. https://doi.org/10.1093/ijnp/pyab023 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/29e8a6a4-89e3-4745-8685-826b0f750718/study-12.png Educational Resources - Bipolar Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Meshkat S, Kaczmarek E, Doyle Z, et al. Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder. Psychedelic Med (New Rochelle). 2025;3(1):53-58. https://doi.org/10.1089/psymed.2024.0032 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/28693a01-6042-4d0b-b1ab-63fd6ebe30e5/study-13.png Educational Resources - Bipolar Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zheng W, Zhou YL, Liu WJ, et al. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. J Affect Disord. 2020;275:38-43. https://doi.org/10.1016/j.jad.2020.06.020 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6c248d7d-5313-453b-a222-aa8b73f29f0f/study-14.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pastuszak M, Cubała WJ, Kwaśny A. Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration. Drugs Real World Outcomes. 2024;11(4):565-571. https://doi.org/10.1007/s40801-024-00453-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a48df03d-f6b8-4b44-9c8f-c8b73039cc89/study-15.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lally N, Nugent AC, Luckenbaugh DA, et al. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4:e469. https://doi.org/10.1038/tp.2014.105 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/08462d86-c45c-4d4f-823f-e007c93b5309/study-16.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zheng W, Zhou YL, Wang CY, et al. Neurocognitive effects of six ketamine infusions and the association with antidepressant effects in treatment-resistant bipolar depression: a preliminary study. PeerJ. 2020;8:e10208. https://doi.org/10.7717/peerj.10208 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7d639fbf-2fca-4927-8601-311ea55cd4ac/study-17.png Educational Resources - Bipolar Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Martinotti G, Dell'Osso B, Di Lorenzo G, et al. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression. Bipolar Disord. 2023;25(3):233-244. https://doi.org/10.1111/bdi.13296 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ae8a57a2-4cfb-42aa-85d1-69c4872d0b05/study-18.png Educational Resources - Bipolar Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nugent AC, Diazgranados N, Carlson PJ, et al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. 2014;16(2):119-128. https://doi.org/10.1111/bdi.12118 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/78e2c4bc-8a0e-4ecc-b913-835d36e7a99c/study-19.png Educational Resources - Bipolar Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ortiz R, Niciu MJ, Lukkahati N, et al. Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. J Affect Disord. 2015;172:307-311. https://doi.org/10.1016/j.jad.2014.09.015 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6ef9185e-1931-4542-b4e2-e787179f5786/study-20.png Educational Resources - Bipolar Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: DellaCrosse M, Pleet M, Morton E, et al. "A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use. PLoS One. 2022;17(12):e0279073. https://doi.org/10.1371/journal.pone.0279073 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/48beea60-c0e7-4411-a190-73aaeb8f235e/study-21.png Educational Resources - Bipolar Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Greene BD, Fijtman A, Yalin N, et al. Thyroid-stimulating hormone is associated with differential antidepressant and anti-anhedonic response to ketamine in bipolar depression but not major depressive disorder. J Affect Disord. 2026;395(Pt B):120780. https://doi.org/10.1016/j.jad.2025.120780 https://www.harmreductionadvocate.com/educational-resources/treatment-resistant-depression monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793223729663-DQ9JSXG34IW4JFVBAZ65/illustration-treatment-resistant-depression.jpg Educational Resources - Treatment-Resistant Depression https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1900eead-bd40-47d3-98ed-5585627747e7/study-1.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648. https://doi.org/10.1056/nejmoa2206443 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/58e5be5f-e04a-442a-bb19-a08637fc8233/study-2.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rosenblat JD, Meshkat S, Doyle Z, et al. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med. 2024;5(3):190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/87f78cc1-1dd9-4b2c-968b-4630534edcb6/study-3.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rucker JJ, Mantingh T, Kerr-Gaffney J, et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nat Med. 2026;32(9):3430-3437. https://doi.org/10.1038/s41591-026-04541-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/eecba2d2-602c-4caf-a8d0-694c812f1fe2/study-4.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655-663. https://doi.org/10.1017/s0033291718001356 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f775e058-9219-4466-810c-c6d968607eae/study-5.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mertens LJ, Betzler F, Brand M, et al. Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial. Psychother Psychosom. 2026:1-18. https://doi.org/10.1159/000552272 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/02884606-cdd4-480e-8327-184ea3fa873e/study-6.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Daly EJ, Trivedi MH, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(9):893-903. https://doi.org/10.1001/jamapsychiatry.2019.1189 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4550f084-896c-47cf-a8a4-c031fe20f662/study-7.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: McIntyre RS, Mattingly G, Godinov Y, et al. Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial. CNS Spectr. 2025;30(1):e26. https://doi.org/10.1017/s1092852924002451 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9824a38b-a1c1-45fe-b194-ba03b4386176/study-8.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023;388(25):2315-2325. https://doi.org/10.1056/nejmoa2302399 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8674f731-385a-4e1e-a83f-a23ff1d87bc9/study-9.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627. https://doi.org/10.1016/s2215-0366(16)30065-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/66bf19eb-9714-44c3-b82d-faed5641f897/study-10.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zhou Y, Zheng W, Liu W, et al. Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. Brain Behav Immun. 2018;74:205-212. https://doi.org/10.1016/j.bbi.2018.09.007 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/03fd1829-a269-4b1b-b9d2-c29da76983b5/study-11.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Varela YM, Cavalcanti-Ribeiro P, de Sousa GM, et al. Exploratory non-randomized clinical trial of subcutaneous esketamine in treatment-resistant depression: Effects of ketamine-assisted psychotherapy. J Affect Disord. 2026;414:122369. https://doi.org/10.1016/j.jad.2026.122369 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4034ac5d-e43b-4d1d-85f9-be8e9944ab45/study-12.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ali MAS, Amirthalingam P, Alshareef H, et al. Real-World Effectiveness and Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: A Retrospective Observational Study. Healthcare (Basel). 2026;14(17):2717. https://doi.org/10.3390/healthcare14172717 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e08cb13f-1d49-443c-8d4e-babde342097b/study-13.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Young AH, Bartova L, Cardoner N, et al. Trajectory of response to esketamine nasal spray for treatment resistant depression: Findings from ESCAPE-TRD. Eur Psychiatry. 2026;69(1):e74. https://doi.org/10.1192/j.eurpsy.2026.12229 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/937e2df7-afc4-43fb-a52c-a856a35b6af7/study-14.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019;176(6):428-438. https://doi.org/10.1176/appi.ajp.2019.19020172 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0bf50acb-3d8b-4493-89f4-b432d08b1349/study-15.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Oliveira-Maia AJ, Rive B, Godinov Y, Mulhern-Haughey S. Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study. Front Psychiatry. 2024;15:1459633. https://doi.org/10.3389/fpsyt.2024.1459633 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1086aae6-ec17-4a2e-ba5f-5bcf957c81f4/study-16.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Reif A, Bitter I, Buyze J, et al. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. N Engl J Med. 2023;389(14):1298-1309. https://doi.org/10.1056/nejmoa2304145 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/578b8180-da19-4e7b-854d-26ceae52b0bd/study-17.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Phillips JL, Norris S, Talbot J, et al. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. Am J Psychiatry. 2019;176(5):401-409. https://doi.org/10.1176/appi.ajp.2018.18070834 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6032eca9-7590-484e-9eda-5c82dc8355ee/study-18.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Xie J, Pu C, Sun M. Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis. Front Psychiatry. 2026;17:1774549. https://doi.org/10.3389/fpsyt.2026.1774549 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3b4a6507-5da2-4575-afd0-fdb0b4bec893/study-19.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: de Granda-Beltrán AM, Porras-Segovia A, Núñez-Arias D, et al. Intranasal Esketamine Versus Other Pharmacological Strategies in Treatment-Resistant Depression with High Suicide Risk: A Six-Month Naturalistic Study. Clin Pract. 2026;16(6):110. https://doi.org/10.3390/clinpract16060110 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2e9027ab-04f7-40a3-a57f-cc803edcce6b/study-20.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Reif A, Baune BT, Buyze J, et al. Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release. Eur Psychiatry. 2025;68(1):e156. https://doi.org/10.1192/j.eurpsy.2025.10123 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/71bdc333-9ccd-459c-ba63-0ca64dde6cf4/study-21.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-1142. https://doi.org/10.1176/appi.ajp.2013.13030392 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6d575928-14ce-4d19-bd9f-2c54e05c05ac/study-22.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Goodwin GM, Nowakowska A, Atli M, et al. Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder. J Clin Psychiatry. 2025;86(1):24m15449. https://doi.org/10.4088/jcp.24m15449 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6cbffc0d-6b7e-43b0-b8b8-96830bf5183b/study-23.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Glue P, Loo C, Fam J, et al. Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nat Med. 2024;30(7):2004-2009. https://doi.org/10.1038/s41591-024-03063-x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1ba93880-ceec-4dd9-9e0b-c63f6c2cbc4c/study-24.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dwyer JB, Landeros-Weisenberger A, Johnson JA, et al. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. Am J Psychiatry. 2021;178(4):352-362. https://doi.org/10.1176/appi.ajp.2020.20010018 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5467c76f-6da7-4112-8db7-9dad382eda26/study-25.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Chen MH, Li CT, Lin WC, et al. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion. J Affect Disord. 2018;241:1-7. https://doi.org/10.1016/j.jad.2018.07.033 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c9a38b36-98b8-4b76-8ea0-62225feb6d5d/study-26.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Falchi-Carvalho M, Palhano-Fontes F, Wießner I, et al. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology. 2025;50(6):895-903. https://doi.org/10.1038/s41386-025-02091-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1260745f-6527-4a36-8ff9-e0366a4ba938/study-27.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sarlon J, Thomi D, Brühl AB, et al. Real-world comparison of intranasal racemic ketamine and esketamine in treatment-resistant depression: A retrospective observational study. J Affect Disord. 2026;400:121208. https://doi.org/10.1016/j.jad.2026.121208 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/86ecb256-4861-4415-a551-b4ce10ad0fe8/study-28.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Price RB, Spotts C, Panny B, et al. A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. Am J Psychiatry. 2022;179(12):959-968. https://doi.org/10.1176/appi.ajp.20220216 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/eb88692b-40d1-4dee-8793-ca7e029400f8/study-29.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry. 2016;173(8):816-826. https://doi.org/10.1176/appi.ajp.2016.16010037 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/452b8ab6-adfe-49fd-b97b-60f340e0abb3/study-30.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kern Sliwa J, Naranjo RR, Turkoz I, et al. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire. CNS Spectr. 2024;29(3):176-186. https://doi.org/10.1017/s1092852924000105 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/aaf1b131-bd77-46e2-b039-8a426189ed70/study-31.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zaki N, Chen LN, Lane R, et al. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology. 2023;48(8):1225-1233. https://doi.org/10.1038/s41386-023-01577-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/af5a66d5-441b-411d-ae13-970d91838d0e/study-32.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kryst J, Kawalec P, Mitoraj AM, et al. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep. 2020;72(3):543-562. https://doi.org/10.1007/s43440-020-00097-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6a317a43-b8bc-4360-93c9-2c8d7c9adfd2/study-33.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Nguyen L, Marshalek PJ, Weaver CB, et al. Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review. Neuropsychiatr Dis Treat. 2015;11:2667-2673. https://doi.org/10.2147/ndt.s88569 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2b88b531-5551-491a-8425-2d772f57df70/study-34.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Llorca PM, Sauvaget A, Olié E, et al. Real-world clinical practice, effectiveness and safety of esketamine nasal spray in major depressive disorder patients: a French prospective cohort (ELLIPSE study). Ther Adv Psychopharmacol. 2026;16:20451253261463652. https://doi.org/10.1177/20451253261463652 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2b692bd6-34ab-4070-ad2f-4a766e485745/study-35.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Tabaac BJ, Shinozuka K, Weisman A, et al. Psychedelic Therapy: A Primer for Primary Care Clinicians-5-Methoxy-N,N-Dimethyltryptamine. Am J Ther. 2026;33(2):e153-e160. https://doi.org/10.1097/mjt.0000000000002106 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/05c53210-8e1c-4f81-b758-66c00548163e/study-36.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Alnefeesi Y, Chen-Li D, Krane E, et al. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. J Psychiatr Res. 2022;151:693-709. https://doi.org/10.1016/j.jpsychires.2022.04.037 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/352ff9d6-93d0-49fb-a8e2-3e2ab73587b4/study-37.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Thase ME, Brennan B, MacIsaac R, et al. GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial. Psychopharmacol Bull. 2026;56(3):8-21. https://doi.org/10.64719/pb.18507 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/066bbe9e-3f23-43cf-9a4c-198afafe405e/study-38.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Su TP, Li CT, Lin WC, et al. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. Int J Neuropsychopharmacol. 2023;26(5):331-339. https://doi.org/10.1093/ijnp/pyad014 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/982b8fa4-718a-4c49-a837-0e738931f721/study-39.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Loo C, Glozier N, Barton D, et al. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. Br J Psychiatry. 2023;223(6):533-541. https://doi.org/10.1192/bjp.2023.79 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8df01b33-4cf0-418c-88e5-554bea421f1d/study-40.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Marcantoni WS, Akoumba BS, Wassef M, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019. J Affect Disord. 2020;277:831-841. https://doi.org/10.1016/j.jad.2020.09.007 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/11642487-b8d4-4da2-ab1b-ff997292e6c8/study-41.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zhou Y, Zheng W, Liu W, et al. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. J Psychopharmacol. 2018;32(10):1118-1126. https://doi.org/10.1177/0269881118798614 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0a06d801-2ae8-4a07-8036-180fc54d2103/study-42.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kevin J L, Natalie E S, Ingrid C, et al. Association of intravenous ketamine with change in depressive symptoms in a large integrated health care system. Psychiatry Res. 2025;343:116273. https://doi.org/10.1016/j.psychres.2024.116273 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5bccdd29-f64b-4fca-8953-82b0332b6d66/study-43.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Chavigny LA, Desbeaumes Jodoin V, Garel N, et al. Cognitive effects of intravenous Ketamine in treatment-resistant depression: A systematic review. Psychol Med. 2026;56:e133. https://doi.org/10.1017/s0033291726103961 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d065aead-ff1b-4a85-b350-11ae037ee913/study-44.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Szawarnoga D, Fojcik J, Górski M, Krzystanek M. Quality of Life in Patients with Treatment-Resistant Depression Treated with Intranasal Esketamine as Add-On Therapy to an SSRI—A Prospective, Comparative Study in Real-World Clinical Practice. Pharmaceuticals (Basel). 2026;19(10). https://doi.org/10.3390/ph19101644 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a92458ef-0b91-473b-9b09-fc953e172d9c/study-45.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: An D, Wei C, Wang J, Wu A. Intranasal Ketamine for Depression in Adults: A Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials. Front Psychol. 2021;12:648691. https://doi.org/10.3389/fpsyg.2021.648691 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d77526ee-70ea-496d-8c96-421c05ede58a/study-46.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Reif A, Anıl YA, Bitter I, et al. Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study. Eur Neuropsychopharmacol. 2026;107:112801. https://doi.org/10.1016/j.euroneuro.2026.112801 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fe1dfc80-6d80-4ac4-90c3-8260862ee863/study-47.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hossein S, Rengasamy M, Uzamere A, et al. Effects of ketamine on individual symptoms and symptom networks of depression in a randomised controlled trial of ketamine for treatment-resistant depression. Br J Psychiatry. 2025;227(5):756-765. https://doi.org/10.1192/bjp.2024.276 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a6006ed1-1a61-412d-b364-2c54723095dc/study-48.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Su TP, Chen MH, Li CT, et al. Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression. Neuropsychopharmacology. 2017;42(13):2482-2492. https://doi.org/10.1038/npp.2017.94 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/225edd74-809c-4ca1-a106-c09be4d0cd96/study-49.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hudgens S, Floden L, Blackowicz M, et al. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant. J Affect Disord. 2021;281:767-775. https://doi.org/10.1016/j.jad.2020.11.066 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d9a7bcee-4887-4ea5-b175-4db32f98ada4/study-50.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Shiroma PR, Albott CS, Johns B, et al. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17(11):1805-1813. https://doi.org/10.1017/s1461145714001011 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6d4a3198-8da9-405c-bf5c-71ad153edbfe/study-51.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Patarroyo-Rodriguez L, Pazdernik VK, Vande Voort JL, et al. Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression: A 6-Month Mirror-Image Study. J Clin Psychiatry. 2025;86(4):25m15941. https://doi.org/10.4088/jcp.25m15941 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f1d52825-d98b-408a-8812-56f07d228455/study-52.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hopwood M, Codyre D, Barton D, et al. Quality of life and productivity among esketamine responders in a real-world study in Australia and New Zealand. J Psychiatr Res. 2026;201:635-640. https://doi.org/10.1016/j.jpsychires.2026.07.011 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/abfe8885-c37d-4ed6-963b-956e42ce6ba4/study-53.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zaki N, Chen LN, Lane R, et al. Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. Int J Neuropsychopharmacol. 2025;28(6):pyaf027. https://doi.org/10.1093/ijnp/pyaf027 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/97ed2fa6-d144-4efc-a7ce-9c809e396c67/study-54.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Glue P, Neehoff S, Beaglehole B, et al. Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. J Psychopharmacol. 2024;38(2):162-167. https://doi.org/10.1177/02698811241227026 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fe1e3d6f-d332-4c9e-8b9f-cb0007239350/study-55.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord. 2023;327:120-127. https://doi.org/10.1016/j.jad.2023.01.108 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/63e25d28-b570-4f42-a055-b4c91a4620e0/study-56.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nagele P, Duma A, Kopec M, et al. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial. Biol Psychiatry. 2015;78(1):10-18. https://doi.org/10.1016/j.biopsych.2014.11.016 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9194e387-754e-479d-a955-8a864bd00f51/study-57.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Loureiro JRA, Leaver A, Vasavada M, et al. Modulation of amygdala reactivity following rapidly acting interventions for major depression. Hum Brain Mapp. 2020;41(7):1699-1710. https://doi.org/10.1002/hbm.24895 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/37ec0e6b-ccdf-4f6f-a25f-8947460930da/study-58.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ji IS, Cheng MCH, Teopiz KM, et al. The effects of ketamine and esketamine on functional outcomes in major depressive disorder and treatment-resistant depression: A systematic review. J Psychiatr Res. 2026;192:280-288. https://doi.org/10.1016/j.jpsychires.2025.10.056 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/01ee2614-8430-43a3-8c77-0def8d4ed3fe/study-59.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Guglielmo R, Facchinetti EL, Cioci D, et al. Cognitive Effects of Esketamine in Treatment-Resistant Depression: A Systematic Review. J Clin Psychopharmacol. 2026;46(5):612-624. https://doi.org/10.1097/jcp.0000000000002165 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f4bf826a-e080-41b2-9d09-25212747beb4/study-60.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lin WC, Cheng LK, Su TP, et al. Shorter to be effective: subanesthetic-dose ketamine infusion reduces the global and regional path length of brain functional connectivity in patients with treatment-resistant depression and suicidal ideation. Psychopharmacology (Berl). 2026. https://doi.org/10.1007/s00213-026-07089-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/679ac272-6b34-4179-bfa6-fd60a8d688e9/study-61.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Katz EG, Hough D, Doherty T, et al. Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression. Clin Pharmacol Ther. 2021;109(2):536-546. https://doi.org/10.1002/cpt.2024 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d75f7b78-4ac1-4b38-bae9-d124443527e2/study-62.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Greenway KT, Garel N, Dinh-Williams LL, et al. The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression. Br J Psychiatry. 2026;228(5):437-445. https://doi.org/10.1192/bjp.2025.102 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/cf93cd53-50cc-4e04-ad28-d56f644d766b/study-63.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Wong S, Kwan ATH, Teopiz KM, et al. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. J Affect Disord. 2024;350:698-705. https://doi.org/10.1016/j.jad.2024.01.142 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4ce94b33-04d0-4e2b-bd11-6da95ce32234/study-64.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Turkoz I, Alphs L, Singh J, et al. Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression. Acta Psychiatr Scand. 2021;143(3):253-263. https://doi.org/10.1111/acps.13260 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/536399bf-44e1-49a9-90a0-6ecc52ce529e/study-65.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Yermus R, Bottos J, Bryson N, et al. Ketamine-Assisted Psychotherapy Provides Lasting and Effective Results in the Treatment of Depression, Anxiety, and Post-Traumatic Stress Disorder at 3 and 6 Months: Findings from a Large Retrospective Effectiveness Study. Psychedelic Med (New Rochelle). 2024;2(2):87-95. https://doi.org/10.1089/psymed.2023.0021 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/16cf901c-80ff-487f-bd7c-f55b65c94c07/study-66.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: de Oliveira Lapa C, Viola T, Delfino R, et al. Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies. J Affect Disord. 2026;401:121257. https://doi.org/10.1016/j.jad.2026.121257 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6aeaefb9-793e-41f5-b44f-013ee8654984/study-67.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Liou YJ, Cheng LK, Lin WC, et al. Low-dose ketamine modulates brain entropy in treatment-resistant depression: Results from two neuroimaging clinical trials. J Affect Disord. 2026:122673. https://doi.org/10.1016/j.jad.2026.122673 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9e57557c-5c32-41f6-b3ef-0bbe9ab99cc0/study-68.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Turkoz I, Nelson JC, Wilkinson ST, et al. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray. Psychiatry Res. 2023;323:115165. https://doi.org/10.1016/j.psychres.2023.115165 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ed55c59e-5c55-4d8e-a6bf-a29acc828084/study-69.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Preiss M, Popper V, Faber LHC, et al. Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: Data from the enTRD registry. Eur Psychiatry. 2026;69(1):e85. https://doi.org/10.1192/j.eurpsy.2026.12234 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/418ca7b0-b2dc-40ef-a058-fbde302788d7/study-70.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kaster TS, Dai Y, Vila-Rodriguez F, et al. Efficacy of intranasal esketamine versus rTMS for treatment-resistant depression: analysis of individual participant data from two clinical trials. EClinicalMedicine. 2025;90:103609. https://doi.org/10.1016/j.eclinm.2025.103609 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/67ca2232-7c22-4928-b37f-7e046d06f57b/study-71.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jha MK, Wilkinson ST, Krishnan K, et al. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024;7(6):e2417786. https://doi.org/10.1001/jamanetworkopen.2024.17786 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ae9f3edf-af52-4872-b7e3-8eff0c0d1c1e/study-72.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Papadimitropoulou K, Vossen C, Karabis A, et al. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin. 2017;33(4):701-711. https://doi.org/10.1080/03007995.2016.1277201 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b9f7a0a2-3c7c-4d8c-8ca9-b2e5fd750a03/study-73.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Li KJ, Slama NE, Chen IL, et al. Outcomes of patients receiving interventional psychiatric procedures in a large integrated healthcare system. Psychiatry Res. 2025;351:116647. https://doi.org/10.1016/j.psychres.2025.116647 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ff4dd711-1c7b-46bb-a264-7d5ccb056431/study-74.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kumpf KT, Wilkinson ST, Hu B, et al. Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial. J Clin Psychiatry. 2025;86(4):25m15781. https://doi.org/10.4088/jcp.25m15781 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3728c633-fdea-4de2-a7e4-23c71b6a910f/study-75.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Scott F, Hampsey E, Gnanapragasam S, et al. Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. J Psychopharmacol. 2023;37(3):268-278. https://doi.org/10.1177/02698811221104058 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f9f98bec-b757-4b78-8f75-66bb031af988/study-76.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Singh B, Kung S, Pazdernik V, et al. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. J Clin Psychiatry. 2023;84(2):22m14548. https://doi.org/10.4088/jcp.22m14548 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/dadbcd9b-7ece-4578-ac03-6ce5fe4d6db2/study-77.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Liu KI, Lin WC, Li CT, et al. Symptom-level and network analyses of ketamine treatment in treatment-resistant depression: A pooled analysis of two randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2026;150:111950. https://doi.org/10.1016/j.pnpbp.2026.111950 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/64d3883e-3625-498f-a788-aa3b9424875d/study-78.png Educational Resources - Treatment-Resistant Depression Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: d'Andrea G, Cavallotto C, Susini O, et al. Dimensional effect profiles in treatment-resistant depression: A naturalistic, prospective head-to-head comparison of arTMS, esketamine nasal spray, and oral brexpiprazole. J Affect Disord. 2026;414:122333. https://doi.org/10.1016/j.jad.2026.122333 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/babc7ecf-cd18-467a-8e5a-b0eceb2f535d/study-79.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Vázquez GH, Bahji A, Undurraga J, et al. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. J Psychopharmacol. 2021;35(8):890-900. https://doi.org/10.1177/02698811211013579 https://www.harmreductionadvocate.com/educational-resources/major-depressive-disorder monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/87112676-3999-4942-9a76-d9483c92cc3f/illustration-2.png Educational Resources - Major Depressive Disorder https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e925995d-3664-46df-a0c3-7f2907970d6d/study-1.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023;330(9):843-853. https://doi.org/10.1001/jama.2023.14530 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/66617008-eb07-44cf-abbb-9fdbeda382d6/study-2.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021;384(15):1402-1411. https://doi.org/10.1056/nejmoa2032994 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/68a02d77-fd5f-4811-a5ad-3b20ece271ec/study-3.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Yngwe H, Plavén-Sigray P, Ekman CJ, et al. Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(5):e2612589. https://doi.org/10.1001/jamanetworkopen.2026.12589 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d828dd85-483d-4e44-aeb4-fe1a84fb585c/study-4.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Erritzoe D, Barba T, Benway T, et al. A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial. Nat Med. 2026;32(2):591-598. https://doi.org/10.1038/s41591-025-04154-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/cb641c78-627c-4089-ad91-14d3a4c7605b/study-5.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: von Rotz R, Schindowski EM, Jungwirth J, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2023;56:101809. https://doi.org/10.1016/j.eclinm.2022.101809 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b9727e6f-7bd0-4779-8133-d305f6a159b1/study-6.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. 2022;36(2):151-158. https://doi.org/10.1177/02698811211073759 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/300d30b8-9fea-41d4-b3d3-5b9442458542/study-7.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hu YD, Xiang YT, Fang JX, et al. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med. 2016;46(3):623-635. https://doi.org/10.1017/s0033291715002159 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0e862983-57e9-4798-9da0-fc10500e6d7a/study-8.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bahji A, Zarate CA, Vazquez GH. Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert Opin Drug Saf. 2022;21(6):853-866. https://doi.org/10.1080/14740338.2022.2047928 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/54f595d3-9493-45f0-b148-42fd861590cd/study-9.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Huang C, Hu L, Liu W, et al. Efficacy and safety of esketamine on major depression, postpartum depression and perioperative depression: a systematic review and meta-analysis. Mol Psychiatry. 2026;31(1):545-558. https://doi.org/10.1038/s41380-025-03320-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/97b40482-de33-43ce-831e-533ac2fb96a8/study-10.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: d'Andrea G, Chiappini S, Ciavoni L, et al. Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes. Transl Psychiatry. 2025;15(1):453. https://doi.org/10.1038/s41398-025-03654-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fe190f24-4b80-482e-9e10-4e1694490411/study-11.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nikolin S, Rodgers A, Schwaab A, et al. Ketamine for the treatment of major depression: a systematic review and meta-analysis. EClinicalMedicine. 2023;62:102127. https://doi.org/10.1016/j.eclinm.2023.102127 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/760b465c-5665-4e18-810e-ae7de4541ba2/study-12.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hock RS, Feeney A, Iovieno N, et al. Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry. 2022;84(1):21r14086. https://doi.org/10.4088/jcp.21r14086 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/aea101fa-bc96-4df9-ba24-f6fdb9883666/study-13.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Rucker JJ, Jelen LA, Flynn S, et al. Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol. 2016;30(12):1220-1229. https://doi.org/10.1177/0269881116679368 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ae75f314-58f8-4a25-85bf-8ca12c0cc53b/study-14.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Metaxa AM, Clarke M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024;385:e078084. https://doi.org/10.1136/bmj-2023-078084 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0afb734f-aa9b-4cd6-bedc-5f670c749da4/study-15.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Højlund M, Kafali HY, Kırmızı B, et al. Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis. Eur Neuropsychopharmacol. 2025;101:41-55. https://doi.org/10.1016/j.euroneuro.2025.09.011 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/83638277-2da6-479b-a0ee-198d2671f64f/study-16.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ryan WC, Heifets BD. Maintenance Intramuscular Ketamine-Assisted Psychotherapy, a Retrospective Chart Review of Efficacy, Adverse Events, and Dropouts from a Community Practice. J Psychoactive Drugs. 2025;57(5):525-539. https://doi.org/10.1080/02791072.2024.2421895 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/433c468f-bf60-4194-85eb-e6d2a1dab183/study-17.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Chmiel J, Rybakowski F. Predictors of the Effectiveness of Psychedelics in Treating Depression-A Scoping Review. Int J Mol Sci. 2026;27(5):2202. https://doi.org/10.3390/ijms27052202 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6b5432c6-30a6-4a69-821f-87e1d79bca39/study-18.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Syed OA, Tsang B, Nestor SM, et al. Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2026;183:106573. https://doi.org/10.1016/j.neubiorev.2026.106573 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e4500385-c0c0-4c52-81eb-732c25289e2c/study-19.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Hietamies TM, McInnes LA, Klise AJ, et al. The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis. J Affect Disord. 2023;335:484-492. https://doi.org/10.1016/j.jad.2023.04.141 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0f374b98-242d-4aea-920d-10680a43c4e4/study-20.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol. 2015;30(3):152-163. https://doi.org/10.1002/hup.2475 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5641eb6e-7007-4ee8-94eb-499989d90995/study-21.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Florineth GA, Klima I, Boeker AL, et al. Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2026;9(1):e2554843. https://doi.org/10.1001/jamanetworkopen.2025.54843 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d78ebc62-b4c4-4225-ad79-5ca2e32da9a3/study-22.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wong S, Jones BDM, Thiyagarajah MT, et al. Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review. Ther Adv Psychopharmacol. 2025;15:20451253251384513. https://doi.org/10.1177/20451253251384513 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f1e1a5fe-6908-4e53-a771-c56587b2b249/study-23.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Han Y, Chen J, Zou D, et al. Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat. 2016;12:2859-2867. https://doi.org/10.2147/ndt.s117146 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/120135f3-0b61-4c4c-9c04-3268cf449771/study-24.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Arabzadeh S, Hakkikazazi E, Shahmansouri N, et al. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. J Affect Disord. 2018;235:236-241. https://doi.org/10.1016/j.jad.2018.02.056 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9d11cba4-ab5f-4d5c-99fa-cd6053f62a44/study-25.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Romeo B, Choucha W, Fossati P, Rotge JY. Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res. 2015;230(2):682-688. https://doi.org/10.1016/j.psychres.2015.10.032 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f256c6d3-a4bd-4e6d-a114-d6f31a5c3b1d/study-26.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(4):693-704. https://doi.org/10.1017/s0033291714001603 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e70a2889-a2ec-41b1-9b5a-2b2205ba08e6/study-27.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Borgogna NC, Owen T, Petrovitch D, et al. Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. Psychopharmacology (Berl). 2025;242(10):2139-2157. https://doi.org/10.1007/s00213-025-06788-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/29a00cbc-8376-4f25-a345-0791b5a52673/study-28.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Santos HC, Rodrigues A, Machado T, et al. (Es)ketamine as a treatment for depressive episodes with psychotic features: systematic review. BJPsych Open. 2025;11(6):e240. https://doi.org/10.1192/bjo.2025.10830 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5ee4fbbf-efa1-4638-a815-0ba367344e77/study-29.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Bahji A, Vazquez GH, Zarate CA. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord. 2021;278:542-555. https://doi.org/10.1016/j.jad.2020.09.071 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/efb03615-ce8c-469f-af43-90c9cd51e721/study-30.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Galvão-Coelho NL, Marx W, Gonzalez M, et al. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology (Berl). 2021;238(2):341-354. https://doi.org/10.1007/s00213-020-05719-1 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8e3fda06-bd22-41bd-9b0c-efe680877c84/study-31.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Chilukuri H, Reddy NP, Pathapati RM, et al. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med. 2014;36(1):71-76. https://doi.org/10.4103/0253-7176.127258 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ba9d4fa0-42be-4b0d-9905-9e99c7b81624/study-32.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Dominiak M, Gędek A, Modrzejewski S, et al. Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials. J Clin Med. 2025;15(1):253. https://doi.org/10.3390/jcm15010253 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e7f08514-daec-4781-9209-efbe8f40a2d6/study-33.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Spangemacher M, Mertens LJ, Färber LV, et al. Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry. Dtsch Arztebl Int. 2024;121(26):868-874. https://doi.org/10.3238/arztebl.m2024.0224 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d01bfb80-1ff5-4a45-9ebf-2e30f98b2694/study-34.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Trenado C, Seifritz E, Olbrich S, Ferrea S. The role of frontal EEG in predicting clinical response of major depressive disorder to intranasal ketamine and esketamine. J Affect Disord. 2026;395(Pt A):120751. https://doi.org/10.1016/j.jad.2025.120751 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/24568f23-90ee-4590-bcb0-b6f2516bbff9/study-35.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kishimoto T, Chawla JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46(7):1459-1472. https://doi.org/10.1017/s0033291716000064 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c5e723aa-b667-4e07-9926-e3ca5488ef83/study-36.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Meshkat S, Haikazian S, Di Vincenzo JD, et al. Oral ketamine for depression: An updated systematic review. World J Biol Psychiatry. 2023;24(7):545-557. https://doi.org/10.1080/15622975.2023.2169349 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e07c917a-ab0f-427b-a030-6c73362767e1/study-37.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970-976. https://doi.org/10.1016/j.biopsych.2014.03.026 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/db28c9bf-cf45-41a8-b17b-9457f2e2ca05/study-38.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Osório Fde L, Sanches RF, Macedo LR, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Braz J Psychiatry. 2015;37(1):13-20. https://doi.org/10.1590/1516-4446-2014-1496 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c99cc8cb-734c-4e00-a3cd-285b4f1831f5/study-39.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Parks AC, Woodward AL, Henry RD, et al. At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Safety, Feasibility, and Clinical Outcomes in Adults With Moderate to Severe Depression, Anxiety, or Posttraumatic Stress Disorder in a Large, Heterogeneous Cohort in the United States: Retrospective Cohort Study. J Med Internet Res. 2026;28:e92647. https://doi.org/10.2196/92647 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8236d582-d8f4-4346-95b1-a50cf31b443e/study-40.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Andrade FRT, Buchborn T, Thalheimer G, et al. Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence. Acta Neuropsychiatr. 2025;37:e86. https://doi.org/10.1017/neu.2025.10039 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6476c7db-eef6-4e02-8d59-ca9a2001cbea/study-41.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Salvetti G, Saccenti D, Moro AS, et al. Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials. Brain Sci. 2024;14(8):829. https://doi.org/10.3390/brainsci14080829 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/25fc6089-bbc8-4dba-8771-a5b6bbc7064f/study-42.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Daws RE, Timmermann C, Giribaldi B, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022;28(4):844-851. https://doi.org/10.1038/s41591-022-01744-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/35d2b560-99c3-42dc-beee-af7df971d4f0/study-43.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. https://doi.org/10.1016/s0006-3223(99)00230-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2f88a84f-5040-4414-8771-d195e0309189/study-44.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Li LJ, Mo Y, Shi ZM, et al. Psilocybin for major depressive disorder: a systematic review of randomized controlled studies. Front Psychiatry. 2024;15:1416420. https://doi.org/10.3389/fpsyt.2024.1416420 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f0be0243-43ac-4605-8710-9f857c2f51e4/study-45.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zhang X, Zhang X, Zhang H, Wei S. Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review. Int J Mol Sci. 2026;27(18):8052. https://doi.org/10.3390/ijms27188052 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/53d06077-7cd8-4d9e-930b-6c0f7c6b65b5/study-46.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Conley AA, Norwood AEQ, Hatvany TC, et al. Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis. Psychopharmacology (Berl). 2021;238(7):1737-1752. https://doi.org/10.1007/s00213-021-05825-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7461f8df-7999-4c5c-ad1c-0278be00f17a/study-47.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Weintraub MJ, Jeffrey JK, Ichinose MC, et al. Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial. J Affect Disord. 2026;403:121423. https://doi.org/10.1016/j.jad.2026.121423 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9f4da93f-499e-4719-8181-0794f0c00154/study-48.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Esterlis I, DellaGioia N, Pietrzak RH, et al. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. Mol Psychiatry. 2018;23(4):824-832. https://doi.org/10.1038/mp.2017.58 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e466fe7f-8ea0-48e7-94f5-1164e94a21c6/study-49.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Jones GM. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes. J Psychopharmacol. 2023;37(1):61-69. https://doi.org/10.1177/02698811221127304 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0947ebfb-7d7b-4482-8b06-57b7c09979e5/study-50.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Liu X, Li L, Li H, et al. Changes in dynamic and static functional connectivity in amygdala subregions in major depressive disorder treated with esketamine in and sertraline: A pilot study. J Affect Disord. 2026;392:120156. https://doi.org/10.1016/j.jad.2025.120156 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b2ea3d8c-8cc9-4158-8a11-f3bc6937b725/study-51.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Henry J, Giribaldi B, Nutt DJ, et al. The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial. Eur Neuropsychopharmacol. 2025;97:51-60. https://doi.org/10.1016/j.euroneuro.2025.06.003 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a27b4cdb-1292-4623-aeb6-8a30da9756da/study-52.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sloshower J, Zeifman RJ, Guss J, et al. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial. Sci Rep. 2024;14(1):8833. https://doi.org/10.1038/s41598-024-58318-x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f73c26a0-2efc-4189-b339-779cbb9f0501/study-53.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Morris LS, Costi S, Tan A, et al. Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. Neuropsychopharmacology. 2020;45(6):975-981. https://doi.org/10.1038/s41386-019-0591-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f6100589-5a99-4eb7-9ec3-0fa79c43cdc0/study-54.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Kosted R, Waddell A, Adolph K, Fonzo GA. Age-related moderation of adjunctive psychotherapy and early life stress effects on depression symptom reductions following ketamine treatment: Initial insights from a large, naturalistic sample. J Affect Disord. 2026;402:121350. https://doi.org/10.1016/j.jad.2026.121350 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5e52470d-3fe7-477e-a1ce-304f64cbced2/study-55.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Erritzoe D, Barba T, Greenway KT, et al. Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. EClinicalMedicine. 2024;76:102799. https://doi.org/10.1016/j.eclinm.2024.102799 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c59fc942-a771-45f2-bce2-8277f1a93d06/study-56.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Avram M, Menegaux A, Müller F, et al. Neuroplastic white matter changes in patients with major depression following lysergic acid diethylamide treatment. Cell Rep Med. 2026;7(6):102791. https://doi.org/10.1016/j.xcrm.2026.102791 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4a41e3d3-d6e1-4168-8107-c0d8143dec12/study-57.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Souza-Marques B, Telles M, Leal GC, et al. Esketamine for Unipolar Major Depression With Psychotic Features: A Retrospective Chart Review and Comparison With Nonpsychotic Depression. J Clin Psychopharmacol. 2022;42(4):408-412. https://doi.org/10.1097/jcp.0000000000001571 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fafe59ca-aeb1-43f6-8da5-d3e22738ced4/study-58.png Educational Resources - Major Depressive Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Swainson J, Grewal P, Polard S, et al. A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults. Npj Ment Health Res. 2026;5(1):43. https://doi.org/10.1038/s44184-026-00226-1 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c4d7859a-d2ca-4cf7-97a3-36424ee82686/study-59.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Szigeti B, Weiss B, Rosas FE, et al. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychol Med. 2024;54(8):1717-1724. https://doi.org/10.1017/s0033291723003653 https://www.harmreductionadvocate.com/educational-resources/depressive-disorders monthly 0.5 2026-10-30 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6f5524eb-b610-4a1e-91f7-4ddabc96d2b1/illustration-1.png Educational Resources - Depressive Disorders https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8f359d03-3cb2-465b-9b25-16721a0ed689/study-1.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Back AL, Freeman-Young TK, Morgan L, et al. Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(12):e2449026. https://doi.org/10.1001/jamanetworkopen.2024.49026 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c99fde33-f55b-41b8-9424-afbf6208ff7f/study-2.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lewis BR, Hendrick J, Byrne K, Odette M, Wu C, Garland EL. Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLoS Med. 2025;22(9):e1004519. https://doi.org/10.1371/journal.pmed.1004519 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0ccb5a9d-3ec2-43aa-8f73-d0b8c2064098/study-3.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hsu TW, Tsai CK, Kao YC, et al. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. BMJ. 2024;386:e078607. https://doi.org/10.1136/bmj-2023-078607 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7ea5e832-484b-4313-ac89-fdacb165a84d/study-4.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Price RB, Kissel N, Baumeister A, et al. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Mol Psychiatry. 2022;27(12):5096-5112. https://doi.org/10.1038/s41380-022-01757-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e5cc6b86-e957-4e44-9788-47ad4b1c6475/study-5.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Perez N, Langlest F, Mallet L, et al. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. Eur Neuropsychopharmacol. 2023;76:61-76. https://doi.org/10.1016/j.euroneuro.2023.07.011 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b05b6d17-cca3-48bd-be4e-fb47e35cfd96/study-6.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Thomas K, Malcolm B, Lastra D. Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders. J Psychoactive Drugs. 2017;49(5):446-455. https://doi.org/10.1080/02791072.2017.1320734 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6d42dbfa-6595-45ec-be51-2e01bf95df1f/study-7.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Yao Y, Guo D, Lu TS, et al. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;335:115886. https://doi.org/10.1016/j.psychres.2024.115886 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4cf6cb46-fc88-442c-922a-be5bf70d55d9/study-8.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Walsh Z, Mollaahmetoglu OM, Rootman J, et al. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open. 2021;8(1):e19. https://doi.org/10.1192/bjo.2021.1061 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5d82d9e9-a408-4707-abea-c2c9aa09951b/study-9.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Yu CL, Liang CS, Yang FC, et al. Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis. J Clin Med. 2022;11(4):938. https://doi.org/10.3390/jcm11040938 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/db774d7d-e29e-41e9-b26f-57c53e4dfff8/study-10.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Raison CL, Jain R, Penn AD, et al. Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States. Front Psychiatry. 2022;13:831092. https://doi.org/10.3389/fpsyt.2022.831092 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9805c212-7b95-49a7-8d93-6df6301aea21/study-11.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Dos Santos RG, Osório FL, Crippa JA, Hallak JE. Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Braz J Psychiatry. 2016;38(1):65-72. https://doi.org/10.1590/1516-4446-2015-1701 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a02d072e-fc21-44ef-84a8-3aef1395551d/study-12.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Luoma JB, Chwyl C, Bathje GJ, et al. A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. J Psychoactive Drugs. 2020;52(4):289-299. https://doi.org/10.1080/02791072.2020.1769878 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b6b2dbce-fa3d-4875-8b27-b999821a692c/study-13.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Lima TM, Visacri MB, Aguiar PM. Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses. Eur J Clin Pharmacol. 2022;78(3):311-338. https://doi.org/10.1007/s00228-021-03216-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/95f182ff-58bd-497f-b79f-b040a55de340/study-14.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Nygart VA, Pommerencke LM, Haijen E, et al. Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. J Psychopharmacol. 2022;36(8):932-942. https://doi.org/10.1177/02698811221101061 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/dd5a3a9a-f210-4e9b-a26c-08a69cddd686/study-15.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ramarushton B, Blumenthal H, Ryals A, et al. The Therapeutic Potential of Psychedelics on Reducing Rumination: A Mini-Review. Psychedelic Med (New Rochelle). 2024;2(3):146-152. https://doi.org/10.1089/psymed.2024.0009 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/464ccf6a-1f97-44c5-8036-557097d64a74/study-16.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nikolaidis A, Lancelotta R, Gukasyan N, et al. Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. J Affect Disord. 2023;324:239-249. https://doi.org/10.1016/j.jad.2022.12.042 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f9979789-88a9-417c-9484-a8185f985d21/study-17.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Meshkat S, Lin Q, Sousa-Ho R, et al. Magnitude of response in treatment and control groups within psychedelic trials for psychiatric disorders: A meta-analysis. Eur Psychiatry. 2026;69(1):e32. https://doi.org/10.1192/j.eurpsy.2026.10168 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bdc86150-267e-4940-a8d6-df4f017e5f15/study-18.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jiménez-Garrido DF, Gómez-Sousa M, Ona G, et al. Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination. Sci Rep. 2020;10(1):4075. https://doi.org/10.1038/s41598-020-61169-x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b4f5c451-43ad-4576-8321-72bfd537468e/study-19.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Ko K, Kopra EI, Cleare AJ, Rucker JJ. Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. J Affect Disord. 2023;322:194-204. https://doi.org/10.1016/j.jad.2022.09.168 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/08ddd71a-2f74-40dc-82aa-dc24d7e28f8e/study-20.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ruffell SGD, Netzband N, Tsang W, et al. Ceremonial Ayahuasca in Amazonian Retreats-Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study. Front Psychiatry. 2021;12:687615. https://doi.org/10.3389/fpsyt.2021.687615 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2dcfe306-50d1-47c1-97a0-b45fbc4da832/study-21.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Agin-Liebes G, Zeifman R, Luoma JB, et al. Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca. J Psychopharmacol. 2022;36(3):295-308. https://doi.org/10.1177/02698811221080165 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3526b301-55ad-412a-9eb0-ab60631873ae/study-22.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Davis AK, So S, Lancelotta R, et al. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse. 2019;45(2):161-169. https://doi.org/10.1080/00952990.2018.1545024 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/434e0242-5358-4f06-bf25-2bfd330af679/study-23.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Goldberg SB, Shechet B, Nicholas CR, et al. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. Psychol Med. 2020;50(16):2655-2666. https://doi.org/10.1017/s003329172000389x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f746b046-190d-40ba-88f0-0f4a6771be0b/study-24.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Agin-Liebes G, Haas TF, Lancelotta R, et al. Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacol Transl Sci. 2021;4(2):543-552. https://doi.org/10.1021/acsptsci.1c00018 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7da67bd4-f0e8-406f-a709-03fac39529ed/study-25.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatr Scand. 2021;143(2):101-118. https://doi.org/10.1111/acps.13249 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/96bcb365-bc1a-4e78-9d24-ae9654e307ac/study-26.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dos Santos RG, Osório FL, Crippa JA, et al. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol. 2016;6(3):193-213. https://doi.org/10.1177/2045125316638008 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/05ad9f16-c365-46f3-9750-90e75101e235/study-27.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pagni BA, Halman A, Sarris J, et al. Long-Term Mental Health and Wellbeing Outcomes Associated with Naturalistic Ayahuasca Consumption. J Psychoactive Drugs. 2026;58(4):441-451. https://doi.org/10.1080/02791072.2025.2465800 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6d5e685b-fa25-467f-9965-da4ed99f691d/study-28.png Educational Resources - Depressive Disorders Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JEC. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev Clin Pharmacol. 2018;11(9):889-902. https://doi.org/10.1080/17512433.2018.1511424 https://www.harmreductionadvocate.com/educational-resources/event-one-8katj-py3ae monthly 0.5 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8e0d647a-72e7-4faa-9450-8df4b760f152/_82e22bb4-280b-4ea8-8d98-528a4532c8f1.jpg Educational Resources - End of Life Distress - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/713f91a0-6595-4dcd-8d0f-0f7eba2d8551/griffiths-2016-title-and-abstract-highlighted.png Educational Resources - End of Life Distress Screenshot of the article as published in Journal of Psychopharmacology (2016), via PubMed Central. CC BY 3.0. Yellow highlighting added. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8231a291-0b6d-4c65-a674-174e4ce56424/ross-2016-title-and-abstract-part-1-highlighted.png Educational Resources - End of Life Distress Screenshot of the article as published in Journal of Psychopharmacology (2016), via PubMed Central, part 1 of 2. CC BY 3.0. Yellow highlighting added. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3f4f8943-4b41-4191-ab35-3d78d3860e3a/ross-2016-abstract-part-2-highlighted.png Educational Resources - End of Life Distress Screenshot of the article as published in Journal of Psychopharmacology (2016), via PubMed Central, part 2 of 2. CC BY 3.0. Yellow highlighting added. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/98a961cc-483d-49c3-8820-22f0ec2b0b17/ross-2025-title-block-clean.png Educational Resources - End of Life Distress Screenshot of the article’s title block as published in General Hospital Psychiatry (2025), via PubMed. The abstract is at the DOI link above. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d4e66836-959e-4bed-a5c8-ae2420e985ab/gasser-2014-title-and-abstract-clean.png Educational Resources - End of Life Distress Screenshot of the article as published in The Journal of Nervous and Mental Disease (2014), via PubMed Central. CC BY-NC-ND 3.0. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9a401db6-11b2-449f-a084-70e79f604d6a/Screen+Shot+2024-01-21+at+9.20.36+PM.png Educational Resources - End of Life Distress - Make it stand out Psilocybin Benefits in Cancer Sustained Nearly 5 Years Later. Medscape. (2020, January 28). https://www.medscape.com/viewarticle/924368?form=fpf https://www.harmreductionadvocate.com/educational-resources/event-one-8katj-tzy3n monthly 0.5 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e42bc86b-9e73-49a9-b755-5d07fbfad6fc/_fc963efa-cee6-4d4f-9100-8751dbbfc64a.jpg Educational Resources - Physical Well Being - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/abfe5c23-cc70-4c17-b865-306387f3de05/study-1.png Educational Resources - Physical Well Being Excerpt of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Simonsson O, Sexton JD, Hendricks PS. Associations between lifetime classic psychedelic use and markers of physical health. J Psychopharmacol. 2021;35(4):447-452. https://doi.org/10.1177/0269881121996863 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/460fe1ee-fcf3-4466-a24d-d85a71e6c831/study-27.png Educational Resources - Physical Well Being Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197. https://doi.org/10.1177/0269881116675513 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e1fc3e7b-d379-49a8-9478-d8449256dead/study-3.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Wen Y, Tang L, Duan W, et al. Targeting peripheral 5-HT2AR enhances antitumor immunity in colorectal cancer. Cell. 2026;189(18):5688-5705.e13. https://doi.org/10.1016/j.cell.2026.07.028 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1452ab9c-0383-4571-82b9-0eac561b7b17/study-4.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Heles M, Pasvolsky L, Sathishkumar H, et al. Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation. Science. 2026;393(6815):eaec6116. https://doi.org/10.1126/science.aec6116 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2d69e625-e532-407a-8df0-470e10b53504/study-5.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Tourino MC, de Oliveira EM, Bellé LP, et al. Tryptamine and dimethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells. Cell Biochem Funct. 2013;31(5):361-364. https://doi.org/10.1002/cbf.2980 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/88f899f5-79d4-414a-8c26-e7d91ba52ed8/study-6.png Educational Resources - Physical Well Being Excerpt of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Frecska E, Bokor P, Winkelman M. The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization. Front Pharmacol. 2016;7:35. https://doi.org/10.3389/fphar.2016.00035 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/39789e99-82c5-44a4-8972-766ce1f435ed/study-7.png Educational Resources - Physical Well Being Excerpt of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Szabo A. Psychedelics and immunomodulation: novel approaches and therapeutic opportunities. Front Immunol. 2015;6:358. https://doi.org/10.3389/fimmu.2015.00358 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7a2f4d18-a6cb-4536-b79e-7745fe974afe/study-8.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: van Waarde A, Rybczynska AA, Ramakrishnan NK, Ishiwata K, Elsinga PH, Dierckx RA. Potential applications for sigma receptor ligands in cancer diagnosis and therapy. Biochim Biophys Acta. 2015;1848(10 Pt B):2703-2714. https://doi.org/10.1016/j.bbamem.2014.08.022 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f05a976f-8a9e-47aa-a79f-50fa27579aec/Screen+Shot+2024-01-21+at+7.19.49+PM.png Educational Resources - Physical Well Being - Make it stand out Schenberg EE. Ayahuasca and cancer treatment. SAGE Open Med. 2013;1:2050312113508389. https://doi.org/10.1177/2050312113508389 · Screenshot of the published record (PubMed). https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ab880d04-66d0-480e-9d03-557dc7315877/study-9.png Educational Resources - Physical Well Being Page of the U.S. National Cancer Institute (public domain), key sentence highlighted in yellow. Source: PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Cannabis and Cannabinoids (PDQ®)–Health Professional Version. National Cancer Institute. Updated May 13, 2025. Accessed October 27, 2026. https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b09c19db-3e27-4212-8fca-f6f2627f8b60/study-11.png Educational Resources - Physical Well Being Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hinz B, Ramer R. Cannabinoids as anticancer drugs: current status of preclinical research. Br J Cancer. 2022;127(1):1-13. https://doi.org/10.1038/s41416-022-01727-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/48595a40-3aaa-41c2-9ce3-9e70f7c7f7df/study-12.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Torres S, Lorente M, Rodríguez-Fornés F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011;10(1):90-103. https://doi.org/10.1158/1535-7163.MCT-10-0688 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/51312353-1d9c-45eb-ba78-a7c8ed85fdd4/study-13.png Educational Resources - Physical Well Being Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. https://doi.org/10.1038/sj.bjc.6603236 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1f96d1d6-55f8-4675-8cc1-330905ee8054/study-14.png Educational Resources - Physical Well Being Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Twelves C, Sabel M, Checketts D, et al. A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. Br J Cancer. 2021;124(8):1379-1387. https://doi.org/10.1038/s41416-021-01259-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/af69aa9e-807c-440c-9f2e-b871f9e7fe31/study-17.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Braun IM, Bohlke K, Abrams DI, et al. Cannabis and cannabinoids in adults with cancer: ASCO guideline. J Clin Oncol. 2024;42(13):1575-1593. https://doi.org/10.1200/JCO.23.02596 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/26f6d299-b660-4a96-96e9-89d7a404baaf/study-21.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Waissengrin B, Leshem Y, Taya M, et al. The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: a sigh of relief? Eur J Cancer. 2023;180:52-61. https://doi.org/10.1016/j.ejca.2022.11.022 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/63f3be53-4577-4bf9-96ba-b3c53d17549b/study-22.png Educational Resources - Physical Well Being Excerpt of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Simonsson O, Osika W, Carhart-Harris R, Hendricks PS. Associations between lifetime classic psychedelic use and cardiometabolic diseases. Sci Rep. 2021;11(1):14427. https://doi.org/10.1038/s41598-021-93787-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/362d4972-1030-4560-8e38-b1a0cb3fc471/study-23.png Educational Resources - Physical Well Being Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Haupt MJ, Carra S, Boehnke KF, Aday JS. Preliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies. Prog Neuropsychopharmacol Biol Psychiatry. 2026;145:111634. https://doi.org/10.1016/j.pnpbp.2026.111634 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7ed2658a-c2a9-4b4e-9896-f006b4a726d5/study-28.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983-992. https://doi.org/10.1177/0269881114548296 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/64c9f6b4-6f65-4aa9-9f5f-1e80b004ea88/study-25.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Swieczkowski D, Kwaśny A, Cubała WJ. Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials. Prog Neuropsychopharmacol Biol Psychiatry. 2025;140:111419. https://doi.org/10.1016/j.pnpbp.2025.111419 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7d72bcc1-2d5e-461c-a7aa-a046148e6a74/study-26.png Educational Resources - Physical Well Being Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Yerubandi A, Thomas JE, Bhuiya NMMA, et al. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7(4):e245960. https://doi.org/10.1001/jamanetworkopen.2024.5960 https://www.harmreductionadvocate.com/educational-resources/event-one-8katj-s4scw monthly 0.5 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0e23b0e1-d9a8-4e96-a22b-ea1ebd078ba1/_9e2f3f2b-80c0-4bcb-bf84-2ea581dcd3ae.jpg Educational Resources - Wellness of the Planet - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/37b78d61-0a62-4d46-aa4d-f992306a6549/_67cc4818-95e5-4235-8fd6-8806e71c15c0.jpg Educational Resources - Wellness of the Planet - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/56172a4f-0d72-46f6-b147-bea8641d7d1b/Screen+Shot+2024-01-28+at+10.56.38+PM.png Educational Resources - Wellness of the Planet - Make it stand out Nilsson M, Stålhammar S. Psychedelics and inner dimensions of sustainability: a literature review. Eur J Ecopsychol. 2024;9:4-47. https://ecopsychology-journal.eu/v9/EJE_v9_Nilsson_and_St%C3%A5lhammar.pdf · Screenshot of the first page of the published review (European Journal of Ecopsychology). https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227370347-B36D9N9CW781AIHDK2DX/study-1.png Educational Resources - Wellness of the Planet Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Rich R, Laird K, Siddarth P, et al. A Nature-Themed Video Intervention Increases Nature Relatedness in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. Psychedelic Med (New Rochelle). 2026;4(3):199-208. https://doi.org/10.1177/28314425251387655 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227371570-8DH9R0ST6GRLADR5R8P3/study-2.png Educational Resources - Wellness of the Planet Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Forstmann M, Sagioglou C. Psychedelics and connectedness to natural and social worlds: An examination of the evidence and a proposed conceptual framework. Curr Opin Psychol. 2025;62:101992. https://doi.org/10.1016/j.copsyc.2025.101992 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227372658-TO0QUMY08IZI1H23P2O6/study-3.png Educational Resources - Wellness of the Planet Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lyons T, Carhart-Harris RL. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. J Psychopharmacol. 2018;32(7):811-819. https://doi.org/10.1177/0269881117748902 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227373694-V3ZSGE2P8BI6UU8W0D5G/study-4.png Educational Resources - Wellness of the Planet Quotation from the abstract of the published study (text from the publisher’s page, Scientific Reports), highlighted in yellow. Source: Teixeira PJ, Cherniak AD, Forstmann M. Lifetime classic psychedelics use is associated with positive environmental attitudes and adopting a vegetarian diet. Sci Rep. Published online September 11, 2026. https://doi.org/10.1038/s41598-026-71275-x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227374811-0V37EW3L89W3G2M0EAZW/study-5.png Educational Resources - Wellness of the Planet Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Forstmann M, Sagioglou C. Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness. J Psychopharmacol. 2017;31(8):975-988. https://doi.org/10.1177/0269881117714049 https://www.harmreductionadvocate.com/educational-resources/event-one-8katj-bst5y monthly 0.5 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5920747b-1c5e-4757-8bf3-35fedf661366/_b0d769d5-8d51-412e-b142-acd3b63e3eac.jpg Educational Resources - PTSD - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227465765-6UZ194JN3GXWLN3B5OTC/study-A.png Educational Resources - PTSD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Poddar A, Raggio M, Concato J. Decisions on non-oncology breakthrough therapy designation requests in 2017-2019. Ther Innov Regul Sci. 2024;58(1):214-221. https://doi.org/10.1007/s43441-023-00589-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227466952-MX6EEQXCS3TSD98TT3O1/study-B.png Educational Resources - PTSD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Herink MC, Johnston K, Breninger K, Wu E, Irwin AN. Pharmacists’ knowledge and perceptions of FDA approval standards and the breakthrough therapy designation. Pharmacy (Basel). 2022;10(5):126. https://doi.org/10.3390/pharmacy10050126 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227468090-X9IKRQ3HQDURRJGFZU08/study-C.png Educational Resources - PTSD Quotation from the journal's retraction notice, highlighted in yellow. Source: Jerome L, Feduccia AA, Wang JB, et al. Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2024;241(11):2407. https://doi.org/10.1007/s00213-024-06665-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227469266-6JOH9LF5HWTRK4D0O9K7/study-D.png Educational Resources - PTSD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033. https://doi.org/10.1038/s41591-021-01336-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227470417-N9J4FVK2K7IJBSILEW7X/study-E.png Educational Resources - PTSD Abstract of the published study (text from Europe PMC), key sentence quoted in the text above. Source: Davis AK, Averill LA, Sepeda ND, Barsuglia JP, Amoroso T. Psychedelic treatment for trauma-related psychological and cognitive impairment among US Special Operations Forces veterans. Chronic Stress (Thousand Oaks). 2020;4:2470547020939564. https://doi.org/10.1177/2470547020939564 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227471589-KH8RUB0V8UJ6GGMOO9XV/study-F.png Educational Resources - PTSD Text of the published study (from Europe PMC), key sentence highlighted in yellow. Source: Kéri S. Psychedelic safety and clinical outcomes across exposure patterns: a structured narrative review. Life (Basel). 2026;16(8):1338. https://doi.org/10.3390/life16081338 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227472662-2RF7KXZSMGULO0ZOASSC/study-1.png Educational Resources - PTSD Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Thomas JE, Dellarole A, Caballero J. Efficacy and risks of psychedelics in the treatment of posttraumatic stress disorder: A systematic review. Am J Health Syst Pharm. 2026;83(16):822-834. https://doi.org/10.1093/ajhp/zxag062 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227473868-U2ENTKYRLU8EARQ48WCM/study-2.png Educational Resources - PTSD Text of the published study (from Europe PMC), key sentence highlighted in yellow. Source: Sze Jing Yong A, Bratuskins S, Sultani MS, Blakeley B, Davey CG, Bell JS. Safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in post-traumatic stress disorder: An overview of systematic reviews and meta-analyses. Aust N Z J Psychiatry. 2025;59(4):339-360. https://doi.org/10.1177/00048674251315642 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227475054-GYH19TOJOBGIU9LP2PIZ/study-3.png Educational Resources - PTSD Text of the published study (from Europe PMC), key sentence highlighted in yellow. Source: Mitchell JM, Ot'alora G M, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29(10):2473-2480. https://doi.org/10.1038/s41591-023-02565-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227476198-JFRN8P9914ZQ1SVNTYPS/study-4.png Educational Resources - PTSD Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Abdallah CG, Roache JD, Gueorguieva R, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022;47(8):1574-1581. https://doi.org/10.1038/s41386-022-01266-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227477383-Y0YPDWW791AMBN309VEB/study-5.png Educational Resources - PTSD Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Sevchik BL, Singleton SP, Lahey A, et al. A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD. Neuropsychopharmacology. Published online October 11, 2026. https://doi.org/10.1038/s41386-026-02575-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227478549-YDGZ6G986ZF7E6PDNHO1/study-6.png Educational Resources - PTSD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jones A, Warner-Schmidt J, Kwak H, et al. Efficacy and safety of the neuroplastogen TSND-201 for the treatment of PTSD: a randomized clinical trial. JAMA Psychiatry. 2026;83(5):469-477. https://doi.org/10.1001/jamapsychiatry.2025.4625 https://www.harmreductionadvocate.com/educational-resources/event-one-8katj-69lhb monthly 0.5 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/751eede4-a88a-4d1f-95b6-3c833c29c2cc/_cdf08c3c-2b17-447f-b98c-258876ccc0a7.jpg Educational Resources - Wellness of the ‘Well’ - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2dc02aa8-93b9-4244-ad1f-28ced32ce21f/Screen+Shot+2024-01-22+at+7.11.46+PM.png Educational Resources - Wellness of the ‘Well’ - Make it stand out “Magic mushrooms have been linked to lower crime rates” Foley KE. Psychedelics may make people less likely to commit violent crimes. Quartz. Published October 19, 2017. https://qz.com/1105554/psychedelics-may-make-people-less-likely-to-commit-violent-crimes · Screenshot of the Quartz article. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c59f36a6-6568-467e-9751-b7a4fbb65ed9/study-1.png Educational Resources - Wellness of the ‘Well’ Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Klučková T, Nikolič M, Tylš F, et al. The phenomenology of psilocybin's experience mediates subsequent persistent psychological effects independently of sex, previous experience, or setting. Pharmacol Rep. 2025;77(4):1024-1039. https://doi.org/10.1007/s43440-025-00742-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f3cd6f01-a5cf-44a7-9b8b-4b9ee0684b6c/study-2.png Educational Resources - Wellness of the ‘Well’ Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology (Berl). 2018;235(2):535-545. https://doi.org/10.1007/s00213-017-4733-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/aba0f794-9cd2-4028-91bd-e160498e3de4/study-3.png Educational Resources - Wellness of the ‘Well’ Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25(11):1453-1461. https://doi.org/10.1177/0269881111420188 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/315c2cb3-e37c-4281-8fe4-4097f4f7bfb5/study-4.png Educational Resources - Wellness of the ‘Well’ Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AK. Long-term effects of psychedelic drugs: A systematic review. Neurosci Biobehav Rev. 2020;113:179-189. https://doi.org/10.1016/j.neubiorev.2020.03.017 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/026ef490-675a-4541-8185-ca7de2bd8594/study-5.png Educational Resources - Wellness of the ‘Well’ Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25(11):1434-1452. https://doi.org/10.1177/0269881110382466 https://www.harmreductionadvocate.com/educational-resources/event-five-7mcnj-xdlse monthly 0.5 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227523597-CB18SNDTD58PKAIEQMF7/study-1.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187(3):268-283. https://doi.org/10.1007/s00213-006-0457-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227524747-RMAU7J2KHVWRDN9JQLIF/study-2.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from the publisher’s page), highlighted in yellow. Source: Samorini G. The oldest archeological data evidencing the relationship of Homo sapiens with psychoactive plants: a worldwide overview. J Psychedelic Stud. 2019;3(2):63-80. https://doi.org/10.1556/2054.2019.008 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227525874-02HR8WQA58CE53BAK0DI/study-3.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from the publisher’s page), highlighted in yellow. Source: Winkelman M. Introduction: evidence for entheogen use in prehistory and world religions. J Psychedelic Stud. 2019;3(2):43-62. https://doi.org/10.1556/2054.2019.024 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227526948-QLIAFPES8S0M8JSVUBDS/study-4.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rodríguez Arce JM, Winkelman MJ. Psychedelics, sociality, and human evolution. Front Psychol. 2021;12:729425. https://doi.org/10.3389/fpsyg.2021.729425 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227528126-Z55MLFPG5Y1XZIJHLVU4/study-5.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Rick JW, Lema VS, Echeverría J, et al. Pre-Hispanic ritual use of psychoactive plants at Chavín de Huántar, Peru. Proc Natl Acad Sci U S A. 2025;122(19):e2425125122. https://doi.org/10.1073/pnas.2425125122 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227529150-6TO8N1GLA70WJMONDFXC/study-n26.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Barrett FS, Griffiths RR. Classic hallucinogens and mystical experiences: phenomenology and neural correlates. Curr Top Behav Neurosci. 2018;36:393-430. https://doi.org/10.1007/7854_2017_474 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2265b41f-9ed1-4538-8cf3-aaf1a56a1c64/Screen+Shot+2024-01-22+at+3.31.34+PM.png Educational Resources - Spiritual Wellness - Make it stand out Hartman S. Researchers are giving religious leaders psychedelic drugs in the interest of science. Quartz. January 6, 2017. https://qz.com/879285/psilocybin-drug-trials-psychedelics-such-as-acid-lsd-might-not-only-make-us-more-spiritual-and-religious-they-make-us-healthier-too. Screenshot of the article’s pull quote. Quartz does not name the survey behind this line; a large published comparison of the two kinds of experience is Study 6 under Key studies below (Griffiths, 2019). https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/23873c85-8f9d-4684-ae74-4f65013542d2/Screen+Shot+2024-01-22+at+3.25.17+PM.png Educational Resources - Spiritual Wellness Hartman S. Researchers are giving religious leaders psychedelic drugs in the interest of science. Quartz. January 6, 2017. https://qz.com/879285/psilocybin-drug-trials-psychedelics-such-as-acid-lsd-might-not-only-make-us-more-spiritual-and-religious-they-make-us-healthier-too. Screenshot of the article’s headline. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227530122-BTW01WBBEA5UYQLEY2TH/study-7.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197. https://doi.org/10.1177/0269881116675513 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227531153-4EDQTJPSJ1XXRZBCIQDC/study-8.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC). Source: Griffiths RR, Jesse R, Richards WA, et al. Effects of psilocybin on religious and spiritual attitudes and behaviors in clergy from various major world religions. Psychedelic Med (New Rochelle). 2025;3(4):172-191. https://doi.org/10.1089/psymed.2023.0044 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227628213-3W420UCWDA2B2V8MHQO8/study-9-publishers-note.png Educational Resources - Spiritual Wellness Publisher’s note (title block from the Crossref record). Source: Publisher’s note re: “Effects of psilocybin on religious and spiritual attitudes and behaviors in clergy from various major world religions.” Psychedelic Med (New Rochelle). 2025;3(4):171. https://doi.org/10.1089/psymed.2025.68798.pn https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227533465-SJFI82JEC9WX87VP3X3C/study-10.png Educational Resources - Spiritual Wellness Published commentary (text from PubMed Central). Source: Simonsson O, Goldberg SB. The promises and pitfalls of psychedelic use among religious leaders. Psychedelic Med (New Rochelle). 2025;3(4):200-201. https://doi.org/10.1177/28314425251392542 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/21acf6c9-567f-45c3-9010-398ea69133e6/_f94113d4-bb85-4a1b-bfa0-3dcecde01345.jpg Educational Resources - Spiritual Wellness - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227534503-OX3BVJ5B6OIBYYWVXO0K/study-11.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Frecska, E., Bokor, P., & Winkelman, M. (2016). The therapeutic potentials of ayahuasca: Possible effects against various diseases of civilization. Frontiers in Pharmacology, 7, 35. https://doi.org/10.3389/fphar.2016.00035 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/95429b48-b874-478f-ba98-cdf544882788/Screen+Shot+2024-01-28+at+8.33.58+PM.png Educational Resources - Spiritual Wellness - Make it stand out Moss C. Did early Christians use psychedelics? The Daily Beast. September 29, 2020. https://www.thedailybeast.com/did-early-christians-use-psychedelics. Screenshot of the article’s headline. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227535547-FIE242VW5AP88KPWA90C/study-12.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Antonopoulos RK, Dadiotis E, Ioannidis K, et al. Investigating the psychedelic hypothesis of kykeon, the sacred elixir of the Eleusinian Mysteries. Sci Rep. 2026;16(1):8757. https://doi.org/10.1038/s41598-026-39568-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5dc6c928-f9e0-4284-b37e-760cd8335672/Screen+Shot+2024-01-28+at+8.52.12+PM.png Educational Resources - Spiritual Wellness - Make it stand out Margolin M, Hartman S. Jews, Christians, and Muslims are reclaiming ancient psychedelic practices, and that could help with legalization. Rolling Stone. April 23, 2021. https://www.rollingstone.com/culture/culture-features/psychedelics-religion-entheogens-1160408/. Screenshot of the article’s headline. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227536747-W8HSP97TAPGR98J5WR5R/study-13.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from the publisher’s page), highlighted in yellow. Source: Arie E, Rosen B, Namdar D. Cannabis and frankincense at the Judahite shrine of Arad. Tel Aviv. 2020;47(1):5-28. https://doi.org/10.1080/03344355.2020.1732046 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9da47766-b5c0-404c-9da4-9790c45b12ee/Screen+Shot+2024-01-22+at+3.15.46+PM.png Educational Resources - Spiritual Wellness - Make it stand out Livni E. Scientists studying psychoactive drugs accidentally proved the self is an illusion. Quartz. February 9, 2018. https://qz.com/1196408/scientists-studying-psilocybin-accidentally-proved-the-self-is-an-illusion. Screenshot of the article’s headline (the article was online and the link working on 27 October 2026). https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227537809-5DU2H3NIMHWF0ERGAE3M/study-14.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC). Source: Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018;32(1):49-69. https://doi.org/10.1177/0269881117731279 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227538745-ZHFJLPEE7DCQ55KX59R0/study-15.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Nour MM, Evans L, Nutt D, Carhart-Harris RL. Ego-dissolution and psychedelics: validation of the Ego-Dissolution Inventory (EDI). Front Hum Neurosci. 2016;10:269. https://doi.org/10.3389/fnhum.2016.00269 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227539902-08U3M868A4EFYN2PIP9Q/study-16.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 33(9), 1088–1101. https://doi.org/10.1177/0269881119845793 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227540977-OEUIIQDH4E5J7J5Y20BR/study-17.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Roseby W, Kettner H, Roseman L, et al. Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies. Front Psychol. 2025;16:1580663. https://doi.org/10.3389/fpsyg.2025.1580663 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227541989-IF5I06XRVAPNY9NOICUD/study-18.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ferreira AE, Reis-Pina P. Exploring the role of psychedelic-assisted therapy in enhancing spirituality and mystical experiences in patients with life-threatening illnesses: A systematic review. J Psychosom Res. 2025;189:112020. https://doi.org/10.1016/j.jpsychores.2024.112020 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227543141-Y0RA8JAIQ95VZRM1XZBU/study-19.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Meling D, Egger K, Aicher HD, et al. Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat. J Psychopharmacol. 2024;38(10):897-910. https://doi.org/10.1177/02698811241282637 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227544250-KEI59ZU4N8PQBRJBOKZI/study-20.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ko K, Knight G, Rucker JJ, Cleare AJ. Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. Front Psychiatry. 2022;13:917199. https://doi.org/10.3389/fpsyt.2022.917199 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227545321-33IBBMXS8IQPT8JLYLUY/study-21.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Smigielski L, Kometer M, Scheidegger M, et al. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep. 2019;9(1):14914. https://doi.org/10.1038/s41598-019-50612-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227546467-6BD97JT9ZBGM2CJYSU3T/study-22.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Griffiths RR, Hurwitz ES, Davis AK, Johnson MW, Jesse R. Survey of subjective “God encounter experiences”: comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS One. 2019;14(4):e0214377. https://doi.org/10.1371/journal.pone.0214377 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227547699-K6RH48VD3JWAB8CFZHWN/study-23.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165-1180. https://doi.org/10.1177/0269881116675512 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227548844-2THT66Y121R56GCLAEB1/study-24.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25(11):1453-1461. https://doi.org/10.1177/0269881111420188 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227549945-X3V6L5RY65IP6NVB13W0/study-25.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22(6):621-632. https://doi.org/10.1177/0269881108094300 https://www.harmreductionadvocate.com/educational-resources/event-one-8katj monthly 0.5 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8fc359b2-4c8c-4b36-a66b-2d6fa3004e72/_2e4e6650-1c11-4d3d-83ce-53425e9d4479.jpg Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9686bf48-8ac0-4804-b3d0-d117d7d0ae1f/Screenshot+2024-03-09+193517.png Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Screenshot (9 March 2024): Canadian Drug Policy Coalition, ‘History of Drug Policy in Canada’. https://drugpolicy.ca/resources/guides/history/ https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2bf25c04-d980-468c-9003-ec2cee8a153b/Screenshot+2024-03-09+193727.png Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Screenshot (9 March 2024): Canadian Drug Policy Coalition, ‘History of Drug Policy in Canada’. https://drugpolicy.ca/resources/guides/history/ https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a8af6b2d-d3b3-4a8f-a902-c3ead3b4bf41/Screenshot+2024-03-09+201023.png Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Screenshot (9 March 2024): Canadian Drug Policy Coalition, ‘History of Drug Policy in Canada’. https://drugpolicy.ca/resources/guides/history/ https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6dfc98ba-36a8-44a1-bd38-a1d6c70e6719/Screenshot+2024-03-09+201137.png Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Screenshot (9 March 2024): Canadian Drug Policy Coalition, ‘History of Drug Policy in Canada’. https://drugpolicy.ca/resources/guides/history/ https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f36d844f-1525-41ab-83f2-c631e5136706/Screenshot+2024-03-09+201911.png Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Screenshot (9 March 2024): Canadian Drug Policy Coalition, ‘History of Drug Policy in Canada’. https://drugpolicy.ca/resources/guides/history/ https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227673130-FGJFX1AO7WMBYJDJ469C/study-n5.png Educational Resources - Educational Resources: Introduction - A New Era Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dishotsky NI, Loughman WD, Mogar RE, Lipscomb WR. LSD and genetic damage. Science. 1971;172(3982):431-440. https://doi.org/10.1126/science.172.3982.431 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227674235-RHNN3632N36X9CHNADQL/study-n6.png Educational Resources - Educational Resources: Introduction - A New Era Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. https://doi.org/10.1001/archpsyc.63.8.856 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227675365-5D02MY21JGT92K7NNG9E/study-n1.png Educational Resources - Educational Resources: Introduction - A New Era Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187(3):268-283. https://doi.org/10.1007/s00213-006-0457-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227676592-GW50FJS0UDO8TB8OEPOT/study-n2.png Educational Resources - Educational Resources: Introduction - A New Era Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033. https://doi.org/10.1038/s41591-021-01336-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227677874-URKAG2OZPIZPQY3WTX2D/study-n3.png Educational Resources - Educational Resources: Introduction - A New Era Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481-489. https://doi.org/10.1001/jamapsychiatry.2020.3285 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227678971-SBTBI7OJ52N0ABUTBW7U/study-n4.png Educational Resources - Educational Resources: Introduction - A New Era Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(10):953-962. https://doi.org/10.1001/jamapsychiatry.2022.2096 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0244dd06-46f8-4981-a73d-361d6b6acdbf/Screen+Shot+2024-01-22+at+7.34.42+PM.png Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Cohen A, Vakharia SP, Netherland J, Frederique K. How the war on drugs impacts social determinants of health beyond the criminal legal system. Ann Med. 2022;54(1):2024-2038. https://doi.org/10.1080/07853890.2022.2100926 (free full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC9302017/) https://www.harmreductionadvocate.com/educational-resources/event-five-7mcnj monthly 0.5 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2eb91f7e-7c58-476e-93a0-55221a25a97b/Screen+Shot+2024-01-17+at+1.41.01+PM.png Educational Resources - Substance Use Disorder - Make it stand out Nordqvist, C. (2010, November 1). Alcohol is most harmful drug, followed by heroin and crack. Medical News Today. Archived copy: https://web.archive.org/web/20101103201423/http://www.medicalnewstoday.com/articles/206300.php https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/aeae01bd-6adf-486d-bf24-9c9fbf239f5d/Screen+Shot+2024-01-17+at+12.40.57+PM.png Educational Resources - Substance Use Disorder - Make it stand out The Economist Newspaper. (2019, June 25). What is the most dangerous drug?. The Economist. https://www.economist.com/graphic-detail/2019/06/25/what-is-the-most-dangerous-drug https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/64083c48-07fb-45ea-b995-6ac96d4d0cab/Screen+Shot+2024-01-17+at+1.27.10+PM.png Educational Resources - Substance Use Disorder - Make it stand out Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143–166. https://doi.org/10.1016/j.neuropharm.2018.05.012 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3aebb4e7-a765-42e6-ab14-0506167361e8/Screen+Shot+2024-01-17+at+2.14.05+PM.png Educational Resources - Substance Use Disorder - Make it stand out Imperial College London. (2010, November 1). Alcohol most harmful drug based on multicriteria analysis. Imperial News. https://www.imperial.ac.uk/news/94042/alcohol-most-harmful-drug-based-multicriteria/ https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227434485-RA6TU29DVUPBY4B2U39A/study-1.png Educational Resources - Substance Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nutt DJ, King LA, Phillips LD; Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376(9752):1558-1565. https://doi.org/10.1016/S0140-6736(10)61462-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7ea165f0-e833-4ac1-b983-e0142842155e/Screen+Shot+2024-01-17+at+2.37.33+PM.png Educational Resources - Substance Use Disorder - Make it stand out Data source is the March 24, 2007 article: Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007). Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet, 369(9566), 1047–1053. https://doi.org/10.1016/S0140-6736(07)60464-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227435547-QF8T5466AQSQY5G92KQ6/study-2.png Educational Resources - Substance Use Disorder Excerpt from the full text of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Frecska E, Bokor P, Winkelman M. The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization. Front Pharmacol. 2016;7:35. https://doi.org/10.3389/fphar.2016.00035 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227436723-7XU0HIA4JF0Z04486WQG/study-3.png Educational Resources - Substance Use Disorder Excerpt from the full text of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fang SP, Yang X, Zhao DC, et al. Ketamine for substance use disorders: a systematic review and meta-analysis. Front Psychiatry. 2026;17:1835709. https://doi.org/10.3389/fpsyt.2026.1835709 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227437838-TPPA4NGNVDERAHOO938P/study-4.png Educational Resources - Substance Use Disorder Excerpt from the full text of the published study (text from Europe PMC). Source: Hendricks PS, Lappan SN, Shelton RC, et al. Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(5):e2611029. https://doi.org/10.1001/jamanetworkopen.2026.11029 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227439081-RC0R4YX8186S221OVG8C/study-5.png Educational Resources - Substance Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Piper T, Small F, Brown S, et al. Psychedelic-assisted treatment for substance use disorder: A narrative systematic review. Addiction. 2025. https://doi.org/10.1111/add.16762 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227440406-Y319UEBIT80FDUKKEQTC/study-6.png Educational Resources - Substance Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dakwar E, Nunes EV, Hart CL, et al. A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Am J Psychiatry. 2019;176(11):923-930. https://doi.org/10.1176/appi.ajp.2019.18101123 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227441479-ZL5YLXP6RPMMVT49FBT3/study-7.png Educational Resources - Substance Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983-992. https://doi.org/10.1177/0269881114548296 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1793227442703-0HIYPUW6MG240UHJZYCE/study-8.png Educational Resources - Substance Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(10):953-962. https://doi.org/10.1001/jamapsychiatry.2022.2096 https://www.harmreductionadvocate.com/blog daily 0.75 2026-10-29 https://www.harmreductionadvocate.com/blog/blog-post-title-one-h5eer monthly 0.5 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/687ae6dd-715d-45d8-8917-d13058fcf8af/1.jpg Blog - Changing Perspectives - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.harmreductionadvocate.com/harmreductionadvocate daily 1.0 2026-09-08 https://images.squarespace-cdn.com/content/v1/6329f526dfa8a56dbab40128/daf61717-83ce-44a7-ae7e-491a77d29f50/image-asset.png https://images.squarespace-cdn.com/content/v1/6329f526dfa8a56dbab40128/1a7a9a0d-4bf0-4a04-ad93-ab1f097ca24c/image-asset.png https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1731384090402-81VJ5SXDZXV4Q4NADKMY/unsplash-image-cNL_7gtBTvY.jpg https://images.squarespace-cdn.com/content/v1/6329f526dfa8a56dbab40128/1a7a9a0d-4bf0-4a04-ad93-ab1f097ca24c/image-asset.png https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1731384034232-MSIGKE7Z18SKG91QHUDB/unsplash-image-5prKIX4JLO0.jpg https://www.harmreductionadvocate.com/about daily 0.75 2026-09-08 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/046e7fd8-fb9c-41f4-bcd7-d43630e72397/3.jpg https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f13a0dea-90d6-4502-8625-1e20883b1f21/4.jpg https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2ff5ad9b-d19a-46b2-889c-c2b95804175a/7.jpg https://www.harmreductionadvocate.com/contact daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/services daily 0.75 2026-09-08 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618497259178-6XJGK9GR6YAVBQL5L519/20140301_Trade-151_012-2.jpg Services https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1607694583486-2PQT0LQ193RL7MCB6DX4/20140228_Trade+151_0046.jpg Services https://www.harmreductionadvocate.com/terms-of-service daily 0.75 2024-11-12 https://www.harmreductionadvocate.com/for-practicum-supervisors daily 0.75 2026-09-14 https://www.harmreductionadvocate.com/education-and-credentials daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/what-a-pharmacist-adds daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/medication-safety-screening daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/publications-and-contributions daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/harm-reduction-in-practice daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/rural-remote-and-northern-practice daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/two-eyed-seeing daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/practicum-faq daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/about-this-archive daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/sophrodelic-legal-magic-mushroom-retreat daily 0.75 2026-10-29 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d6bd992a-4e23-44f6-b37c-702e769393f3/cacona.png https://www.harmreductionadvocate.com/sophrodelic-legal-magic-mushroom-retreat/7-day-morning-flow-challenge monthly 0.5 2024-11-18 https://www.harmreductionadvocate.com/sophrodelic-legal-magic-mushroom-retreat/mindful-meditation monthly 0.5 2024-11-18 https://www.harmreductionadvocate.com/sophrodelic-legal-magic-mushroom-retreat/yoga-for-beginners monthly 0.5 2024-11-18 https://www.harmreductionadvocate.com/sophrodelic-legal-magic-mushroom-retreat/v/how-does-sophrology-work monthly 0.5 2026-10-29 https://www.harmreductionadvocate.com/sophrodelic-legal-magic-mushroom-retreat/v/what-is-sophrology monthly 0.5 2026-10-29